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Summary
Serine proteases in cytoplasmic granules of neutrophils (NSPs), namely neutrophil elastase,
cathepsin G (CG) and proteinase 3, have been under intense investigation for several decades.
They are mainly known for their role in intracellular killing of pathogens and are also increas-
ingly recognized as key regulators of innate immune responses. In 2009, I identified a fourth
serine protease in neutrophils that has been completely overlooked and neglected so far. The aim
of this thesis was an in-depth biochemical and functional characterization of this novel serine
protease 4 (NSP4) of human neutrophils.
Using monoclonal antibodies to NSP4, the distribution of NSP4 in normal human tissues was
studied. NSP4 was observed only in neutrophils and neutrophil precursors of the bone marrow.
The content of NSP4 in neutrophil lysates was about 20-fold lower compared to CG. Never-
theless, NSP4 was found to be released into the supernatant upon neutrophil activation. NSP4
could be further identified as a novel azurophil granule protein of neutrophils by Western blot
analyses of subcellular fractions. For the functional analysis, the production and yield of re-
combinant NSP4 was clearly improved using different expression systems and DNA construct
modifications. The proteolytic specificity was analyzed using E. coli peptide libraries, mass
spectrometry and several synthetic peptide libraries. All these analyses clearly revealed an
arginine specificity for NSP4. Consistent with this, NSP4 was strongly inhibited by heparin-
accelerated antithrombin and C1 inhibitor and, with lower efficacy, by α1-proteinase inhibitor
(α1PI). The data allowed me to generate an NSP4-specific α1PI variant that was shown to form
covalent complexes with all NSP4 of neutrophil lysates and supernatants of activated neutro-
phils. This finding strongly indicated that NSP4 is fully processed and stored as an already
activated enzyme in azurophil granules. In addition, dipeptidyl peptidase I (DPPI) was identi-
fied as the activator of NSP4 in vivo, as DPPI deficiency resulted in complete absence of NSP4
in a Papillon-Lefèvre patient. Analysis of cell-based calcium assays revealed that proteinase-
activated receptor-2 may represent a potential natural substrate of NSP4. So far, NSP4-deficient
mice did not show an abnormal phenotype under clean housing conditions. Activation of iso-
lated neutrophils by phorbol esters or immune complexes was also not impaired. This study
establishes NSP4 as the only arginine-specific pre-activated serine protease stored in azurophil
granules of neutrophils that may fullfil a quite distinct, supportive role in neutrophil responses
to tissue damage and bacterial infections.
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Zusammenfassung
Die Granula-assoziierten Serinproteasen der Neutrophilen, genannt Neutrophilen-Elastase, Ca-
thepsin G (CG) und Proteinase 3, werden bereits seit über 30 Jahren intensiv erforscht. Sie sind
hauptsächlich für ihre Funktion bei der intrazellulären Degradation von pathogenen Keimen
bekannt. Außerdem werden sie zunehmend als wichtige Regulatoren der angeborenen Immun-
antwort angesehen. Im Jahr 2009 identifizierte ich eine vierte Serinprotease in Neutrophilen, die
bis dahin komplett übersehen wurde. Das Ziel dieser Arbeit war eine ausführliche Untersuchung
der Biochemie und Funktion dieser neuen Serinprotease 4 (NSP4) in humanen Neutrophilen.
NSP4 konnte in immunhistochemischen Analysen normaler Gewebe nur in Neutrophilen und
deren Vorläuferzellen im Knochenmark nachgewiesen werden. Die Menge von NSP4 im Ge-
samtzelllysat von Neutrophilen war 20-fach geringer als die von CG. Dennoch konnte ich nach-
weisen, dass NSP4 von aktivierten Neutrophilen sezerniert wird. In subzellulären Neutrophilen-
Fraktionen war NSP4 in erster Linie mit azurophilen Granula assoziiert. Die Produktion und
Ausbeute rekombinanter, aktiver NSP4 wurde mithilfe verschiedener DNA-Konstrukte und
Expressionssysteme deutlich verbessert. Für die Bestimmung der proteolytischen Spezifität
wurden E. coli Peptidbibliotheken, Massenspektrometrie und synthetische Peptidbibliotheken
eingesetzt. Alle Ergebnisse ergaben eindeutig eine Arginin-Spezifität für NSP4. NSP4 wur-
de sehr gut von Heparin-Antithrombin, C1 Inhibitor und mit geringerer Effizienz von α1-
Proteinase-Inhibitor (α1PI) blockiert. Die Ergebnisse ermöglichten die Herstellung einer NSP4-
spezifischenα1PI Variante, die nachweislich mit der gesamten NSP4 aus Neutrophilen-Zelllysat
und aus Überständen aktivierter Neutrophilen einen kovalenten Komplex bildete. Dies war ein
klarer Hinweis für die Speicherung und Sekretion der NSP4 als aktive Endoprotease. Außer-
dem konnte ich zeigen, dass NSP4 in vivo von Dipeptidylpeptidase I (DPPI) aktiviert wird,
da in einem Papillon-Lefèvre Patienten ohne funktionelle DPPI auch NSP4 nicht nachweisbar
war. Intrazelluläre Kalziummessungen in HaCaT-Zellen ergaben, dass der Proteinase-aktivierte
Rezeptor-2 ein mögliches natürliches Substrat für NSP4 sein könnte. In einer Pathogen-freien
Reinraumumgebung zeigten NSP4-defiziente Mäuse bislang noch keinen Phänotyp. Auch die
Aktivierung isolierter Neutrophilen durch Phorbolester oder Immunkomplexe war nicht be-
einträchtigt. In dieser Arbeit gelang es mir, die erste aktive Arginin-spezifische Serinprotease
(NSP4) in azurophilen Granula von Neutrophilen zu identifizieren. Wegen ihres Vorkommens
in allen sequenzierten Genomen höherer Vertebraten könnte NSP4 eine wichtige Rolle bei der
Steuerung und Verstärkung Neutrophilen-abhängiger Immunantworten zukommen.
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1 Introduction
1.1 Neutrophil granulocytes
Differential blood counts show the percentage of different blood cell populations in the periph-
eral blood. Normally, neutrophil granulocytes, in the following briefly called neutrophils, are
most abundant and make up 50 - 70% of all white blood cells in the circulation. The abundance
of these cells already points to the importance of these cells for immune defense responses.
Neutrophils are relatively short-lived cells that develop from myeloid progenitor cells in the
bone marrow to mature band and segmented neutrophils. Neutrophils are constantly released
into the blood stream. In response to local inflammatory danger signals, neutrophils are among
the first immune cells that extravasate from the blood stream and migrate into infected or dama-
ged tissues to form the early immune response (Nathan, 2006).
One hallmark of fully differentiated neutrophils is their lobulated nucleus. Hence, together with
the other granulocytes, they were also specified as polymorphonuclear cells (PMN) of which
they constitute the major part. Eosinophil and basophil granulocytes constitute only 1 - 5% and
0.5 - 1% of total leukocytes, respectively.
1.1.1 Formation of granules and of granule proteins
As the name granulocyte suggests, neutrophils are densely packed with a multitude of gran-
ules that are filled with bactericidal peptides and proteins like alpha-defensins, bactericidal/
permeability-increasing protein (BPI), myeloperoxidase (MPO) and several proteases (Faur-
schou and Borregaard, 2003). The granules are formed consecutively during neutrophil matu-
ration in the bone marrow. Primary or azurophil granules are formed in myeloblasts and pro-
myelocytes, secondary or specific granules appear during the myelocyte and metamyelocyte
1
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stage and tertiary or gelatinase granules are made in band and segmented cells. The three dis-
tinct subsets were classified based on the presence of characteristic proteins: MPO, neutrophil
gelatinase associated lipocalin (NGAL) and gelatinase B (matrix metalloproteinase 9, MMP-
9) are markers for azurophil, specific and gelatinase granules, respectively. Secretory vesicles
constitute the fourth type of storage organelles in neutrophils. These are created by endocytosis
during the late stages of neutrophil development (Borregaard, 2010).
Le Cabec et al. (1996) have demonstrated that the storage process in granules is regulated by
timing and not by sorting. The primary granules contain proteins that are expressed at the very
early stage of neutrophil differentiation, the proteins in the secondary granules are expressed
later and the content of the tertiary granules is made during the late maturation phase of band
and segmented cells. Therefore, the time of expression of a gene can indicate in which granules
the corresponding protein is stored.
1.2 Neutrophil immune response
The human body is firstly protected from microbe infections by the physical barriers provided
by the skin and mucus membranes. If pathogenic microorganisms have overcome this barrier
and gained access to tissues, local endothelial cells are activated by signals from microbes and
macrophages in the tissues. Neutrophils are then recruited by activated endothelium and enter
the tissue after extravasation. This transmigration through the blood vessel wall involves a multi-
step cascade of tethering, rolling, firm attachment and diapedesis (Zarbock and Ley, 2008). In
the course of this process, neutrophils are activated by integrin signaling and G-protein coupled
receptor activation. At the site of infection, the central function of neutrophils is the elimination
of pathogens. This is mainly achieved by phagocytosis and fusion of the endosome with the
neutrophil cytoplasmic granules. Engulfed microorganisms can be destroyed in several ways,
e.g. by reactive oxygen species (ROS), generated by NADPH-oxidase and MPO, bactericidal
peptides and proteins or proteases like the neutrophil serine proteases. Activation of neutrophils
also results in granule exocytosis. Secretory vesicles are released after priming of neutrophils
and with increasing levels of neutrophil activation, also the tertiary, secondary and primary
granules are sequentially released in this order.
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While neutrophils are indespensable in the innate immune defense against intruding microor-
ganisms (Newburger, 2006), prolonged neutrophil accumulation can also lead to pathological
tissue damage as seen in several inflammatory diseases, like rheumatoid arthritis, inflammatory
bowel disease and chronic lung diseases (Weiss, 1989).
1.3 Neutrophil serine proteases (NSPs)
1.3.1 Biosynthesis
Three NSPs have been known for more than 30 years (Baggiolini et al., 1978): neutrophil elas-
tase (NE), cathepsin G (CG) and proteinase 3 (PR3). The genes for NE (ELA2, ELANE) and
PR3 (PRTN3) are tightly linked in a cluster found on the short arm of human chromosome 19
(19p13.3) (Zimmer et al., 1992), whereas CTSG encodes CG and is found in a separate cluster
on human chromosome 14 (14q11.2) with genes encoding granzymes and mast cell chymases
(Caughey et al., 1993). All three are expressed as inactive precursors (zymogens) featuring a
signal peptide and an N-terminal propeptide. After signal peptide processing, the two residues
of the propeptide, actually a dipeptide, are removed by dipeptidylpeptidase I (DPPI, cathepsin
C). Like all serine proteases of the chymotrypsin/trypsin family, the NSPs can only take up their
mature form if the conserved N-terminal Ile16 is free to interact with Asp194 (numbering ac-
cording to bovine chymotrypsinogen). This process leads to a conformational change rendering
the active site accessible for potential substrates (Freer et al., 1970). After processing by DPPI,
the NSPs are stored as mature enzymes in the azurophil granules of neutrophils (Adkison et al.,
2002; Korkmaz et al., 2010).
1.3.2 Role of NSPs
The NSPs contribute to the bactericidal activity of neutrophils. Investigation of NSP-deficient
mouse models has shown that CG and NE are important in killing certain Gram-negative and
Gram-positive bacteria (Belaaouaj et al., 1998, 2000; Reeves et al., 2002) and clearing certain
fungi (Tkalcevic et al., 2000; Reeves et al., 2002).
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In addition, NSPs are also attributed a potential key function in the regulation of inflammation
(Wiedow and Meyer-Hoffert, 2005; Pham, 2008; Kessenbrock et al., 2011). As the NSPs are
also partly released by activated neutrophils, they can proteolytically modify chemokines, cyto-
kines or cell surface receptors and thereby shape the immune response at a very early stage.
For instance, Sambrano et al. (2000) have demonstrated that CG can activate the proteinase-
activated receptor 4 (PAR-4) on platelets. In addition, Raptis et al. (2005) have revealed a role
for CG in integrin clustering on neutrophils after interaction with immobilized immune com-
plexes, leading to cytoskeletal rearrangements and increased ROS production. And PR3 and NE
were both shown to degrade anti-inflammatory progranulin after immune complex-mediated
inflammation in vivo, resulting in enhanced neutrophil dependent inflammation (Kessenbrock
et al., 2008).
1.3.3 NSPs in human diseases
Papillon-Lefèvre syndrome (PLS)
All three NSPs are affected in PLS (Gorlin et al., 1964), a rare autosomal recessive disease that
is caused by loss-of-function mutations in the gene encoding DPPI, the natural convertase of
NE, CG and PR3. PLS is characterized by severe early-onset periodontitis and palmoplantar
hyperkeratosis. Pham et al. (2004) have shown that the levels of NSPs are severely reduced in
neutrophils of PLS patients. The unconverted zymogens of NE, CG and PR3 are thought to be
lost by degradation, continuous secretion or other unknown mechanisms. However, neutrophils
of PLS patients are not uniformly defective in their antimicrobial activity against common bac-
teria. This illustrates that the neutrophil bactericidal activity is not purely dependent on NSPs
(Pham et al., 2004).
Hereditary neutropenias
Cyclic neutropenia and severe congenital neutropenia are caused by maturation arrest of neutro-
phil precursors during myelopoiesis. Mutations in the ELA2 gene (encoding NE) were linked
to hereditary neutropenias (Horwitz et al., 2004) and are thought to disrupt normal intracellular
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trafficking of NE. Intracellular accumulation of mutant NE could then result in apoptosis after
induction of the unfolded protein response (Köllner et al., 2006).
Non-infectious inflammatory diseases
Animal model analysis has implicated NSPs in several non-infectious inflammatory diseases.
Both a mouse model deficient in DPPI (convertase of NE, CG and PR3) and a mouse model de-
ficient in NE and CG were protected against acute arthritis induced by anti-collagen antibodies
(Adkison et al., 2002). Mouse models deficient in NE were found to be partially protected from
smoke-induced emphysema (Shapiro, 2003) as well as from bleomycin-induced pulmonary fi-
brosis (Chua et al., 2007). Furthermore, Shimoda et al. (2007) reported that CG accelerates
pathogenic inflammation in mice after ischemia/reperfusion injury.
Based on their anticipated broad impact on inflammatory processes, NSPs as a whole appeared
to represent a very attractive therapeutic target. Indeed, both industry and academia have at-
tempted to suppress the activity of NE, CG and PR3 by therapeutic inhibitors (Groutas et al.,
2011; Korkmaz et al., 2010). However, besides α1-proteinase inhibitor (α1PI, α1-antitrypsin),
a natural inhibitor of NE, small-molecule inhibitors have yielded unsatisfactory therapeutic re-
sults and did not receive clinical registration so far (Lucas et al., 2013).
1.4 Class 6 serine proteases
Based on their exon-intron organization, NE, CG and PR3 can be grouped to the sixth sepa-
rate class of serine proteases (Jenne, 1994). The exon-intron organization refers to the number
of exons and introns, and the phases of the introns. Introns can interrupt exons between two
codons, after the first or after the second codon base, termed phase 0, 1 or 2, respectively. Intron
phases are highly conserved and relatively stable in evolution, as mutations changing the intron
phase requires concerted mutations both at the donor and acceptor site of an intron.
This sixth class in humans further encompasses the five lymphocyte granzymes A, B, H, K and
M, the catalytically inactive serine protease homolog azurocidin, the mast cell chymase and
complement factor D (CFD). All class members are implicated in immune defense reactions.
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The granzymes and NSPs are important for the elimination of virally infected cells and bacteria,
respectively, while CFD and mast cell chymase amplify the innate immune response by different
mediator-dependant mechanisms.
1.5 Neutrophil serine protease 4 (NSP4)
A total of 178 serine protease homologs were identified in humans (Page and Di Cera, 2008).
One of these could be identified as an additional member of the class 6 serine proteases, based
on its exon-intron structure. PRSS57, the gene encoding NSP4, was annotated by computer
algorithms as "protease, serine, 57". It exhibited 39% sequence identity to NE and PR3 and also
featured four introns with the same phases, 1-2-0-0, and at identical positions as in granzymes
and NSPs.
In my diploma work, 14 monoclonal antibodies (mAbs) to NSP4 were generated in cooperation
with Dr. Elisabeth Kremmer (Helmholtz Zentrum München) and characterized by myself in
much detail. In these studies, I showed that three of these mAbs were specific for NSP4 and did
not cross-react with NE, CG, PR3, azurocidin or the five granzymes. Applying them in Western
blot analyses of total cell lysates of different human blood cell populations, I demonstrated that
NSP4 is present in neutrophils, but not in natural killer cells or other peripheral blood mono-
nuclear cells (PBMCs). Furthermore, NSP4 showed enzymatic activity by cleaving the synthetic
substrate Boc-Ala-Pro-Nva-Sbzl after norvaline, thus displaying a similar substrate specificity
as NE and PR3. Based on the presence of this novel active serine protease in neutrophils, I
designated it neutrophil serine protease 4, abbreviated as NSP4 in the following.
1.6 Protease specificity
1.6.1 The Schechter and Berger nomenclature
The specificity of a protease denotes the amino acid sequence that is preferentially cleaved by
this protease. Schechter and Berger (1967) have introduced a widely accepted nomenclature for
describing the interaction of a protease and its substrate. A prerequisite for successful peptide
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bond hydrolyzation is the proper interaction between amino acid residues close to the peptide
bond that is to be cleaved (scissile bond) and the active site of the protease. The active site
in serine proteases accommodates the catalytic triad which is a highly coordinated structure
consisting of His57, Asp102 and Ser195 (numbering according to bovine chymotrypsinogen).
The cooperative action of the catalytic triad enables a nucleophilic attack of the hydroxyl group
of Ser195 on the carbonyl carbon of the scissile bond of the substrate.
The substrate amino acids close to the scissile bond were designated P-residues (peptide).
Thereby the residues N-terminal of the scissile bond are referred to as P1, P2, P3, P4, etc.
and the residues on the C-terminal side P1’, P2’, P3’, P4’, etc. The scissile bond is located
between P1 and P1’, as illustrated in Figure 1.1. Accordingly, the protease subsites close to the
active site that take up the respective substrate amino acids are called S1 and S1’, S2 and S2’,
S3 and S3’, etc.
1.6.2 Proteolytic specificities of NE, CG and PR3
NE preferentially cleaves substrates with medium to small aliphatic residues in P1, like Val,
Ile, Leu or Ala (Bode et al., 1989). The specificity of PR3 is similar to NE, small aliphatic
residues like Ala and Val are preferred in P1 (Rao et al., 1991). CG features chymotrypsin-like
activity and strongly prefers Phe or Tyr at the P1 substrate position, but also cleaves substrates
after Lys or Arg with much lower efficacy (Wysocka et al., 2007). This additional low Lys/Arg
specificity of CG was only reported for human CG and was not seen in analyses of mouse or
other mammalian CG. The slight change in specificity is thought to result from the Ala226Glu
change that occured late in primate evolution and is only present in human CG (Raymond et al.,
2010).
1.7 Inhibitors of neutrophil serine proteases
Under normal circumstances, excessive extracellular activity of NE, CG and PR3 is antago-
nized by distinct protease inhibitors. NE is inhibited by α1-proteinase inhibitor (α1PI, α1-
antitrypsin), elafin (also known as skin-derived antileukoprotease), monocyte neutrophil elas-
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H2N COOH
P1P2
P3
P1‘ P2‘
P3‘
S3
S2 S1 S1‘ S2‘
S3‘
Scissile bond
Substrate
Protease
Figure 1.1: The Schechter and Berger nomenclature. Schematic representation of the inter-
action of the amino acids of the substrate next to the cleavage site (scissile bond)
(P3-P3’) and the protease subsites close to the active site (S3-S3’). Hydrolyzation
of the substrate can only occur if the amino acids of the substrate fit well into the
subsites of the protease.
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tase inhibitor (MNEI), secretory leukocyte protease inhibitor (SLPI) and α2-makroglobulin.
α1PI, elafin, MNEI and α2makroglobulin are also inhibitors of PR3. CG is inactivated by anti-
chymotrypsin (ACT), SLPI, MNEI and α1PI (Korkmaz et al., 2008).
There are, however, several mechanisms by which neutrophil serine proteases can escape en-
dogenous inhibition. As described in Owen and Campbell (1999), proteinase inhibitors can be
inactivated by oxidative or proteolytic mechanisms and overwhelmed by the high local concen-
tration of proteases at inflammation sites.
1.7.1 Serpins
α1PI, MNEI and ACT belong to the serpin family of serine protease inhibitors. These high-
molecular weight protease inhibitors represent a suicide trap for serine proteases. The so-called
reactive center loop (RCL) is an extended loop that is initally recognized as a substrate by the
protease. In this way, the rate of inhibition is also dependent on how well the amino acids on
the RCL fit to the proteolytic specificity of the protease.
Hydrolysis by serine proteases normally consists of five steps. (i) The formation of an initial
non-covalent Michaelis complex is followed by (ii) the Ser195 attack on the scissile bond to
form a tetrahedral intermediate. Next, (iii) the peptide bond is cleaved which results in a cova-
lent acyl ester intermediate of the protease and the N-terminal part of the substrate while the
C-terminal part of the substrate is released. After a water attack, (iv) a second tetrahedral in-
termediate is formed, which is followed by (v) separation of protease and cleaved substrate. In
the case of the serpins, this process is arrested after (iii). Cleavage of the RCL allows the ser-
pin to undergo a substantial conformational change in which the covalently attached protease
is translocated to the distal end of the serpin and the active site of the protease is distorted. In
this way, the acyl-enzyme intermediate is kinetically trapped representing the covalently linked
serpin-protease complex (Olson and Gettins, 2011).
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1.8 Proteinase-activated receptor-2 (PAR-2)
The family of proteinase-activated receptors (PAR) so far includes members 1-4. These recep-
tors are activated after a proteolytic cleavage in their extracellular N-terminal part. This leads
to exposure of a previously cryptic sequence that acts as activating ligand (tethered ligand) of
the receptor (Steinhoff et al., 2005). Proteases can also cleave downstream of the activating
sequence, thereby inactivating the respective receptor. The PAR can be activated by several pro-
teases. Thrombin is classically reported as activator of PAR-1, PAR-3 and PAR-4 (Vu et al.,
1991; Ishihara et al., 1997; Kahn et al., 1998) and trypsin can activate PAR-2 (Nystedt et al.,
1995). Trypsin can also activate PAR-1, PAR-3 and PAR-4 to a lower extent, but thrombin does
not activate PAR-2 (Shpacovitch et al., 2008).
Considering NSP4, PAR-2 appeared to be a very interesting natural substrate target, based on
its sequence around the activation site, SKGR-/-SLIG. Like the other three, PAR-2 is expressed
in various cells and organs and the functions reported so far reflect this variety (reviewed in
Steinhoff et al. (2005)). It was already reported that proteases of neutrophils can activate PAR-2
on epithelium resulting in increased epithelial permeability (Chin et al., 2008). On the other
hand, Ramachandran et al. (2011) revealed that none of NE, CG or PR3 can activate G-coupled
PAR-2 calcium signaling, but all three can disarm and inactivate PAR-2. Hence, the PAR-2
activating protease in neutrophils could be NSP4.
1.9 NSP4-deficient mouse model
I was planning to generate an NSP4-deficient (NSP4-/-) mouse line. A homologous gene inde-
ed exists in the mouse genome and has been designated Prss57. While cloning the mouse DNA
constructs, I learned that Lexicon Pharmaceuticals Inc. (The Woodlands, TX, USA) in coopera-
tion with Genentech Inc. (San Francisco, CA, USA) had already developed an NSP4 deficient
mouse model (project PRT354N1) by targeting exons 2 and 3 with a lacZ-neomycin cassette
(Figure 2.1). This mouse model was part of a large collection of knockout mouse lines for 472
genes encoding secreted and membrane proteins in mice (Tang et al., 2010). All mouse models
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were subjected to a phenotypical screen to uncover alterations in embryonic development, me-
tabolism, the immune system, the nervous system and the cardiovascular system. The results
of the screens can be accessed and studied online (http://mmrrc.mousebiology.org/phenotype/
index.php).
Four to six Prss57-deficient mice on a mixed 129S5/SvEvBrd × C57BL/6J-Tyrc-Brd hybrid
background were investigated by Lexicon Pharmaceuticals and Genentech. No notable phe-
notype could be observed other than a marginal decrease in pheripheral blood CD8 and NK
cells, a slight increase in B cells and slightly higher levels of tumor necrosis factor α (TNF-α)
and monocyte chemotactic protein-1 after intraperitoneal challenge with lipopolysaccharides
(LPS).
Expression of NSP4 in their study was investigated by lacZ encoded β-galactosidase and RT-
PCR. LacZ activity was reported to be missing in all tissues they had studied (panel size and
tissue range not mentioned). Expression of mRNA in wildtype (WT) mice was restricted to
thymus and spleen. The cell type transcribing the gene, however, has not been identified. Bone
marrow tissue was not analyzed by RT-PCR.
Hence, neutrophil functions and inflammatory models other than LPS stimulation were not
specifically explored as NSP4 was not suspected to be expressed in neutrophils.
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1.10 Objectives
Despite numerous studies on neutrophils, only NE, CG and PR3 were identified as active serine
proteases in these short-lived cells. In my diploma thesis, I identified the fourth neutrophil
serine protease, NSP4, which was completely overlooked so far. Nothing was known about this
novel serine protease despite its expression in human neutrophils. The aim of this thesis was
an in-depth characterization of NSP4. This new knowledge should then facilitate a functional
comparison with the other NSPs and help to uncover the physiological functions of NSP4.
At first, the production and purification of recombinantly expressed NSP4 had to be improved.
Before, NSP4 was expressed in a stably transfected HEK 293 cell line. Due to the low expres-
sion levels and many other proteins in the cell culture supernatant, this previous method was
not satisfactory for the production and purification of NSP4. To this end, different expression
systems and improvement steps for the expression of NSP4 in the stably transfected HEK 293
line were tested.
So far, I had only tested the presence of NSP4 in different human blood cell populations. For a
better classification of the role of NSP4, protein expression in other tissues was studied. More-
over, with regard to NSP4 in neutrophils, a characterization of its biosynthesis, storage, acti-
vation and release by neutrophils was required. This basic knowledge helps to narrow down
the broad range of potential natural substrates of NSP4 and enables us to assess its role in the
correct biological context and in relationship to the long-known other three members, NE, CG
and PR3.
To uncover the function of NSP4, it is indispensable to know which substrate sequences are
preferentially hydrolyzed and when and where NSP4 is enzymatically active. In order to an-
swer these questions, the proteolytic specificity of NSP4 was analyzed and possible inhibitors
were tested. In addition, efforts were undertaken to determine the activity status of NSP4 in bio-
logical samples. To investigate the role of NSP4, I also assessed potential natural substrates of
NSP4. Since I was interested in analyzing the evolutionary conserved function of NSP4, I also
addressed NSP4 in the mouse regarding proteolytic specificity, activity and expression in com-
parison to human NSP4. Finally, isolated neutrophils of NSP4-/- and WT mice were examined
in cell based in vitro assays.
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2.1 Materials
2.1.1 Chemicals and consumables
Chemicals were obtained from the companies BD Biosciences (Franklin Lakes, NJ, USA),
Bio-Rad Laboratories (Hercules, CA, USA), Biozym (Hessisch Oldendorf, Germany), Life
Technologies (Carlsbad, CA, USA), Merck (Darmstadt, Germany), PAA Laboratories GmbH
(Pasching, Austria), GE Healthcare (Little Chalfont, Buckinghamshire, UK), Qiagen (Hilden,
Deutschland), Roth (Karlsruhe, Germany), and Sigma-Aldrich (St Louis, MO, USA), unless
mentioned otherwise. Restriction enzymes and T4 DNA ligase were purchased from New Eng-
land Biolabs (Ipswich, MA, USA). Consumables such as pipette tips, reaction tubes, centrifuge
tubes and microwell plates were procured from Kisker (Steinfurt, Germany), Biozym, Eppen-
dorf (Hamburg, Germany), BD Biosciences and Nunc/Thermo Fisher Scientific (Waltham, MA,
USA). Cell culture flasks and dishes were from Corning (Corning, NY, USA) and BD Biosci-
ences.
2.1.2 Oligonucleotides
Oligonucleotides were synthesized by Metabion (Martinsried, Germany). Oligonucleotide se-
quences can be found in the Appendix (7.2).
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2.1.3 Plasmids
Plasmid Construct Origin
pcDNA5 FRT-V5-H6-TOPO Invitrogen, Life Technologies
S-NSP4(human)-pcDNA5 SigIgκ-S-EK-NSP4-H6 Heike Kittel, Arbeitsgruppe PD Dr. Jenne (AG Jenne)
pTT5 - NRC Biotechnology Research Institute
(Ottawa, Ontario, Canada)
NSP4_precursor(human)-pcDNA3.1 SigNSP4-NSP4_precursor-cMyc-H6 Heike Kittel, AG Jenne
MOG(human)-pTT5 SigIgκ-MOG-H6 Heike Kittel, AG Jenne
Lamp2a(human)-pTT5 SigIgκ-Lamp2a-H6 Heike Kittel, AG Jenne
pFASTBAC1 - Invitrogen
Sumo3(human)-NSP4(human)-pET28M Sumo3-EK-NSP4-H6 Johannes Trambauer, AG Jenne
α1PI(human)-pTT5 SigIgκ-α1PI-H6 Therese Dau, AG Jenne
SUMOstar-pTT5 SigIgκ-H6-SUMOstar Therese Dau, AG Jenne
Ubiquitin(human)-pCR2.1 Ubiquitin Eurofins MWG
The vector maps can be found in the Appendix (7.1).
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2.1.4 Cell lines
Cell line ATCC no. Origin
Flp-InTM-293 [S-NSP4] CRL-1573 Heike Kittel, AG Jenne; Invitrogen
HEK 293 EBNA1 CRL-10852 NRC Biotechnology Research Institute
HT1080 CCL-121 Luisa-Astrid Fratila, AG Sommerhoff
HaCaT Luisa-Astrid Fratila, AG Sommerhoff
2.1.5 Recombinant and purified proteins
Protein Origin
α1PI, human Athens Research & Technology (Athens, GA, USA)
Antichymotrypsin, human Athens Research & Technology
Antithrombin, human Athens Research & Technology
Cathepsin G, human Calbiochem (Merck, Darmstadt, Germany)
C1 inhibitor, human Athens Research & Technology
Elafin, human Proteo Biotech AG (Kiel, Germany)
Heparin, porcine Sigma-Aldrich
MNEI, human Creative Biomart (Shirley, NY, USA)
Neutrophil elastase, human Elastin Products (Owensville, MO, USA)
Proteinase 3, human Athens Research & Technology
SLPI, human R&D Systems (Minneapolis, MN, USA)
Thrombin, bovine BioCentrum, Krakow, Poland
Trypsin, bovine Sigma-Aldrich
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2.1.6 Antibodies
Primary antibodies
Antigen Species Clone Provider Cat. No.
Human NSP4 Rat 2F6 AG Jenne/AG Kremmer, IMI -
Human α1PI† Rabbit polyclonal Dako A0012
Human CG Mouse 19C3 Abcam ab75572
Ovalbumin Rabbit serum Sigma C6534
Human haptoglobin Rabbit polyclonal Dako A0030
†Anti-α1PI antibodies were biotinylated by Bert Utecht, Utecht & Lüdemann GmbH,
Klausdorf, Germany.
Secondary antibodies
Antigen Species Label Provider Cat. No.
Rat IgG+IgM Goat Peroxidase Jackson ImmunoResearch 112-035-068
Mouse IgG+IgM Goat Peroxidase Pierce (Thermo Scientific) 31444
Rabbit IgG Goat Peroxidase Jackson ImmunoResearch 111-035-006
Other
Protein Label Provider Cat. No.
Streptavidin Peroxidase Millipore OR03L
2.1.7 Synthetic substrates
The list of substrates that were used for this thesis can be found in the Appendix (7.4).
2.1.8 Mouse strain
The NSP4 knockout mouse model was established by Lexicon Pharmaceuticals Inc. in a col-
laboration with Genentech Inc. The mouse model was generated on a mixed 129S5/SvEvBrd×
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C57BL/6J-Tyrc-Brd background. NSP4-deficient mice were purchased as cryo-preserved hetero-
zygous embryos from the Mutant Mouse Regional Resource Center (MMRRC) at the Univer-
sity of California in Davis (UC Davis, Davis CA, USA) (stock no. 032536-UCD, strain name
B6;129S5-Prss57tm1Lex/Mmucd).
2.1.9 Laboratory equipment
Autoklave Varioklav, H+P Labortechnik, Oberschleissheim, Germany
Balances PM 4800 Delta Range, Mettler-Toledo, Columbus, OH, USA
2001 MP2, Sartorius, Göttingen, Deutschland
Centrifuges 5417R, Eppendorf
5417C, Eppendorf
Rotanta 460R, Hettich, Tuttlingen, Germany
Rotanta/R, Hettich
Film developer X-Omat M35, Kodak
FPLC ÄKTAprimeT M, Amersham-Pharmacia
Gel electrophoresis chambers
and power supplies Bio-Rad, Amersham-Pharmacia, MPI workshop
Incubation shaker HT Multitron, Infors, Bottmingen, Switzerland
Incubator BBD6220, Heraeus, Thermo Scientific, Waltham, MA, USA
Incubator Jouan, Germany
Icemachine Ziegra, Isernhagen, Germany
Laminar flow LaminAir HB 2472S, Heraeus, Hanau, Germany
Magnetic stirrer MR3003, Heidolph, Kelheim, Germany
KMO2 basic, IKA, Staufen, Germany
Microplate reader FLUOStar Optima, BMG Labtech, Offenburg, Germany
Microscope Leica DM IL, Leica Microsystems, Wetzlar, Germany
pH-meter Inolab pH Level 1, WTW, Weilheim, Germany
PCR cycler T3 Thermocycler, Biometra, Göttingen, Germany
Semidry blotter Biometra, Göttingen, Germany
Shakers 130 basic, IKA KS
260 basic, IKA KS
Spectrophotometer ND-1000, peqlab, Erlangen, Germany
Biophotometer, Eppendorf
Stirring cell MPI workshop
Thermoblock Thermomixer 5436, Eppendorf
Ultrasonic bath Sonorex digital 10P, Bandelin, Berlin, Germany
Water bath incubator MA6, Lauda, Lauda-Königshofen, Germany
Water preparation Milli Q Advantage, Millipore
17
2 Materials and Methods
2.2 Molecular biological methods
2.2.1 Preparation of competent bacteria with CaCl2
A single colony of E. coli DH5α was inoculated into 50 ml LB medium (Luria-Bertani-Broth)
without antibiotics and grown in an Erlenmeyer flask at 37 ◦C with shaking (250 rpm) overnight.
Then 4 ml of the preculture were added to 400 ml fresh LB medium. The cells were grown until
the OD600nm reached 0.375-0.6. The culture was kept on ice for 5-10 min in pre-cooled 50 ml
tubes and pelleted by centrifugation at 3000 rpm and 4 ◦C for 7 min without brake. The cell
pellets from 50 ml culture volume were resuspended in 10 ml ice-cold CaCl2 solution and kept
on ice for 30 min. For the remaining steps the cells were kept on ice and all flasks, pipette
tips and tubes were pre-cooled at 4 ◦C. After centrifugation at 3000 rpm and 4 ◦C for 5 min,
the pellets were taken in 2 ml ice-cold CaCl2 solution and aliquots of 250 µl were stored at
-80 ◦C.
CaCl2-Solution 60 mM CaCl2
15% (w/v) glycerol
10 mM PIPES [piperazine-N,N’-bis(2-ethanesulfonic acid)]
pH 7
LB medium 1% (w/v) bacto tryptone
0.5% (w/v) yeast extract
1% (w/v) NaCl
pH 7.5
autoclaved
(100 µg/ml ampicillin)
LB agar (plates) 1 × LB medium
1.5% (w/v) bacto agar
autoclaved
2.2.2 Transformation of competent bacteria by heat shock
Competent E. coli DH5α were thawed on ice for 10 min. I used 100 µl bacterial cells and 3-
10 µl ligation preparation or 10 ng plasmid DNA in 1-10 µl per transformation. The DNA was
added to the cells and left on ice for 30 min. This should allow the DNA to attach to the cell
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walls. The heat shock was performed at 42 ◦C for 30 s. This permeabilizes the cell membrane
for a short duration and the plasmid DNA can enter the cell. Directly after the heat shock, 900 µl
pre-warmed LB medium without antibiotics was added and the cells were grown for 60 min at
37 ◦C and 250 rpm. Both the pTT5 and the pFASTBAC1 vector included the beta-lactamase
gene which renders the bacterial clones resistant to the antibiotic ampicillin. I plated 100-200 µl
of the cell suspension onto LB agar plates with 100 µg/ml ampicillin and they were incubated
at 37 ◦C overnight.
2.2.3 Plasmid DNA purification from E. coli
For purification of plasmid DNA from 2-5 ml overnight culture of E. coli, the QIAprep Spin
Miniprep Kit (Qiagen) and a microcentrifuge were used. The bacteria were lysed under alka-
line conditions followed by adsorption of plasmid DNA onto silica in high salt. The EndoFree
Plasmid Maxi Kit (Qiagen) was employed for purification of plasmid DNA from larger cultures
(200-300 ml). Here, the bacteria were disrupted by alkaline lysis and the plasmid DNA was
bound to QIAGEN anion-exchange resin. Both kits were used according to the manufacturer’s
instructions. The EndoFree kit includes an endotoxin removal buffer which prevents endotoxins
(lipopolysaccharides, LPS) from binding to the anion-exchange resin. Purified plasmid DNA
was then used for transfection of mammalian cells (HEK 293E) in cell culture. Endotoxins
were removed because increased levels can lead to reduced transfection efficiencies.
2.2.4 Polymerase chain reaction (PCR)
The PCR enables the amplification of short DNA segments (50 bp - 10 kbp) from larger DNA,
e.g. plasmids or genomic DNA. One forward and one reverse primer are required, which flank
the desired DNA segment. The DNA polymerase can then add and link nucleotides to the prim-
ers, thereby extending the amplicon. The PCR is done in cycles, beginning with a denaturation
step in which the strands of the DNA double helix separate, followed by an annealing step in
which the primers bind to the ends of the desired DNA segment. The cycle is completed by the
extension step in which the DNA polymerase extends the primers. Two different polymerases
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were employed. The HotStarTaq DNA polymerase from Qiagen was used for mouse geno-
typing analyses and RT-PCR. The Phusion High-Fidelity DNA polymerase from Finnzymes
(New England Biolabs) was applied for cloning of expression constructs. The latter one is a
pyrococcus-like enzyme fused with a processivity enhancing domain increasing fidelity and
speed.
HotStarTaq PCR reaction (25 µl) 1 µl DNA template (mouse tail DNA, ∼100-200 ng)
0.2 mM dNTP-mix
1 × PCR buffer (Qiagen)
0.4 µM forward primer (10 pmol absolute)
0.4 µM reverse primer (10 pmol absolute)
0.2 µl HotStarTaq DNA polymerase
HotStarTaq PCR programme
"Touch down" 15 min 95 ◦C Denaturation
10 s 95 ◦C Denaturation
 3 cycles30 s 60 ◦C Annealing30 s 72 ◦C Extension
10 s 95 ◦C Denaturation
 3 cycles30 s 57 ◦C Annealing30 s 72 ◦C Extension
10 s 95 ◦C Denaturation
 21 cycles30 s 54 ◦C Annealing30 s 72 ◦C Extension
10 min 72 ◦C Annealing
Phusion PCR reaction (25 µl) 2-10 ng plasmid DNA
or 50-100 ng genomic DNA
0.2 mM dNTP-mix
1 × HF Buffer (Finnzymes)
0.4 µM forward primer (10 pmol absolute)
0.4 µM reverse primer (10 pmol absolute)
0.2 µl Phusion DNA polymerase
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Phusion PCR programme
"Touch down" 30 s 98 ◦C Denaturation
10 s 98 ◦C Denaturation
 3 cycles30 s * Annealing30 s 72 ◦C Extension
10 s 98 ◦C Denaturation
 3 cycles30 s ** Annealing30 s 72 ◦C Extension
10 s 98 ◦C Denaturation
 18 cycles30 s *** Annealing30 s 72 ◦C Extension
10 min 72 ◦C Annealing
* primer specific annealing temperature + 6 ◦C
** primer specific annealing temperature + 3 ◦C
*** primer specific annealing temperature
2.2.5 Formation of oligoduplexes
For the exchange of short sequences, two complimentary oligonucleotides were ordered and
mixed at equimolar concentrations (e.g. 10 µM). The incubation at 95 ◦C for 5 min was followed
by 2 min at room temperature and 5 min on ice.
2.2.6 Restriction digests
Restriction endonucleases are enzymes which cleave DNA, mostly at a specific recognition
sequence. One unit is defined as the amount of restriction enzyme that completely digests 1 µg
of substrate DNA (often Lambda DNA) in one hour at the optimal temperature. Restriction
enzymes were purchased at New England Biolabs or SibEnzyme (AbsI; Novosibirsk, Russia)
and used according to the manufacturer’s instructions with the provided buffers. The substrate
DNA (500 ng - 5 µg) was digested in 15-50 µl volume for 60 min.
21
2 Materials and Methods
2.2.7 Dephosphorylation of vector DNA
To avoid self-ligation of the vector plasmid without insert, the vectors were dephosphorylated
after restriction digest. After restriction digest, 2-5 µg of the vector DNA was incubated with
0.5 µl Calf Intestinal Alkaline Phosphatase (New England Biolabs) in a volume of 30-50 µl at
37 ◦C.
2.2.8 Agarose gel electrophoresis
As DNA fragments are negatively charged, they can be separated in a gel matrix in an electric
field on the basis of their size. Agarose gels were prepared in TAE buffer with SYBR Safe
(Life Technologies) 1:10 000 or 1 µg/ml ethidium bromide for visualization of DNA under
UV (λ= 254-366 nm). Depending on the size of expected DNA fragments, the percentage of
agarose in the gels ranged from 0.7% to 3.5% (w/v). The samples were loaded into the gel slots
after addition of loading buffer and run in TAE buffer at 90 V for gels of 40 ml. The size of
the migrating DNA fragments was determined by comparison with molecular weight standards
(Gene Ruler 1 kb, Fermentas, Thermo Fisher Scientific and 50 bp ladder, Roth).
TAE buffer (50 × ) 242 g Tris
100 ml 0.5 M EDTA pH 8.0
57.1 ml acetic acid
H2O to 1 L
DNA loading buffer (10 × ) 0.25% (w/v) bromphenol blue
0.25% (w/v) xylenecyanol
50% (v/v) glycerol
2.2.9 DNA purification
After restriction digest or PCR, DNA fragments were purified by gel extraction (QIAquick Gel
Extraction Kit, Qiagen) or with the QIAquick PCR Purification Kit (Qiagen) in accordance with
the manufacturer’s instructions.
22
2.2 Molecular biological methods
2.2.10 Determination of DNA concentration
At the wavelength of 260 nm, the extinction coefficient for double stranded DNA in water is
0.020 (µg/ml)−1 cm−1. With this, the concentration of DNA was measured using a spectropho-
tometer and the Beer-Lambert law (Absorption = (extinction coefficient) × (length of solution)
× (concentration of solution)).
2.2.11 Ligation of DNA
T4 DNA Ligase or the Quick Ligation Kit (both from New England Biolabs) were used for
the ligation of insert and vector DNA. The manufacturer’s instructions were followed. I used
50 ng vector DNA and a molar ration of 1 to 10 of vector and insert in a total volume of 20 µl.
Ligation reactions employing T4 DNA Ligase were carried out for 2-4 h at room temperature.
The Quick Ligation Kit enabled ligation within 5-15 min at room temperature.
2.2.12 Sequence analysis of DNA
DNA samples were sent to Eurofins MWG GmbH (Ebersberg, Germany) for sequence analy-
sis.
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2.2.13 Expression constructs
Expression in mammalian cells (HEK 293E)
Name Construct Insert Vector Primer AT [◦C]
S-NSP4(human)-pTT5 SigIgκ-S-EK-NSP4-H6 NheI/PmeI digest of S-EK-NSP4-
pcDNA5
NheI/NaeI digest of pTT5 - -
SigPR3-NSP4(human)-
pTT5
SigPR3-EK-NSP4-H6 Oligoduplex coding for PR3 signal
peptide
NheI/PmlI digest of S-
NSP4-pTT5
DJ3305/
DJ3306
-
NSP4_precursor(human)-
pTT5
SigNSP4-AQ-NSP4-cMyc-H6 EcoRI/BsrGI digest of NSP4
precursor-pcDNA3.1
EcoRI/BsrGI digest of S-
NSP4-pTT5
- -
SUMOstar-
NSP4(human)-pTT5
SigIgκ-SUMOstar-EK-NSP4-H6 PCR with SUMOstar vector
LIC7121; KpnI/DraIII
KpnI/DraIII digest of S-
NSP4-pTT5
DJ3324/
DJ3325
50
MOG(human)-
NSP4(human)-pTT5
SigIgκ-MOG-EK-NSP4-H6 NheI/HincII digest of MOG-pTT5 NheI/PmlI digest of S-
NSP4-pTT5
- -
Lamp2a(human)-
NSP4(human)-pTT5
SigIgκ-Lamp2a-EK-NSP4-H6 PCR with Lamp2a in pTT5;
NheI/PmlI
NheI/PmlI digest of S-
NSP4-pTT5
DJ3312/
DJ3314
60
NGS-NSP4(human)-
pTT5
SigIgκ-NGS-EK-NSP4-H6 Oligoduplex coding for NGS-
peptide
KpnI/PmlI digest of S-
NSP4-pTT5
DJ3385/
DJ3386
-
α1PI*-pTT5 SigIgκ-α1PI(RCL=IKPR)-H6 Oligoduplex coding for IKPR AbsI/AccI digest of
α1PI(human)-pTT5
DJ3559/
DJ3560
-
mNSP4-pTT5 SigIgκ-H6-EK-mNSP4 PCR with cDNA clone (imaGenes,
Berlin, Germany); PstI/AgeI
Sbf I/AgeI digest of H6-
SUMOstar-pTT5
DJ3352/
DJ3353
55
S-mNSP4-pTT5 SigIgκ-S-EK-mNSP4-H6 PCR with mNSP4-pTT5; PmlI/AgeI PmlI/AgeI digest of S-
NSP4-pTT5
DJ3368/
DJ3369
55
AT = Annealing temperature; Sig = Signal peptide; S = S-tag peptide; H6 = 6× His tag; EK = enterokinase cleavage site; AQ = natural
propeptide of NSP4, Ala-Glu; cMyc = cMyc tag; MOG = myelin oligodendrocyte glycoprotein; Lamp = lysosomal-associated membrane
protein; NGS = peptide sequence with glycosylation site, SRMHRNGSH; RCL = reactive center loop of a serpin; IKPR = RCL sequence of α1PI*;
mNSP4 = mouse NSP4
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Expression in insect cells (High Five, Sf9)
Name Construct Insert Vector
SigGP67-pFASTBAC1 SigGP67 Gene synthesis of SigGP67 (Eurofins,
Ebersberg); EcoRI/BglIII
EcoRI/BamHI digest of
pFASTBAC1
Sumo3(human)-NSP4(human)-
pFASTBAC1
SigGP67-Sumo3-EK-NSP4-H6 NdeI digest of Sumo3-NSP4-pET28M NdeI digest of SigGP67-
pFASTBAC1
Ubiquitin(human)-pFASTBAC1 SigGP67-Ubiquitin Gene synthesis of Ubiquitin (Eurofins);
NdeI/StuI
NdeI/StuI digest of
SigGP67-pFASTBAC1
Ubiquitin(human)-
NSP4(human)-pFASTBAC1
SigGP67-Ubiquitin-EK-NSP4-H6 PmlI/BamHI digest of S-NSP4 pTT5 PmlI/BamHI digest of
Ubiquitin pFASTBAC1
AT = Annealing temperature; Sig = Signal peptide; GP67 = acidic glycoprotein of AcNPV baculovirus; H6 = 6× His tag; EK = enterokinase
cleavage site; S = S-tag peptide;
25
2 Materials and Methods
2.3 Recombinant protein expression
All cell culture methods described were carried out in a sterile laminar flow hood. Cell cul-
ture media and other solutions were autoclaved or sterile filtered using a filter with pore size
0.22 µm.
2.3.1 Expression of S-NSP4 in Flp-InTM-293
The Flp-InTM system from Invitrogen (Life Technologies) enables expression of a protein of
interest after stable integration of the gene of interest. Integration is achieved employing Flp-
recombinase and FRT sites in host cell and expression vector. I was working with Flp-InTM-293
cells that were already stably transfected with S-NSP4 in pcDNA 5 (Heike Kittel, AG Jenne).
Flp-InTM-293 cell culture in cell stacks
For protein expression, Flp-InTM-293 cells were grown in adherent cell culture in 5-level cell
stacks (Invitrogen) at 37 ◦C and 5% CO2 in a humidified atmosphere. The supernatant was
harvested after 10-14 days. The cells were then detached from the vessel surface with trypsin
preceded by a wash in 1 × phosphate buffered saline (PBS). One fifth of the cells was then
again seeded in the cell stacks in 500 ml fresh medium.
Flp-In medium 1 × DMEM
10% (v/v) FCS
75 µg/ml hygromycin B (Invitrogen)
PBS 137 mM NaCl
2.7 mM KCl
10 mM Na2HPO4 × H2O
1.8 mM KH2PO4
pH 7.4
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Flp-InTM-293 single cell culture
The cells were cultured as single cell clones to enable a comparison of expression on this level.
To ameliorate the growth of single cells, I used a 1:1 mixture of fresh Flp-In medium and con-
ditioned Flp-In medium. Conditioned medium is medium in which the cells have been growing
in for one passage and that was filtered through 0.22 µm. The cells were diluted to 7 cells/ml
and 100 µl were seeded per well into 96-well cell culture plates. This should result in a statistic
number of 0.7 cells per well. The growth at 37 ◦C and 5% CO2 in a humidified atmosphere
was monitored daily under a microscope. When single cell colonies of similar sizes were for-
med, the culture medium was refreshed and harvested after 9 days. The supernatants were then
assayed for NSP4 by Western blot analysis. Well expressing clones were chosen and used for
adaptation to low-serum and suspension growth.
Adaptation to low serum and suspension growth
The cells were adapted stepwise from Flp-In medium to low-serum medium with each split. Af-
ter reaching confluency, the cells were split 1 to 10 and taken in medium with 7.5%, 5%, 2.5%,
1% and then 0.3% serum. The cells cultured in medium with 0.3% serum were transferred into
Erlenmeyer flasks for suspension culture and grown in the 37 ◦C incubation shaker containing
a humidified atmosphere of 8% CO2 in air at 110 rpm. For suspension growth, the non-ionic
surfactant Pluronic R© F-68 (Invitrogen) was added to protect the cells from shear stress. I used
125 ml, 250 ml, 1 L and 3 L Erlenmeyer shaker flasks for cell cultures of 10-50 ml, 50-100 ml,
150-400 ml and 600-1200 ml, respectively. Supernatants were harvested after 7-9 days.
Flp-In low-serum medium 1 × FreestyleTM 293 Expression Medium (Invitrogen)
0.3% (v/v) FCS
50 µg/ml hygromycin B (Invitrogen)
(0.1% (v/v) Pluronic R© F-68)
Freezing and thawing of Flp-InTM-293
Flp-InTM-293 were frozen at a concentration of 1 × 107 cells/ml in freezing medium. For this
the cells were pelleted for 6 min at 330× g and 4 ◦C, taken into freezing medium and aliquoted
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into cryotubes. The cryotubes were then put into an ice-cold freezing container (Nalgene, Ther-
mo Fisher Scientific) filled with isopropanol and at -80 ◦C. The freezing container provided the
cooling rate of 1 ◦C/min. For long time storage, the cells were transferred into liquid nitrogen.
Flp-InTM-293 aliquots were carefully thawed in a 37 ◦C water bath. Just before complete
thawing, the cells were taken into 10 ml pre-warmed low-serum Flp-In medium and centri-
fuged for 6 min at 330 × g. The supernatant was removed to reduce the DMSO concentration
and the cells were taken into 30 ml pre-warmed low-serum Flp-In medium and grown in the
incubation shaker at 37 ◦C in a humidified atmosphere with 8% CO2 and 110 rpm.
Freezing medium 1 × FreestyleTM 293 Expression medium (Invitrogen)
1% FCS
10% (v/v) DMSO
2.3.2 Expression of α1PI*, S-mNSP4 and all NSP4 constructs in
pTT5 in HEK 293E
All constructs that were cloned into the pTT5-plasmid and listed in section 2.2.13 (Expression
in mammalian cells) were expressed in the HEK 293 EBNA 1 (HEK 293E) cell line. The ex-
pression of S-NSP4, NGS-NSP4 and S-mNSP4 could be enhanced by using additional filler
DNA for transfection of HEK 293E (please see below).
HEK 293E is a modified human embryonic kidney cell line stably transfected with a plasmid
encoding the nuclear EBV-antigen 1 (EBNA-1). The plasmid also carries a geneticin resistance
marker (G418) for maintenance of the plasmid within the cell. EBNA-1 transactivates the episo-
mal replication of plasmids carrying the EBV specific replication of origin ’oriP’ (Reisman and
Sugden, 1986; Durocher et al., 2002), e.g. pTT5. Cells were cultured in suspension in 293 EB-
NA medium in Erlenmeyer flasks in the incubation shaker at 37 ◦C in a humidified atmosphere
with 8% CO2 and 110 rpm.
293 EBNA medium 1 × FreestyleTM 293 Expression Medium (Invitrogen)
0.1% (v/v) Pluronic R© F-68
25 µg/ml Geneticin R© G418
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Transfection of HEK 293E
Prior to transfection of HEK 293E with the expression constructs, cells were brought to a den-
sity of 1 × 106 cells/ml. Polyethyleneimine (PEI)/DNA complexes were prepared by adding
PEI to DNA, both prediluted in Optipro serum free medium (Invitrogen), incubated at room
temperature for 15 min and added to the cells. I used 2 µg PEI and 1 µg DNA for 1 ml of cell
culture suspension. After 1 day, Bacto TC Lactalbumin Hydrolysate (BD Biosciences), which
is the enzymatically hydrolyzed portion of milk whey, was added as an amino acid supplement
to 0.5% final concentration. Supernatants were harvested after 4 days.
The use of filler DNA for improved transfection and expression of S-NSP4,
NGS-NSP4 and S-mNSP4 in HEK 293E
Transfection was carried out as described above, but I mixed, or ’diluted’ the plasmid of interest
in ratios of 1:10 to 1:1000 with non-specific filler DNA. As filler DNA I used a bacterial plasmid
without mammalian expression elements (Ubiquitin-pCR2.1).
2.4 Cell biological methods
2.4.1 Determination of cell count and viability
The number of viable cells/ml was determined in a hemacytometer (Neubauer improved) after
mixing trypan blue solution and cell suspension in a 1:1 ratio. Trypan blue can enter the per-
forated membranes of dead cells and allows for discrimination from living cells. The number
of cells in each of the four large quadrants was counted and the average of this was multiplied
by the dilution factor. As the volume over one of the large quadrants is 100 nl, the result was
multiplied by 104 to get the number of cells/ml.
Trypan blue solution 0.1% (w/v) trypan blue
1 × PBS pH 7.4
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2.4.2 Analysis of human PMN
Isolation of human PMN from blood
Fresh blood from volunteering healthy donors or from a PLS patient was taken into 9 ml EDTA
tubes to prevent blood clotting. I mixed 18 ml EDTA blood with 17 ml PBS, transferred it
into a 50 ml tube and carefully underlaid it with 10 ml Pancoll human (Pan Biotech, Aiden-
bach, Germany). The tubes were centrifuged for 20 min at 500 × g at 20 ◦C without brake.
After successful gradient centrifugation, erythrocytes and polymorphonuclear cells (PMN) can
be found at the bottom of the tube whereas plasma, thrombocytes and peripheral blood mono-
nuclear cells (PBMC, lymphocytes and monocytes) are still on top of the Pancoll layer. Plasma,
thrombocytes, PBMC and Pancoll were removed and the rest was filled to 40 ml with PBS and
mixed with 8 ml of 6% dextran in PBS. After 45 min dextran sedimentation of erythrocytes
at room temperature, the PMN in the supernatant were taken and pelleted for 5 min at 500 ×
g. Residual erythrocytes were lysed in 5 ml 0.2% NaCl. After 1 min, 5 ml of 1.6% NaCl was
added followed by 20 ml PBS after another min. The cells were centrifuged again and taken in
PBS or RPMI 1640 (Gibco, Life Technologies). Neutrophil purity was determined by forward
and sideward scatter flow cytometry and was routinely found ∼95%.
Isolation of PMN from a patient with Papillon-Lefèvre syndrome (PLS)
The PLS patient was a 18-year-old man that presented with mild skin findings. The patient
carried a homozygous 854 C > T nucleotide exchange in the cathepsin C gene leading to a
substitution of the normal proline residue 285 by leucine (P285L mutation). This mutation has
already been reported and characterized and was associated with an almost complete loss of
protein function (Noack et al., 2008). PMN were isolated from heparinized peripheral blood as
described above.
Preparation of total cell lysates
For Western blot analysis, purified PMN were totally lysed. Cells were taken in cold RIPA buffer
at 3 × 104 cells/µl and left on ice for 15 min. In thin-walled PCR tubes (0.5 ml, New England
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Biolabs), cells were incubated 4 × 3 min in the ultrasonic bath, with intermittent incubations
on ice for 5 min. Cell debris and DNA were pelleted by centrifugation for 10 min at 20 000 × g
and 4 ◦C. For subsequent measurements of enzymatic activity of serine proteases, RIPA buffer
without PMSF was used.
RIPA buffer 50 mM Tris
150 mM NaCl
0.5 M EDTA
(1 mM PMSF)
0.5% (w/v) deoxycholic acid
0.1% (w/v) SDS
0.5% (v/v) Nonidet P-40
pH 8.0
Degranulation of PMN
To analyze the granule content of neutrophils, PMN were activated with cytochalasin B (cytB)
and phorbol-12-myristate-13-acetate (PMA). To this end, isolated PMN were taken in RPMI
1640 at 1.7 × 105 cells/µl and incubated with cytB (5 µg/ml) at 37 ◦C for 5 min. PMA was
then added to a final concentration of 200 ng/ml. CytB and PMA were both solved in DMSO,
therefore, DMSO alone was added to the control sample. After another 30 min at 37 ◦C, samples
were centrifuged for 10 min at 500 × g and for 5 min at 20 000 × g. Resulting supernatants
were analyzed by immunoblotting.
Detection of NSP4 in subcellular fractions of human neutrophils
The fractionation of human neutrophils was done in the laboratory of Prof. Dr. Niels Borregaard
(The Phagocyte Laboratory, University of Copenhagen, Copenhagen, Denmark). Samples of 1-
5 µl of each of the 5 fractions representing azurophil granules, specific granules, gelatinase
granules, secretory vesicles with plasma membranes or cytoplasm were assayed by Western
blotting with rat anti-NSP4 mAbs. The bands appearing after immunoblotting were quantitated
in Image Lab 4.1 (Bio-Rad).
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2.4.3 Calcium signaling in HaCaT and HT1080
Measurements of calcium signaling were done together with Luisa-Astrid Fratila in the labora-
tory of Prof. Dr. Christian Sommerhoff, Institut für Laboratoriumsmedizin, LMU, München.
HaCaT (immortalized human keratinocytes) or HT1080 (fibrosarcoma cell line) were cultured
in 24-well tissue culture plates until they were confluent. DMEM with 10% FCS was exchanged
to HEPES buffer with 1 mM calcium chloride (0.5 ml per well). The calcium indicator Fluo-4
AM (Molecular Probes, Life Technologies) was added to a final concentration of 4 µM and
Pluronic R© F-127 (Life technologies) was added to 0.04%. Pluronic R© F-127 is a non-ionic sur-
factant that has been found to facilitate the solubilization and loading of water-insoluble dyes
into cells. Fluo-4AM features an ester group which enables crossing of the cell membrane and
esterolysis in the cytosol. Although the charged dye molecules leak out of cells far more slowly
than the uncharged precursor molecules, anion transporters promote the leakage of the fluores-
cent dye over time. Probenecid was used to inhibit anion transporters and block the efflux of
intracellular Fluo-4. Intracellular calcium bound to Fluo-4 increases the fluorescence 100-fold.
The cells were left in the dark incubator for 1 h and washed twice with HEPES buffer con-
taining calcium chloride. For baseline measurements, the cells were first measured without any
stimulators and then with stimulators at λEx = 494 nm and λEm = 516 nm. Negative controls
were treated with HEPES buffer plus calcium alone or containing proNSP4 (S-NSP4 before
EK-digest). Positive controls included bovine trypsin and thrombin.
HEPES buffer with Calcium 10 mM HEPES
12.4 mM NaHCO3
137 mM NaCl
2.7 mM KCl
5 mM D-Glucose × H2O
1 mM CaCl2 (H2O)
4 mM Probenecid, freshly added
Desensitization of PAR-1 and PAR-2
The cells were pretreated with agonist peptides for PAR-1 (TFLLR-amide, H5848) and PAR-2
(SLIGKV-amide, H4624) at final concentrations of 200 µM and 50 µM, respectively. Both were
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purchased from Bachem (Bubendorf, Switzerland).
2.5 Protein analysis
2.5.1 Purification of recombinant proteins
After centrifugation at 500 × g for 15 min, the cell culture supernatant was filtered through a
0.22 µm membrane (Millipore). Employing a stirring chamber under nitrogen pressure (2.5 ×
105 Pa) and an ultrafiltration membrane with 10 kDa cut-off, the supernatant was concentrated
fivefold, and then dialyzed against binding buffer at 4 ◦C. Nickel-affinity chromatography was
used to purify 6 × His-tagged S-NSP4, NSP4 precursor, NGS-NSP4, S-mNSP4 or α1PI* af-
ter expression in Flp-InTM-293 cells (S-NSP4, see 2.3.1) or HEK 293E cells (S-NSP4, NSP4
precursor, NGS-NSP4, S-mNSP4 and α1PI*, see 2.3.2). The protein solution was applied to a
HisTrap HP column (GE Healthcare) previously equilibrated in binding buffer. The column was
washed with binding buffer, and bound proteins were eluted applying a linear imidazole gradi-
ent from 50 mM to 1 M imidazole in binding buffer. Fractions were collected and analyzed by
SDS PAGE and silver staining. The expected size is 31 kDa. The fractions that contained the
protein of interest were pooled and concentrated.
Binding buffer 20 mM Na2HPO4
500 mM NaCl
50 mM imidazole
pH 7.5 (adjusted using HCl)
2.5.2 Processing of S-, NGS-NSP4 and S-mNSP4 by
enterokinase
Purified proteins featuring an enterokinase cleavage site were concentrated about 20-fold by
ultrafiltration using Amicon Ultra-4 centrifugal filter units with a cut-off of 10 kDa. With the
same centrifugal devices, the residual buffer was exchanged 3 times to EK-buffer. CaCl2 was
added to a final concentration of 2 mM. The amino-terminal extension, the S-tag peptide or the
NGS-peptide and the enterokinase (EK) recognition sequence was cleaved off by Tag- Off High
33
2 Materials and Methods
Activity Enterokinase (Novagen, Merck) to generate mature 6×His-tagged NSP4. EK cleavage
was accomplished by 1 U EK per 50 µg NSP4 for 16 h at room temperature. Conversion of
NSP4 was verified by SDS PAGE and subsequent silver staining. There is a molecular weight
shift of ∼3 kDa after removal of these synthetic propeptides.
EK-buffer 20 mM Tris-HCl
500 mM NaCl
(2 mM CaCl2)
pH 7.4
2.5.3 Conversion of NSP4 precursor by dipeptidyl peptidase I
Dipeptidyl peptidase I (DPPI, cathepsin C) was first activated with 1 mM dithioerythritol (DTE)
at 37 ◦C in DPPI buffer for 60 min. After purification, NSP4 precursor was incubated with 0.5
U/mg activated DPPI in DPPI buffer for 4 h at room temperature. The sample was analyzed by
Edman sequencing before and after incubation with DPPI.
DPPI-buffer 50 mM CH3COONa
100 mM NaCl
pH 5.5
2.5.4 Determination of protein concentration
Bicinchoninic acid (BCA) assay
Protein concentration was determined with BCA using the Uptima MicroBC Assay kit (Inter-
chim, Montluçon Cedex, France) according to the manufacturer’s instructions.
Spectrophotometric determination of protein concentration
Protein concentration was determined spectrophotometrically using the molar absorption coef-
ficient as described by Grimsley and Pace (2004). For this, I measured the absorbance at 280
nm and applied the following equation: c = (A280 × MW) / (280 × l) (c, concentration; A,
34
2.5 Protein analysis
absorption; MW, molecular weight; , extinction coefficient; l, length of solution). Extinction
coefficients of each protein were determined based on the amino acid sequence employing the
programme ProtParam (http://us.expasy.org/tools/ protparam.htm).
2.5.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS PAGE)
SDS PAGE enables separation of proteins on the basis of their size. Gel, sample and running
buffer contained the anionic detergent SDS which binds to proteins and thereby unfolds their
secondary structure. SDS treatment also confers a negative charge to all proteins in accordance
with the length of their polypeptide chain. This enables a discrimination of proteins only by size
and irrespective of their inherent charges. β-mercaptoethanol was added to the sample buffer
for reduction of disulfide bridges. Prior to loading, protein samples were taken in sample buffer
and incubated at 95 ◦C for 5 min. I used a discontinuous gel system that included a stacking
gel and a separating gel. Low acrylamidic concentration and slightly acidic pH in the stacking
gel permitted the formation of thin, sharply defined bands before entering the separating gel.
The higher polyacrylamide content and the more basic pH in the separating matrix enabled the
separation according to protein size. The narrower pores in the separation gel allowed smaller
proteins to travel more rapidly through the gel matrix. For comparison of protein sizes, molecu-
lar weight standards were used (Prestained protein marker broad range, New England Biolabs;
Roti-Mark prestained, Roth).
8 SDS polyacrylamide gels (15%)
Stacking gel Separating gel
13.6 ml 9.4 ml H2O
3.32 ml 20 ml 30% Acrylamid
2.56 ml 1 M Tris HCl, pH 6.8
10 ml 1,5 M Tris HCl, pH 8.8
100 µl 200 µl 20% SDS
200 µl 400 µl 10% APS
20 µl bromphenolblue
20 µl 16µl TEMED
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Running buffer (10 ×) 250 mM Tris HCl
1.92 M glycine
1% (w/v) SDS
Sample buffer (4 ×), reducing 200 mM Tris HCl, pH 6.8
40% (v/v) glycerol
10% (w/v) SDS
30% (w/v) β-mercaptoethanol
0,2% (w/v) bromphenolblue
2.5.6 Protein detection
Coomassie Blue staining
After SDS PAGE, the gel was incubated in Coomassie Blue staining solution for at least 30 min
and then in Coomassie Blue destaining solution until the protein bands were visualized (1-3
hours).
Coomassie Blue staining solution 0.25% (w/v) Coomassie Brilliant Blue
45% (v/v) methanol, p.a.
10% acetic acid
Coomassie Blue destaining solution 45% (v/v) methanol, p.a.
10% acetic acid
Silver staining
After SDS PAGE, the gel was incubated in fixation solution for 60 min on a shaker. The gel was
washed 3 × 20 s in dH2O and sensitized in thiosulfate solution for 1 min. After rinsing with
water, the gel was submerged into silver nitrate solution, incubated for 20 min and washed again
in water. In developer solution, the protein bands became visible and the reaction was stopped
in 50% methanol and 12% acetic acid after rinsing in water. The final fixation was achieved in
50% methanol.
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Fixation solution 50% (v/v) methanol
12% (v/v) acetic acid
0,5 ml/l 37% formaldehyde
Thiosulfate solution 0.2 g/l Na2S2O3 × 5 H2O
Silver nitrate solution 2 g/l AgNO3
750 µl/l 37% formaldehyde
Developer solution 60 g/l Na2CO3
4 mg/l Na2S2O3 × 5 H2O
0.5 ml/l 37% formaldehyde
2.5.7 Edman sequencing
Ten micrograms of NSP4 precursor before and after incubation with DPPI was separated by re-
ducing SDS PAGE and transferred in Edman transfer buffer to a polyvinylidene fluoride (PVDF)
membrane. The membrane was stained with Coomassie Blue and the bands representing NSP4
were analyzed by N-terminal Edman sequencing (Reinhard Mentele, MPI Biochemistry).
Edman transfer buffer 90 mM Tris
90 mM boric acid
1 mM EDTA
10% (v/v) methanol, p.a.
2.5.8 Measurement of enzymatic activity
2.5.9 Proteomic identification of protease cleavage sites (PICS)
For the initial specificity profiling, active recombinant NSP4 was sent to Dr. Oliver Schilling
(University of Freiburg, Freiburg, Germany). As described in Schilling and Overall (2008), the
cleavage sites of NSP4 were determined in peptide libraries from E. coli.
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Thiobenzyl ester (Sbzl) substrates
Enzymatic activity of NE, PR3 and CG (100 nM) was determined using thiobenzyl ester sub-
strates and Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid) or DTNB). The free thiobenzyl
ester group can react with DTNB which results in yellow 2-nitro-5-thiobenzoate ions. The rate
of hydrolysis was read out at 405 nm. I used Boc-Ala-Pro-Nva-4-chloro-Sbzl for NE and PR3
and Suc-Phe-Leu-Phe-Sbzl for CG, both at 1 mM final concentration and with 0.5 mM DTNB
in activity buffer.
Activity buffer 50 mM Tris
150 mM NaCl
0.01% Triton X-100
pH 8.0
7-Amino-4-methylcoumarin substrates (AMC substrates)
Enzymatic activity of NSP4 towards substrates with Arg in P1 compared to Lys in P1 was
determined with 1 mM H-Tyr-Arg-Phe-Arg-AMC or H-Tyr-Arg-Phe-Lys-AMC. Substrate hy-
drolysis was recorded as fluorescent signal after incubation with 250 nM NSP4 at λEx = 370
nm and λEm = 450 nm.
FRETS peptide libraries (Peptanova)
NSP4 (0.5 µM) or NE (0.1 µM) were incubated with 100 µM of each pool designated as FRETS
25-Ala, FRETS 25-Arg, FRETS 25-Ile, FRETS 25-Leu, FRETS 25-Met or FRETS 25-Val
(PeptaNova GmbH, Sandhausen, Germany). Each library contained 25 peptides of the gener-
al structure D-A2pr(Nma)-Gly-[Phe/Ala/Val/Glu/Arg]-[Pro/Tyr/Lys/Ile/Asp]-P1-Ala-Phe-Pro-
Lys(Dnp)-D-Arg-D-Arg, with different residues in P1 position. The proteolytic activity was
monitored at λEx = 320 nm and λEm = 450 nm. The initial linear portion of the progress curve
was used to calculate the enzymatic activity.
The peptides in the FRETS 25-Arg library were further analyzed by liquid chromatography
- mass spectrometry (LC-MS). The library was incubated at a concentration of 0.5 mM with
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6 µM NSP4, NE, PR3 or CG and given to Elisabeth Weyher-Stingl (MPI Biochemistry) for
LC-MS analysis (ESI-TOF).
FRET peptide libraries (EMC microcollections)
I used 49, 49 and 19 individual FRET peptides for screening of positions P1’P2’, P4P3 and
P2, respectively. The FRET peptides were provided by Prof. Dr. Karl-Heinz Wiesmüller (EMC
microcollections). All FRET peptides featured the structure Mca-Gly-P4-P3-P2-Arg-P1’-P2’-
Pro-Lys (Dnp)-rr (r = D-Arg). The concentration of these substrates was determined by using
the molar extinction coefficient of 2,4-Dinitrophenyl (17 300 M-1cm-1 at λ = 365 nm) and the
Beer-Lambert law (see 2.2.10). The hydrolysis of the FRET peptides by NSP4, NE, PR3, CG
or mNSP4 was followed at λEx = 320 nm and λEm = 405 nm in activity buffer. The proteases
were used at concentrations from 25 to 100 nM and the FRET peptides were present at 1-
20 µM. Specificity was assessed by recording the increase of fluorescence over time for each
FRET substrate. Only the initial linear portion of the progress curve was used to calculate the
enzymatic activity in RFU/min (increase of relative fluorescence units per minute).
PAR-2 FRET peptide
Cleavage of the PAR-2 derived FRET substrate Abz-GSKGR-SLIG-Y (NO2)-D (EMC micro-
collections) was determined at λEx = 320 nm and λEm = 405 nm in activity buffer. The FRET
peptide was present at 200 µM and NSP4 was added to a final concentration of 2.4 µM. For
controls, I used 2.4 µM proNSP4 (unconverted S-NSP4) and enterokinase at the same concen-
trations as present in the NSP4 sample (1.2 × 10-3 U/µl). NSP4 was converted by enterokinase
into its mature form.
2.5.10 Inhibition tests
Potential chemical inhibitors
PMSF. Inhibition of NSP4 by phenylmethylsulfonyl fluoride (PMSF) was assayed in com-
parison with NE. Both proteases were used at 50 nM and pretreated with different amounts
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of PMSF (0.1-10 mM). After 40 min incubation at 37 ◦C, the best FRET-substrate of NSP4
(Mca-GFKVR-SRP-Lys (Dnp)-rr) and the α1PI FRET substrate (Mca-GEAIPM-SIPPEV-Lys
(Dnp)-rr) were added to NSP4 and NE, respectively, at 13 µM. The residual activities of both
enzymes after inhibitor treatment were used to estimate the concentration of inhibitor yielding
50% inhibition (IC50).
FPR-cmk. Inhibition of NSP4 by H-D-Phe-Pro-Arg-chloromethylketone (FPR-cmk, Bachem)
was tested after preincubation of 100 nM NSP4 with 10, 50 or 100 µM FPR-cmk and subsequent
activity assay with the FRET substrate Mca-GFPR-SRP-Lys (Dnp)-rr at a final concentration of
10 µM.
Potential natural inhibitors
Enzymatic inhibition of NSP4 (0.25 µM) was assayed after 45 min of incubation at 37 ◦C using
the following inhibitors and concentrations, elafin, 10 µM; secretory leukocyte peptidase in-
hibitor (SLPI), 10 µM; α1-proteinase inhibitor (α1PI), 25 µM; monocyte/neutrophil elastase
inhibitor (MNEI) with 1mM DTT, 3.3 µM; antithrombin with 300 U/mL heparin, 5.6 µM;
C1 Inhibitor, 2.5 µM; or antichymotrypsin (ACT), 5.6 µM. The final volume was 50 µl. The
residual enzymatic activity was determined as described for AMC substrates using H-Tyr-Arg-
Phe-Arg-AMC. NSP4 without inhibitor was treated accordingly.
Complexation with inhibitors
To test whether NSP4 forms covalent complexes with serpins, NSP4 (0.8 µM) was incubated
at 37 ◦C with 40 µM α1PI, 5 µM antithrombin and 300 U/mL heparin or 4 µM C1 inhibitor in
PBS. Samples of 2 µl were taken after 0.5, 5, 30, and 100 min and analyzed by SDS PAGE and
Western blot with anti-NSP4 mAbs.
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2.6 Immunological methods
2.6.1 Western blot
Analysis by Western blotting or immunoblotting facilitates detection of specific proteins of
interest after SDS PAGE applying specific antibodies. After separation by SDS PAGE, the pro-
teins were transferred from the gel matrix onto PVDF membranes by semi-dry electroblotting.
The PVDF membrane was first activated in 100% methanol, then gel and membrane were equi-
librated in transfer buffer for 5-10 min. The transfer was carried out between 4 sheets of blot-
ting paper soaked in transfer buffer. The proteins were transferred for 30 min at 5 mA/cm2 in
the Fastblot semi-dry blotter (Biometra). The membrane was washed in PBS-T and shaken in
blocking milk for 60 min to avoid unspecific binding. The incubation with the first antibody
in PBS-T was done overnight at 4 ◦C. After washing in PBS-T, the membrane was incubated
with the secondary antibody in PBS-T for 60 min at room temperature while shaking. All sec-
ondary antibodies used for Western blotting were conjugated to horseradish peroxidase (HRP).
The membrane was washed and bound HRP-conjugates were visualized using a chemilumines-
cent substrate (SuperSignal West Pico Chemiluminescent Substrate, Pierce). Membranes were
developed with an ECL-Film (CL-XPosure, Thermo Fisher Scientific) or using the Chemidoc
imaging system (Bio-Rad).
Dilutions Rat anti-NSP4 2F6 (rat hybridoma SN) 1:25
Rabbit anti-α1PI-biotin 1:13000
Mouse anti-CG 1:50
Rabbit anti-haptoglobin 1:1000
Goat anti-rat-HRP 1:5000
Goat anti-mouse-HRP 1:2500
Goat anti-rabbit-HRP 1:5000
Streptavidin-HRP 1:1000
Further information on antibodies is provided in 2.1.6.
41
2 Materials and Methods
Western transfer buffer 10% (v/v) methanol, p.a.
150 mM glycine
35 mM Tris
pH 8,3
PBS-T 140 mM NaCl
2,7 mM KCl
3,2 mM Na2HPO4 × 12 H2O
1,5 mM KH2PO4
0,05% (v/v) Tween 20
pH 7,4
Blocking milk 1 × PBS-T
5% (w/v) Non-Fat Dry Milk Blocker, Bio-Rad
pH 7,4
2.6.2 Immunohistochemistry
Immunological staining of formalin-fixed tissue samples was carried out by Dr. Walter Back
(Pathological Institute Bremerhaven, Bremerhaven, Germany) using our rat anti-NSP4 anti-
bodies. The rat hybridoma supernatants were diluted 1:30 and incubated with the sections over-
night at 4 ◦C. Slides were developed with the Ultravision LP staining kit (Thermo Fisher Scien-
tific) and counterstained with hematoxylin.
2.7 Mouse model analysis
The NSP4 knockout mice were purchased as cryo-preserved heterozygous embryos from the
Mutant Mouse Regional Resource Center (MMRRC) at the University of California in Davis
(see section 2.1.8). The gene of NSP4, Prss57, consists of 5 exons. By homologous recombina-
tion, the coding exons 2 and 3 had been targeted as shown in Figure 2.1.
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DJ3511 DJ3512
DJ3513
DJ3610 DJ3569
Forward primer
Reverse primer
1 kb 1 2 543
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1 54
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Figure 2.1: Strategy for genotyping and analysis of NSP4 mRNA in the NSP4 knockout
mouse model. Schematic representation of the WT NSP4 locus and the targeted
allele. Gene targeting resulted in deletion of exons 2 and 3. Heterozygous frozen
embryos were supplied by MMRRC at UC Davis. Primers used for determination
of genotype by PCR and for RT-PCR analysis of NSP4 are shown as arrow heads.
2.7.1 Isolation of genomic DNA from mouse tails
Mouse distal tail pieces of 2-5 mm were immersed in 500 µl tail buffer with 1 mg/ml proteinase
K (Roth) and incubated overnight at 56 ◦C while shaking. After 5 min centrifugation at 20 000
× g, 400 µl of the supernatant was added to 500 µl isopropanol and briefly mixed. Precipitated
DNA was pelleted for 10 min at 20 000 × g at 4 ◦C and the supernatant was removed. The
precipitate was taken in 1 ml 70% ethanol and centrifuged for 5 min at 20 000 × g. The super-
natant was discarded and the pellet was left to dry for 10 min. The DNA was solved in 100 µl
Tris buffer shaking at 55 ◦C.
Tris buffer 20 mM Tris
150 mM NaCl
pH 7.4
2.7.2 Genotyping of mice
After isolation of genomic DNA from mouse tails, 1-2 µl were analyzed by PCR with HotStar-
Taq polymerase (see 2.2.4). The PCR with primers DJ3511 and DJ3512 amplifies the WT-allele
represented by a band of 291 bp whereas the PCR with primers DJ3513 and DJ3512 amplifies
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the knockout allele corresponding to a band of 237 bp after agarose gel electrophoresis (Figure
2.1). If only one of the PCR results in a positive band, the corresponding mouse is homozygous
for the NSP4 gene and is either a WT mouse or an NSP4-/- mouse. If both PCR yield a positive
band, the corresponding mouse is heterozygous for the NSP4 locus (NSP4+/-). As WT controls,
I used non-transgenic littermates.
2.7.3 Isolation of bone marrow cells
Mice were sacrificed by CO2 inhalation and the femurs of both hind legs were taken out and
freed of soft tissue attachments. After cutting off the ends at both sides, the bone marrow was
flushed out by forcing 5 ml RPMI 1640 through the bone using a syringe with a 21-gauge
needle. To disperse the cells, the bone marrow solution was sent through a cell strainer.
2.7.4 Reverse transcriptase (RT) PCR
Isolation of mRNA
After isolation of bone marrow cells, the cells were pelleted for 5 min at 500 × g and resus-
pended in erythrocyte lysis buffer for 1-3 min. The cells were again pelleted and washed in
RPMI 1640, pelleted and taken in 1 ml TRIzol R© (Life technologies) and left for 5 min at room
temperature. After addition of 200 µl chloroform, it was mixed for 15 s and left for 15 min at
room temperature. The solution was centrifuged for 10 min at 13 000 × g at 4 ◦C and the upper
aqueous phase was added to 500 µl isopropanol and left for 15 min at room temperature before
centrifuging for 10 min at 13 000 × g at 4 ◦C. The pellet was taken in 1 ml 75% ethanol and
pelleted for 5 min at 5000 × g at 4 ◦C. The pellet was left to dry for 10 min and resuspended
in 20 µl RNase free water. RNA concentration was determined by measuring the absorbance
at 260 nm. According to the Beer-Lambert law and using the extinction coefficient of RNA
(0.025 (µg/ml)-1 cm-1) a reading of 1.0 (absorption at 260 nm) is equivalent to 40 µg/ml single
stranded RNA.
Erythrocyte lysis buffer (10 ml) 9 ml 0.8% NH4Cl
1 ml 0.2 M Tris HCl pH 7.5
44
2.7 Mouse model analysis
Reverse transcription of mouse bone marrow mRNA
First-strand cDNA was generated employing the Verso cDNA synthesis kit (Thermo Fisher
Scientific). One µg RNA was added to 0.5 µM reverse primer (Oligo dT) in a total volume of
12 µl and denatured at 65 ◦C for 10 min. The mix was kept on ice and 4 µl 5 x synthesis buffer,
2 µl 20 mM dNTPs, 1 µl RT-Enhancer and 1 µl Verso enzyme mix was added. The conditions
for reverse transcription included 30 min at 42 ◦C and 2 min at 95 ◦C.
PCR of mouse bone marrow cDNA
Detection of the mouse NSP4 transcript in bone marrow cDNA was carried out by PCR as
described in section 2.2.4 for HotStarTaq PCR with 1 µl cDNA and primers DJ3610 and DJ3569
((Figure 2.1). I used a touchdown programme including 3, 3 and 24 cycles with annealing
temperatures of 61, 58 and 55 ◦C, respectively. As a positive control, I used primers for mouse
β-actin. The touchdown PCR programme for the β-actin transcript comprised 3, 3 and 24 cycles
with annealing temperatures of 65, 52 and 59 ◦C, respectively. The primer sequences are given
in the Appendix (7.2).
2.7.5 Isolation of neutrophils
After isolating the bone marrow cells from 3-4 mice, the cells were taken in 20 ml RPMI 1640 in
a 50 ml tube. The suspension was carefully underlaid with 10 ml 62.1% Percoll (GE Healthcare)
in 2 × HBSS. After centrifugation at 500 × g at 20 ◦C for 30 min without brake, the cell pellet
containing PMN and erythrocytes is taken in erythrocyte lysis buffer (see section 2.7.4). After
1-3 min, the suspension is centrifuged for 5 min at 500× g and the cells were washed in RPMI.
The purity of isolated mouse neutrophils was determined by forward and sideward scatter in
flow cytometry. The percentage of PMN in bone marrow cells could be routinely enriched from
32% to 85%.
62.1% Percoll (15 ml) 3 ml 10 × HBSS (Gibco, Life Technologies)
2.69 ml H2O
9.32 ml Percoll (GE Healthcare)
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2.7.6 Determination of neutrophil oxidative burst
Activation by PMA
After isolation of mouse neutrophils, the cells were resuspended in RPMI 1640 with 1% BSA
at a density of 2 × 106 cells/ml and incubated with or without 200 ng/ml PMA for 15 min.
Dihydrorhodamine 6 G (indicator for reactive oxygen species, Molecular Probes, Life Techno-
logies) was added to a final concentration of 100 µM. Oxidative burst was followed at 37 ◦C
by measuring fluorescence at λEx = 485 nm and λEm = 520 nm. The oxidative burst signals
were compared between WT and NSP4-/- neutrophils using the linear portion of the enzymatic
progress curve.
Activation by immune complexes
Immune complexes (IC) were prepared by coating 5 mg/ml ovalbumin (Sigma A5503) on Im-
mulon 4 HBX plates (Thermo Fisher Scientific), at 4 ◦C overnight. After washing with PBS-T,
rabbit anti-ovalbumin at 25 µg/ml was added to the plates and incubated for 60 min at room
temperature. Residual antibodies were removed by three wash steps in PBS-T. After isolation
of mouse neutrophils, the cells were dispensed in RPMI with 1% BSA at 2 × 106 cells/ml
and incubated with 10 ng/ml mouse TNF-α. After 15 min preincubation at 37 ◦C, the cells
were transferred to the preformed immune complexes or into control wells with only ovalbumin
coating. Generation of reactive oxygen species was detected with Dihydrorhodamine 6 G as
described above for PMA activated neutrophils.
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3.1 Production of NSP4
Production of natively folded NSP4 was not feasible in bacterial cells (Heike Kittel, Dieter
Jenne, unpublished observations). After recombinant protein expression in E. coli, NSP4 could
be detected only in inclusion bodies. Several refolding protocols were applied by Heike Kittel,
but none of these yielded enzymatically active NSP4. The only possibility to produce active
NSP4 was in Flp-InTM-HEK 293 cells (Invitrogen, human embryonic kidney cell line), as re-
ported previously (Natascha Perera, diploma thesis). In view of the low yields and many im-
purities in the cell culture medium, the method described previously was not satisfactory for
the production and purification of NSP4. After nickel-chelate affinity chromatography, the elu-
tion fractions still contained other proteins. The main contaminant was suspected to be albumin
originating from the cell culture medium which contained 5 to 10% FCS (Figure 3.1 A). In the
presence of this major albumin impurity, it was impossible to measure the protein concentration
and the yield of the NSP4 production. I estimated by SDS PAGE analysis that 1 L cell culture
medium contained about 100-200 µg NSP4. As the Flp-InTM-293 is growing adherently, it was
difficult to scale up the cell culture. The maximum cell volume that I could cultivate was 500
ml in cell stacks with five levels and 3180 cm2. The supernatant was routinely harvested after
10-14 days.
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Figure 3.1: Production of NSP4 in Flp-InTM-293. Elution fractions after purification of S-
NSP4 from Flp-InTM-293 cells stably transfected with SigIgκ-S-EK-NSP4-H6-
pcDNA5. A, Production in adherent FlpIn cell line (cell stacks). Flp-In 293 cells
were cultivated for 14 days in cell stacks. The supernatant was harvested and 820
ml were purified using nickel-chelate chromatography. The volume of each elution
fraction was 2 ml. Of each fraction a sample of 12 µl was analysed by SDS PAGE
and Coomassie Blue staining. Albumin was suspected to be the major contaminant
(top arrow). B, Improved production in Flp-InTM-293 cell line, after serum reduction
and adaptation to suspension culture. Flp-InTM-293 cells were cultivated for nine
days in suspension culture with low-serum medium. By nickel-chelate chromatog-
raphy, 600 ml culture supernatant was purified. Each elution fraction contained 4 ml
and samples of 21 µl of each fraction were analyzed by SDS PAGE and Coomassie
Blue staining. NSP4 is represented by two bands which are probably the result of
differential glycosylation, as NSP4 features two N-glycosylation sites.
3.1.1 Improved production in Flp-InTM-293
The Flp-InTM-293 were stably transfected with an NSP4 construct featuring an Igκ-signal pep-
tide, an N-terminal S-tag peptide, an enterokinase cleavage site at the mature aminoterminus of
NSP4 and a C-terminal 6×His-tag for purification (S-NSP4-pcDNA5). To improve the yields,
I firstly established single cell clones from the cell line to compare expression levels of NSP4.
The supernatants of the single cell clones were analyzed for NSP4 by Western blotting with
rat anti-NSP4 mAb and the four best expressing clones were chosen for further culture. For
additional improvement of yield and purity, the FCS in the cell culture medium was reduced.
The serum content of the cell culture medium was stepwise reduced from 10% to 1% and at
the same time, the cells were also adapted to grow in suspension. The concentration of 0.3%
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FCS was found to enable both a sufficient growth rate of the cells and a satisfactory purification
protocol of NSP4. Figure 3.1 B shows the purification of NSP4 from Flp-InTM-293 growing in
low-serum medium. With these improvements, the yields were 327 ± 61 µg (n = 12, ± SD) of
pure NSP4 per 1 L of cell culture. The maximum volume for suspension cultures was 1200 ml
in 3 L Erlenmeyer cell culture flasks. The culture was harvested after seven to nine days.
NSP4 migrates as two distinct bands, a dominant and a minor band. This cannot be the result
of C- or N-terminal truncation. The S-NSP4 construct features a C-terminal 6× His-tag. If this
was removed, purification by nickel-chelate chromatography would not have been feasible. The
construct also features an N-terminal S-tag followed by an enterokinase cleavage site. After
enterokinase digest (see Figure 3.3), both forms of NSP4 underwent a comparable molecular
weight shift. Hence, the N-terminus was preserved in both forms. The difference in size of
the two NSP4 forms is probably the result of heterogenous glycosylation. NSP4 features two
potential N-glycosylation sites.
3.1.2 Production in HEK 293E
The ’HEK 293E Large Scale Transient Expression System’ was developed by Yves Durocher
(NRC Biotechnological Research Institute). The system was chosen for NSP4 production be-
cause it uses serum-free cell culture conditions and a convenient transient transfection protocol.
The latter advantage permitted me to test different NSP4 cDNA constructs in a short period of
time. Transfection of HEK 293E with the S-NSP4 construct (as described in 3.1.1) subcloned
into the pTT5 vector resulted in very low yields of S-NSP4 in the cell culture supernatant. To
improve the production, different signal peptides and fusions with solubility enhancing carri-
ers such as Sumostar (a version of yeast SUMO, Lifesensors Inc.) were tested. Proteins which
were secreted from HEK 293E cells at very high yields, such as MOG (myelin oligodendro-
cyte glycoprotein) and Lamp2A (lysosome associated membrane protein 2A) were also tried
as fusion partners for NSP4. Improvement could be achieved by exchanging the N-terminal
S-tag peptide to an N-terminal presequence including an N-glycosylation site (SRMHRNGSH;
NGS-NSP4) as described in Liu et al. (2009) for MIC1.
The production could be further enhanced by partially replacing or ’diluting’ the NSP4 plasmid
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with filler DNA for the transfection. To this end, the NSP4 plasmid of interest was mixed with
a bacterial plasmid devoid of any mammalian transcription elements (filler DNA). Figure 3.2 A
depicts a Western blot analysis of S-NSP4 and NGS-NSP4 expressed after transfection with
plasmid of interest in different ratios with filler DNA. For both constructs a plasmid mixture
of 1 to 100 lead to the highest yield of NSP4 in culture supernatants. The yield of NGS-NSP4
was higher than that of S-NSP4 in HEK 293E. NGS-NSP4 is also represented by two to three
bands which is probably the result of heterogenous glycosylation. Transfection of NGS-NSP4
partially replaced with filler DNA resulted in 373 ± 28 µg (n = 2, ± SD) of pure NSP4 from 1
L cell culture volume (Figure 3.2 B).
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Figure 3.2: Production of NSP4 in HEK 293E. A, Cell culture supernatants after transfection
of HEK 293E with S-NSP4 or NGS-NSP4 were analyzed by SDS PAGE and West-
ern blotting with rat anti-NSP4 mAb. The expression was optimized by partially
replacing or ’diluting’ the plasmid of interest (S-NSP4 or NGS-NSP4) with filler
DNA (bacterial plasmid without mammalian elements) for the transfection of HEK
293E. Samples of 24 µl of each supernatant (10 ml in total) were analyzed. The
highest expression yields were obtained with NGS-NSP4 and a ratio of 1:100 of
plasmid of interest and filler DNA (arrow). S-NSP4 is represented by two bands and
NGS-NSP4 is represented by two to three bands which are probably the result of dif-
ferential glycosylation. S-NSP4 features two N-glycosylation sites and NGS-NSP4
three N-glycosylation sites. B, Elution fractions after nickel-chelate chromatogra-
phy of NGS-NSP4 after production in HEK 293E cells in a volume of 350 ml. For
the transfection of cells, the amount of NGS-NSP4 plasmid DNA was reduced to
0.2% and filler DNA was added to 100% (1:500). A sample of 18 µl of each frac-
tion, containing 4 ml in total, was analyzed by SDS PAGE and Coomassie Blue
staining.
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3.1.3 Other recombinant expression systems
Production of NSP4 was also attempted in insect and yeast cells. Insect cell protein expression
was carried out both by Judith Scholl at the MPI Biochemistry (High Five and Sf9) and by
Novartis. The production yields were too low for purification. The expression in yeast cells was
done in pichia pastoris by U-Protein Express (Utrecht, The Netherlands), but NSP4 protein was
undetectable in Western blot analysis.
3.1.4 Conversion of S- or NGS-NSP4 to mature NSP4 by
enterokinase (EK)
Serine proteases of the trypsin/chymotrypsin family like NSP4 are only active after the gen-
eration of a free mature N-terminus. All NSP4 constructs carried N-terminal extensions of the
mature N-terminus to prevent proteolytic activity during recombinant protein expression. The
N-terminal extension consisted of an EK cleavage site and either the S-tag peptide or the NGS-
peptide. Both N-terminal extensions could be removed by EK, resulting in mature NSP4. Figure
3.3 displays S-NSP4 before and after EK digestion. As incubation with EK resulted in a mole-
cular weight shift of all S-NSP4, I assumed that S-NSP4 was completely converted to mature
NSP4.
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Figure 3.3: Conversion of S-NSP4 to mature NSP4 by enterokinase (EK) digestion. Purified
S-NSP4 was concentrated 21-fold and is shown before and after incubation with EK.
Three µl of both samples was analyzed by SDS PAGE and Coomassie Blue staining
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3.2 Characterization of NSP4 in human neutrophils
3.2.1 NSP4 expression is restricted to the myelomonocyte cell
lineage
NSP4 is expressed in polymorphonuclear leukocytes (PMNs), but not in other subsets of white
blood cells. This was already shown in my diploma work. Other tissues, however, were not
tested. To investigate the protein expression of NSP4 in different human tissues, immunohisto-
chemistry was performed by PD Dr. Walter Back (Pathological Institute Bremerhaven, Bremer-
haven, Germany) in cooperation with us. NSP4 was only detected in neutrophils and neutrophil
precursors of bone marrow tissue, but not in lymph node, spleen, neural network, pancreas, pro-
state, or arteries (Figure 3.4). Hence, NSP4 exhibited a tissue-restricted expression pattern very
similar to NE, CG, and PR3.
3.2.2 The amount of NSP4 is 20-fold lower than that of CG in
neutrophils
NE, CG and PR3 are stored in large amounts in neutrophil granules (Campbell et al., 1989) and
they are commonly prepared by purification from human neutrophils. In contrast, the content of
NSP4 in neutrophils was suspected to be low. This would explain why NSP4 was always over-
seen in the past. Using purified NSP4 and CG as a protein standard, semiquantitative Western
blotting with PMN lysates was performed. An exemplary Western blot comparison is shown in
Figure 3.5 (A and B). To compare the expression of CG with NSP4 in human neutrophils, the
content of NSP4 was calculated as a percentage of CG. The results are summarized in Figure
3.5 C. NSP4 in PMNs amounts to only 5% of the CG content.
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Figure 3.4: NSP4 staining of different human tissue samples. NSP4 was detected in neutro-
phil granulocytes and precursors in bone marrow tissue (A and B, at higher mag-
nification in B with arrows). NSP4 was not detected in lymph nodes (C), arteries
(D), neural network (E), spleen tissues (F), prostate (G) or pancreas (H). Scale bars:
A and C-H, 100 µm; B, 50 µm. Staining was carried out by PD Dr. Walter Back
(Pathological Institute Bremerhaven, Bremerhaven, Germany) using our rat anti-
NSP4 mAb (2F6).
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Figure 3.5: The content of NSP4 was 20-fold lower compared to CG. A and B, Western blot
comparisons of different amounts of commercially available CG (purified from hu-
man neutrophils) and PMN lysate (A) and different amounts of recombinant S-NSP4
and PMN lysate (B). CG was detected with mouse anti-CG and NSP4 with rat anti-
NSP4. In this exemplary Western blot, 8 ng of CG was detected in 9 × 103 PMNs
(A, arrows) and 4 ng NSP4 was found in 1× 105 PMNs (B, arrows). Hence, 1× 106
PMNs contain 890 ng CG and 40 ng NSP4. Recombinant S-NSP4 features a higher
molecular weight than natural NSP4 in human neutrophils because of additional N-
and C-terminal sequences (S-tag, EK-site and 6× His-tag, approx. 4.2 kDa in total).
Additionally, in contrast to recombinant NSP4 from HEK 293 cells, natural NSP4
presumably features truncated carbohydrate chains as was already shown for NE
and CG (Watorek et al., 1993). M denotes the molecular weight standard. C, Data
were pooled from three Western blot comparisons of CG and NSP4 in PMNs (n = 3,
± SD). For this comparison, the content of NSP4 in PMNs is given as a percentage
of the content of CG in PMNs.
3.2.3 NSP4 is released after neutrophil activation
In response to neutrophil activation, NE, CG, and PR3 are released into the pericellular en-
vironment. In vitro, this effect can be induced by stimulation of purified human PMNs with
the phorbol ester PMA. Pretreatment with cytochalasin B (cytB), a fungal toxin, was shown
to further increase the release of azurophil granules (Yurewicz and Zimmerman, 1977). To test
whether NSP4 is also released after activation of neutrophils, PMNs were stimulated with cytB
and PMA. After this stimulation, NSP4 was detected in the supernatants by Western blot analy-
sis with anti-NSP4 mAb (Figure 3.6). NSP4 could not be detected in supernatants of PMNs that
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were treated likewise but without cytB and PMA. NSP4, therefore, most likely acts in concert
with the other NSPs.
30
25
kDa + - PMA
+ - cyt B
Figure 3.6: NSP4 was released by activated neutrophils. PMNs were incubated with or with-
out cyt B and PMA for 30 min at 37 ◦C. The cell free supernatants of 4.5 × 106
PMN were analyzed by immunoblotting with rat anti-NSP4 mAb. NSP4 was de-
tected in supernatants of activated PMNs, but not in cells treated without cytB and
PMA.
3.2.4 NSP4 localizes to the azurophil granules of neutrophils
NE, CG and PR3 are found in the primary or azurophil granules of neutrophils. Targeting of
proteins to different subsets of neutrophil storage granules is determined by the time of their
expression (Le Cabec et al., 1996). Expression of a gene during a certain stage of granulocyte
development in the bone marrow is correlated with the intracellular localization of its product.
This question was addressed with the help of Prof. Dr. Niels Borregaard (University of Copen-
hagen, Copenhagen, Denmark). In collaboration with his laboratory, he detected the highest
mRNA levels of NSP4 in the very early stage of myeloblasts/promyelocytes. This finding al-
ready suggested a targeting and sequestration of NSP4 into azurophil granules.
To confirm that NSP4 is stored in the azurophil granules, different subcellular fractions of
neutrophils were assayed (provided by Prof. Dr. Niels Borregaard, Udby and Borregaard (2007)).
After subcellular fractionation of neutrophils, the portions were assayed for specific marker pro-
teins using ELISA by Prof. Dr. Niels Borregaard (Figure 3.7 A). In this way, different fractions
were defined that corresponded (from the bottom) to the α-band, containing primarily the azu-
rophil granules, the β1-band, which comprises the specific granules, the β2-band enriched for
the gelatinase granules, the γ-band including secretory vesicles and plasma membranes, and
the cytosolic fraction (c). All five portions were analyzed by Western blotting using anti-NSP4
mAb. Immunoreactivity was found in the α- and to a minor extent in the β1-band (Figure 3.7
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B,C), which fully agrees with the distribution of MPO, a marker of azurophil granules (Faur-
schou and Borregaard, 2003). This comparison with MPO confirmed that the vast majority of
NSP4 is targeted to and stored in azurophil granules of neutrophils alongside with NE, CG and
PR3.
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Figure 3.7: NSP4 is stored in azurophil granules of neutrophils. A, ELISA analysis showing
the relative concentration of MPO (a marker of azurophil granules), NGAL (a mar-
ker of specific granules), MMP-9 (gelatinase granule marker), HSA (human serum
albumin, marker of secretory vesicles) and HLA (HLA class I antigen, plasma mem-
brane marker) in the subcellular fractions. The fractions were classified into α-, β1-,
β2-, γ-band and the cytosolic fraction (c) as indicated below the graph. This data
was provided by Prof. Dr. Niels Borregaard. B, 2 µl of each subcellular fraction,
representing the amount of sample from 1 × 106 neutrophils, was analyzed by SDS
PAGE and Western blotting with anti-NSP4 mAb. C, The immune-reactive bands in
(B) were quantified using Image Lab 4.1 (Bio-Rad). The results were normalized to
the signal of the α-fraction (n = 3, ± SD).
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3.2.5 Processing of NSP4 precursor by DPPI
The human gene of NSP4 (PRSS57) encodes both a potential signal peptide and a prodipepti-
de (Ala-Gln) at the N-terminus of NSP4. This N-terminal organisation was already reported for
the other NSPs (Korkmaz et al., 2010). During translocation into the endoplasmic reticulum, the
signal peptide is assumedly cleaved off by signal peptidase. The remaining NSP4 precursor is
inactive until its presumed propeptide is removed from the mature N-terminus (Ile-Ile-Gly-Gly)
(see section 1.3.1). To investigate biosynthetic conversion of NSP4 into its mature form, I ex-
amined the processing of the natural NSP4 (NSP4 precursor) by dipeptidyl peptidase I (DPPI,
cathepsin C) in-vitro. DPPI also activates the other NSPs during storage into azurophil gran-
ules. To this end, the full-length natural cDNA sequence of NSP4 with a C-terminal 6×His-tag
was expressed in HEK 293E and purified. Edman sequencing of the purified precursor identi-
fied Ala-Gln-Ile-Ile as the N-terminal residues. As expected, signal peptidase cleavage occured
right before the prodipeptide. The NSP4 precursor was then treated with DPPI and sequenced
again. The sequence obtained was indeed that of the predicted mature N-terminus Ile-Ile-Gly-
Gly. I therefore hypothesized that NSP4 is processed by DPPI to its mature form in neutrophil
precursor cells like all other NSPs.
3.2.6 Patients with Papillon-Lefèvre syndrome (PLS) lack NSP4
in their neutrophils
The absence of DPPI in PLS patients is associated with a severe reduction of all three NSP
activities. Moreover, NE, CG and PR3 are barely detectable in these patients at the protein
level, neither as zymogens nor as mature enzymes (Pham et al., 2004). The effect of DPPI
deficiency on NSP4 in humans was analyzed using PMNs from a PLS patient. The patient was
an 18-year-old man who presented with mild skin findings. He carried a homozygous 854 C >
T mutation in the DPPI gene leading to a P285L amino acid exchange. This mutation has been
reported and characterized and was associated with an almost complete loss of enzyme activity
(Noack et al., 2008). NSP4 was completely undetectable in total cell lysates or supernatants
of activated PMNs in this patient (Figure 3.8). Haptoglobin was used as a control and this
neutrophil granule protein (Theilgaard-Mönch et al., 2006) was detected at comparable levels in
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PMNs from the PLS patient and the healthy control. This finding proves that proNSP4 is indeed
another physiological substrate of cathepsin C and that N-terminally processing is required for
its accumulation in neutrophil granules in vivo.
P PH H
Lys. SN
58
46 Anti-haptoglobin
25
30 Anti-NSP4
kDa
Figure 3.8: NSP4 was not detected in PMNs of a PLS patient. PMNs were isolated from a
PLS patient (P) and compared with PMNs of a healthy control subject (H). Total cell
lysates of 1 × 105 PMNs (Lys.) and supernatants of 3 × 105 PMNs after activation
with cytB and PMA (SN) were probed with rat anti-NSP4 mAb and rabbit anti-
haptoglobin antibody in immunoblotting.
3.3 Functional analysis of NSP4
3.3.1 Proteolytic specificity of NSP4
It is absolutely necessary to determine the proteolytic activity and cleavage specificity of an
unknown protease to elucidate its function. Detailed information about cleavable peptide se-
quences facilitates the discovery of potential protein substrates, which can then point to a bio-
logical role for this protease in a specific biological context. The determination of the specificity
of a protease is furthermore useful to construct specific reporter substrates or inhibitors. In this
way, the activity of a specific protease can be monitored or inhibited, sometimes even in vivo.
Identification of NSP4 cleavage sites in an E. coli proteome
For the initial characterization of the cleavage specificity of NSP4, I collaborated with Dr. Oli-
ver Schilling (University of Freiburg). Purified active NSP4 was analyzed by a recently deve-
loped method called proteomic identification of protease cleavage sites (PICS) (Schilling and
Overall, 2008). Dr. Oliver Schilling used three proteome-derived peptide libraries, generated
with either chymotrypsin, GluC (Staphylococcus aureus Protease V8) or trypsin digestion of
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total E. coli proteins. Chymotrypsin generates peptides by cleaving after aromatic amino acids,
GluC cleaves C-terminal of glutamic acid and trypsin hydrolyzes peptide bonds after basic ami-
no acids, namely lysine or arginine. Some cleavage sites are always eliminated during library
generation due to the cleavages generated by the protease. These cleavage sites are lost in the
peptide library and cannot be analyzed by adding the protease of interest. Three peptide libraries
were generated using three different proteases, as the cleavage specificity of NSP4 was com-
pletely unknown so far. Based on sequence comparisons between NSP4 and the other NSPs, I
expected a specificity similar to NE or PR3. NE and PR3 cleave peptide bonds after aliphatic
residues like Ile, Leu or Val. However, there was also evidence for a trypsin-like specificity and
hydrolysis after Arg.
All peptides that were cleaved by NSP4 can be found in the Appendix (7.5). The results are
summarized in Figure 3.9 A. Indeed, NSP4 showed a strong preference for arginine in P1 with
both GluC and chymotrypsin PICS libraries. The peptides in the trypsin library were already
cleaved by trypsin after arginine residues. Hence, analysis of the trypsin library showed addi-
tional P1 preferences for Gln and Ala. However, without Arg in P1, the preference for Gly in
P1’ is stronger than any preference in P1. The preferred cleavage before Gly in P1’ was shared
in all three libraries.
Comparison of Arg and Lys in P1
Considering size and charge of the side chain, arginine is very similar to lysine. In the prepa-
ration process of peptide libraries for PICS, lysines have to be dimethylated. A specificity to-
wards non-methylated lysines cannot be revealed using the PICS technique. To overcome this,
I compared Arg and Lys in two custom-made fluorescent substrates that were at hand in our
laboratory. These fluorescent AMC (7-Amino-4-methylcoumarin) substrates were alike except
for Arg/Lys in P1 (H-Tyr-Arg-Phe-[Arg/Lys]-AMC). NSP4 displayed a strong selectivity for
Arg in P1, as only cleavage of the Arg-substrate could be observed (Figure 3.9 B).
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Figure 3.9: NSP4 cleaves after Arg in P1 position. A, PICS (proteomic identification of pro-
tease cleavage sites) specificity profile for NSP4 with chymotrypsin, GluC (Staphy-
lococcus aureus Protease V8), and trypsin libraries (from top to bottom) generated
from E. coli. The order and size of the letters for each position corresponds to the
frequency of occurence of these amino acids in the cleaved peptides. Sequence lo-
gos were generated with IceLogo (Colaert et al., 2009). PICS analysis was carried
out by Dr. Oliver Schilling. B, Proteolytic activity of 0.25 µM NSP4 and 1 mM
AMC (7-Amino-4-methylcoumarin) substrates with either Arg or Lys in P1 posi-
tion. Fluorescent signal intensity was determined with excitation at λEx = 370 nm
and light emission at λEm = 450 nm (n = 3, ± SD).
Comparison of NE-substrates and Arg-substrates
To ensure that Arg in P1 is indeed preferred over NE-substrates with aliphatic residues in
P1, six FRET (fluorescence resonance energy transfer) libraries were purchased from Pepta-
nova. Each library contained 25 different FRET substrates of the structure D-A2pr(Nma)-Gly-
[Phe/Ala/Val/Glu/Arg]- [Pro/Tyr/Lys/Ile/Asp] -P1- / -Ala-Phe-Pro-Lys(Dnp)-D-Arg-D-Arg. For
each library, only the P1 position was different. I used libraries with Arg, Ala, Ile, Leu, Met or
Val in P1. The libraries were chosen because too many fixed amino acids in a substrate library
can influence the P1 specificity of a protease. The use of five different amino acids in P3 and
P2 reduces the influence of these positions and enables a better screening of the preferred P1
position. Figure 3.10 shows the activity of NSP4 towards the six libraries in comparison with
NE. Whereas NE showed hydrolyzing activity in all libraries, NSP4 only cleaved substrates in
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the P1-arginine library.
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Figure 3.10: NSP4 prefers Arg in P1 over aliphatic residues. The proteolytic activities of re-
combinant NSP4 and NE (Elastin products) were assayed with six different FRET
libraries (25 peptides in each) with different amino acids in P1 position. The activ-
ity was determined as increasing fluorescence over time for each library and each
enzyme. The initial linear portion of the progress curve was used to calculate the
enzymatic activity in RFU/min (increase of relative fluorescence units per minute).
Average values with standard deviations (SD) are given as a percentage of the va-
lue of the library that was cleaved best by the tested protease. The maximum value
was set to 100%. (NSP4: n=3, NE: n=2; ± SD).
3.3.2 Chemical inhibitors of NSP4
PMSF
A standard irreversible inhibitor for serine proteases is PMSF. The inhibition of NSP4 by PMSF
was tested with different concentrations of PMSF and compared to the inhibition of NE by
PMSF (Figure 3.11). The initial linear portion of the graph was used to evaluate the concentra-
tion of PMSF needed for 50% inhibition (IC 50). The IC 50 for NE was estimated to be 80 µM
± 4.4 µM and the IC 50 for NSP4 was estimated 705 µM± 51 µM. PMSF inhibited NE 9-fold
better than NSP4.
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Figure 3.11: PMSF inhibits NE better than NSP4. Inhibition of 50 nM NSP4 or NE by in-
creasing amounts of PMSF. NSP4 and NE were preincubated with PMSF and the
residual activity was measured using FRET substrates (the α1PI FRET substrate
Mca-GEAIPM-SIPPEV-Lys [Dnp]-rr for NE and Mca-GFKVR-SRP-Lys [Dnp]-rr
for NSP4) at 13 µM. The activity of protease without inhibitor was set to 100%
(n=3 ± SD).
FPR-cmk
In search for more efficient inhibition of NSP4, a chloromethylketone was tested with Phe-Pro-
Arg in the P3-P1 positions (FPR-cmk), a specific inhibitor for serine proteases with arginine-
specificity. NSP4 was preincubated with this inhibitor and Figure 3.12 illustrates that NSP4 was
completely inhibited by 50 µM FPR-cmk.
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Figure 3.12: NSP4 is strongly inhibited by FPR-cmk. Inhibition of 100 nM NSP4 by different
amounts of FPR-cmk. The residual activity was measured using a FRET substra-
te (Mca-GFPR-SRP-Lys [Dnp]-rr) at 10 µM final concentration. The activity of
protease without inhibitor was set to 100% (n = 3 ± SD).
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3.3.3 Natural inhibitors of NSP4
The inhibitory capacity of natural human serine protease inhibitors from blood or neutrophils on
NSP4 was assayed by cleavage of H-Tyr-Arg-Phe-Arg-AMC by NSP4 after preincubation with
inhibitors. I tested the inhibitors in different concentrations. I tried to use high molar excess
of inhibitor over protease but of some inhibitors I had to use less than of others because of
the amounts that were at hand in our laboratory at that time. However, I tested all inhibitors
in at least 10-fold molar excess over NSP4. Many proteases are not inhibited at equimolar
concentrations of inhibitor and protease, but only at molar excess of inhibitor over protease.
Addition of 100-fold excess ofα1PI, 22-fold excess of heparin accelerated antithrombin and 10-
fold excess of C1 inhibitor completely prevented NSP4 activity. NSP4 activity was not inhibited
by 40-fold excess of elafin, 40-fold excess of SLPI, 13-fold excess of MNEI or 22-fold excess
of ACT (Figure 3.13 A).
Complexation with Serpins
α1PI, antithrombin and C1 inhibitor are serpins that, in most cases, form covalent complexes
with the inhibited protease. The covalent complexes can only form after the protease has hy-
drolyzed a specific bond in the reactive center loop (RCL) of the serpin. Complex formation
between NSP4 and these three serpins was studied by immunoblotting after different incuba-
tion times with these inhibitors using anti-NSP4 mAb. As I intended to analyze which of these
potential natural inhibitors would be the fastest to inhibit NSP4 in in vivo situations, α1PI,
heparin-activated antithrombin and C1 inhibitor were used at concentrations found in human
plasma (Hortin et al., 2008), resulting in a 50-, 6.5-, or 5-fold molar excess of inhibitors, respec-
tively. NSP4 formed covalent complexes with all three serpins as shown by the immunoreactive
bands at approximately 80-90 kDa (Figure 3.13 B). Complexes with α1PI could be detected
only after 30 min of incubation, whereas the complexation with heparin-activated antithrombin
and C1 inhibitor could be observed already after 1 min and 5 min, respectively. The cleavage
site in the RCL (reactive center loop) of α1PI is after Met, while antithrombin and C1 inhibitor
feature an arginine residue in the P1 position of their RCL. This observation again confirms that
NSP4 preferably hydrolyzes peptide bonds C-terminal of arginine. After prolonged incubation
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times with α1PI, antithrombin or C1 inhibitor, there was still some uncomplexed NSP4 seen by
Western blotting. As the proteolytic activity of NSP4 was completely abolished by these three
serpins (Figure 3.13 A), a proportion of NSP4 is most likely inactive due to incorrect folding or
aggregation.
A
B
NS
P4
+ e
laf
in
+ S
LP
I
+ α
1P
I
+ M
NE
I
+ a
nti
thr
om
bin
+ C
1 I
nh
ibi
tor
+ A
CT
100
80
60
40
0
20
A
ct
iv
ity
 [%
]
175
80
58
46
30
25
kDa
α1PI C1 inhibitor antithrombin
0.5 100305time [min] - - - 0.5 100305 0.5 100305- -
NSP4 + ++- + +++ - ++ + ++- + +
Serpin - ++++ ++++ ++ - ++++ +
NSP4
NSP4-
serpin-
complexes 
Figure 3.13: NSP4 is inhibited by α1PI, antithrombin and C1 inhibitor and forms cova-
lent complexes with these serpins. A, 0.25 µM NSP4 was incubated with 10 µM
elafin, 10 µM SLPI, 25 µM α1PI, 3.3 µM MNEI with 1 mM DTT, 5.6 µM anti-
thrombin with 300 U/mL heparin, 2.5 µM C1 inhibitor, or 5.6 µM ACT in 50 µl.
The residual activity of NSP4 was determined by measuring the hydrolysis rate
of H-Tyr-Arg-Phe-Arg-AMC. The activity of NSP4 without inhibitor was set to
100%. Shown data are the mean from three independent experiments (n = 3, ±
SD) with exception of MNEI and ACT (n = 2, ± SD). B, 0.8 µM NSP4 were
kept at 37 ◦C with 40 µM α1PI, 4 µM C1 inhibitor or 5 µM antithrombin with
300 U/mL heparin and samples of 2 µl were analyzed after different timepoints
by immunoblotting with anti-NSP4 mAb. NSP4 or the serpins alone were treated
similarly for comparisons.
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3.3.4 Positional specificity profiling of NSP4
Specificity analysis has unequivocally revealed a preference of NSP4 for arginine in P1. With
this in mind, I wanted to study the impact of residues in the adjacent positions in more de-
tail. Additional amino acids in close proximity to the scissile bond can also potently influence
the cleavage preferences of NSP4. Analysis of the extended specificity of NSP4 for P4-P2’
should facilitate the construction of specific substrates and inhibitors. Furthermore, information
on amino acids that were preferred, accepted or excluded in certain positions by NSP4 will
assist in selecting potential natural substrates of NSP4. For the detailed analysis of the posi-
tions P4-P2’, intramolecularly quenched fluorogenic (förster resonance energy transfer, FRET)
substrates with arginine in P1 were used. FRET substrates can by synthesized with extended
peptide sequences before and after the scissile bond. Extended peptide sequences around the
scissile bond are known to increase both sensitivity and specificity of proteases towards a sub-
strate.
P3P2 preference of NSP4 (FRETS25Arg)
The starting point was the FRETS-25Arg library from Peptanova. The library was analyzed by
LC-MS after incubations with NSP4. The company provides the user with information on ac-
curate molecular weights of the resulting peptide fragments after all possible cleavage events.
Using this information, the LC-MS data generated by Elisabeth Weyher-Stingl (MPI Bioche-
mistry) permitted me to identify those substrates that were cleaved by NSP4. As early as 5
min of incubation with NSP4, cleavages of substrates with the P3-P2 combinations Phe-Pro,
Phe-Tyr, Phe-Ile, Val-Pro, Arg-Pro, Val-Ile, Val-Lys and Arg-Ile could be detected. To identify
unique substrates for NSP4, the library was also incubated with NE, CG and PR3. None of
the peptide substrates was cleaved by CG and PR3. NE, however, was capable of digesting all
substrates carrying an Ile in the P2 position. On account of this elastase activity, a Phe and a
Pro was chosen for the positions P3 and P2, respectively, in further profiling experiments. This
substrate was cut by NSP4 very fast. Pro confers a high degree of peptide resistance to other
serine proteases as serine proteases do not cleave before and after proline residues. Placing a
Pro in P2 prevents the cleavage after P3 as well as before P1.
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P1’P2’ preference of NSP4
A small collection of FRET peptide substrates with varying amino acids at the P1’ and P2’ posi-
tions was kindly provided by Prof. Dr. Karl-Heinz Wiesmüller (EMC microcollections, Tübin-
gen, Germany). This library of 49 individual FRET substrates featured the sequences Mca-Gly-
Phe-Pro-Arg-[Phe/Val/Ser/Asn/Glu/Arg/Gly]-[Phe/Val/Ser/Asn/Glu/Arg/Gly]-Pro-Lys(Dnp)-D-
Arg-D-Arg. All substrate sequences are given in the Appendix (7.4). Seven characteristically
different amino acids were used for the P1’ and P2’ positions. The enzymatic activity of NSP4
with each substrate is shown in Figure 3.14 A. For the enzymatic activity on FRET substrates
only 25-40 nM NSP4 and 1-2 µM substrate were used. As expected, the efficacy of cleavage
was already much better than with AMC substrates. The four best FRET substrates from this
P1’P2’ library (P1’-P2’: S-F, S-S, S-N, S-R) were also examined for potential susceptibility
to NE, CG or PR3-mediated hydrolysis (Figure 3.15 A). None of the three NSPs showed en-
zymatic activity towards these substrates. For further profiling studies, positions P1’ and P2’
were fixed to Ser-Arg as this combination was most efficiently cleaved by NSP4 and specific
for NSP4.
P4P3 preferences of NSP4
The amino acid residues in P4 and P3 were varied in a similar manner yielding 49 individual
FRET substrates (a kind gift from Prof. Dr. Karl-Heinz Wiesmüller) with the following se-
quences, Mca-Gly-[Phe/Ala/Ser/Asn/Glu/Arg/Gly]-[ Tyr/Ala/Ser/Asn/Asp/Lys/Gly]-Pro-Arg-
Ser-Arg-Pro-Lys(Dnp)-D-Arg-D-Arg. The enzymatic turnover of these individual substrates by
NSP4 is shown in Figure 3.14 B. To demonstrate specificity, the three best substrates (P4-P3:
F-K, A-K, A-N) were assayed for cleavage by the other NSPs. Figure 3.15 B shows that all
three are specific for NSP4 as they were not hydrolyzed by NE, CG or PR3. For the final step
of improving the P2 residue, the best combination Phe-Lys was fixed at the P4 and P3 position,
respectively.
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Figure 3.14: NSP4 specificity analysis with FRET substrates. Fluorescent signals were moni-
tored at λEx = 320 nm and λEm = 405 nm. Results were normalized to the signal
of the best substrate and are given in percent (n = 3, ± SD). A, Enzymatic activity
of NSP4 cleaving FRET substrates with 49 different amino acid combinations at
positions P1’ and P2’. NSP4 was added to a final concentration of 40 nM, each
FRET substrate was present at 2 µM. B, Profiling of positions P4 and P3. Proteo-
lytic activity of NSP4 towards 49 FRET substrates differing in positions P4 and
P3. NSP4 was added to a final concentration of 40 nM, each FRET substrate was
present at 1 µM. C, Profiling of the P2 position. Enzymatic activity of NSP4 cleav-
ing 19 FRET substrates with different amino acids in P2. NSP4 was added to a
final concentration of 25 nM, each FRET substrate was present at 1 µM.
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Figure 3.15: Specificity of FRET substrates towards NSP4. Fluorescent signals were moni-
tored at λEx = 320 nm and λEm = 405 nm. Results were normalized to the signal
initiated by NSP4 and are given in percent (n = 3, ± SD).A, Enzymatic activity
of NSP4 in comparison to NE, CG and PR3 using the best substrates from Figure
3.14 A. All proteases were used at 100 nM and the FRET substrates at 20 µM.
B, Enzymatic activity of NSP4 in comparison to NE, CG and PR3 using the best
substrates from Figure 3.14 B. All proteases were used at 100 nM and the FRET
substrates at 10 µM. C, Enzymatic activity of NSP4 in comparison to NE, CG and
PR3 using the best substrates from Figure 3.14 C. All proteases were used at 50
nM and the FRET substrates at 5 µM.
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P2 preferences of NSP4
The P2 preferences of NSP4 were determined in a library of 19 individual FRET substrates
(kindly synthesized by Prof. Dr. Karl-Heinz Wiesmüller). The substrates of the structure Mca-
Gly-Phe-Lys-P2-Arg-Ser-Arg-Pro-Lys (Dnp)-D-Arg-D-Arg comprised all natural amino acids
in position P2 except Cys. Cysteine was omitted due to its potential to form disulfide bonds
by oxidation. The five substrates cleaved best by NSP4 featured Val, Leu, Ala, Pro or Ile in
P2 (Figure 3.14 C). All in all, these data agree with our initial screening of the FRETS-25Arg
library yielding Pro, Ile, Tyr and Lys in P2. Cleavage of the four best substrates (the substrate
with Pro in P2 was already given in Figure 3.15 B) by CG or PR3 was not detectable. There
was, however, a very low activity of NE towards the substrates with Ile or Val in P2. Even if
Val in P2 increases the cleavage efficacy by NSP4, Pro in P2 increases the specificity of the
substrates by preventing cleavages N- or C-terminal of Pro by all NSPs.
With these highly improved and specific substrates of NSP4, detection of NSP4 activity in PMN
lysate and after PMN degranulation was examined. Unfortunately, it was not possible to detect
NSP4 activity in these biological samples. Considering the low levels of NSP4 in neutrophils
(see 3.2.2), I suspected that our FRET substrates were still not sensitive enough.
3.3.5 Production of an NSP4 reactive serpin forming covalent
complexes (α1PI*)
The proteolytic activity of a protease can be demonstrated by the formation of a covalent com-
plex with a serpin, as shown in section 3.3.3. To test whether NSP4 is active in neutrophil lysates
and after neutrophil activation, a specific serpin for NSP4 was required. α1PI could not be used
because it reacts much faster with NE than with NSP4. Antithrombin could not be used be-
cause it is degraded very rapidly by NE (Jochum et al., 1981; Jordan et al., 1987). To overcome
these problems, I constructed a tailor-made, optimized α1PI variant with targeted specificity
for NSP4. The P4 to P1 residues of the RCL of α1PI were changed from Ala-Ile-Pro-Met to
Ile-Lys-Pro-Arg (α1PI*). Ile in P4 was adopted from antithrombin. Lys-Pro-Arg in P3-P2-P1
were taken from the specificity profiling in section 3.3.4. I chose Pro in P2 over Val, Ile and
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Ala, because it prevented the cleavage by other serine proteases before and after the P2 posi-
tion. This Pro was expected to increase the stability of α1PI*. The sequence of the optimized
RCL was evaluated as a FRET peptide substrate (Mca-Gly-Ile-Lys-Pro-Arg-Ser-Arg-Pro-Lys
(Dnp)-D-Arg-D-Arg). This FRET substrate perfomed comparably well against the best FRET
derived from the specificity profiling (Mca-Gly-Phe-Lys-Val-Arg-Ser-Arg-Pro-Lys (Dnp)-D-
Arg-D-Arg) (Figure 3.16 A). Moreover, the other NSPs did not cleave this FRET substrate
(Figure 3.16 B).
α1PI* was produced in HEK 293E after transient transfection and was represented by two bands
after SDS PAGE and silver staining (Figure 3.16 C). Figure 3.16 D depicts α1PI* analyzed by
Western blotting with anti-α1PI antibody after incubation with NSP4, NE, PR3 or CG. α1PI*
formed a covalent complex with NSP4 that is visible after 5 min and 30 min of incubation.
Without NSP4, the upper α1PI* band was the major α1PI*-band. After addition of NSP4, only
α1PI* of the upper band appears to have formed a complex with NSP4, as only the density of
this band was reduced. α1PI* that is represented by the lower band seems to be inactive. PR3
did not form a covalent complex with α1PI* or degrade it. After 5 min of incubation with NE,
the upper band of α1PI* was not detected anymore and after 5 min of incubation with CG,
α1PI* was probably completely degraded. Formation of the covalent complex of α1PI* and
NSP4 is specific for NSP4 as it did not occur with PR3, NE or CG.
The two bands of α1PI* could be explained either by proteolytic truncation or differential gly-
cosylation patterns. α1PI* features three potential N-glycosylation sites. Proteolytic truncation
of α1PI* could have occurred during expression in HEK 293E. Several matrix metalloprotein-
ases including collagenase (MMP-1) (Mast et al., 1991) or gelatinase B (MMP-9) (Liu et al.,
2000) can cleave α1PI and destroy its inhibitory activity. Both of these proteases were shown
to be expressed in HEK cells (Liu and Wu, 2006). This would also explain, why the lower band
of α1PI* seems inactive. α1PI* of the upper band was probably cleaved and inactivated by NE
which results in a merge of the two bands in a single lower band.
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Figure 3.16: Production of an NSP4 specific serpin and detection of active NSP4 in neutro-
phil lysate and released by activated neutrophils. A, Enzymatic activity of
25 nM NSP4 cleaving the best substrate from Figure 3.14 (FKV, Mca-Gly-Phe-
Lys-Val-Arg-Ser-Arg-Pro-Lys [Dnp]-D-Arg-D-Arg) in comparison to the FRET
peptide sequence designed for α1PI* (IKP, Mca-Gly-Ile-Lys-Pro-Arg-Ser-Arg-
Pro-Lys [Dnp]-D-Arg-D-Arg), both at 1 µM (n = 3, ± SD). B, Enzymatic activity
of NSP4 cleaving the α1PI* FRET (5 µM) in comparison to the other NSPs. All
proteases were used at final concentrations of 50 nM (n = 2, ± SD). C, α1PI*
was recombinantly expressed in HEK 293E and is shown after SDS PAGE and sil-
ver staining. α1PI* is represented by two bands that either result from proteolytic
truncation during expression in HEK 293E or from heterogenous glycosylation. D,
α1PI* was incubated with NSP4, NE, PR3 or CG and analyzed after different in-
cubation times by immunoblotting with anti-α1PI antibody. E, Total cell lysates of
human neutrophils or supernatants of cytB and PMA stimulated neutrophils were
incubated with or without α1PI* and analyzed by Western blotting with anti-NSP4
mAb. 71
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3.3.6 Detection of active NSP4 in neutrophil lysate and released
by neutrophils
The NSP4-optimized serpin α1PI* was employed to detect active NSP4 in total cell lysates
of human neutrophils. Furthermore, human neutrophils were activated by cytB and PMA and
the resulting supernatants were also incubated with α1PI*. The samples were analyzed after
different incubation times by Western blotting with anti-NSP4 mAb. Figure 3.16 E shows that
NSP4 in neutrophil lysates and after degranulation is completely active and forms a covalent
complex with α1PI*. As early as 1 min, the heterodimeric band of α1PI* and NSP4 could be
observed. After 30 min, the complex was most likely degraded by other proteases in the sample,
while NSP4 in the sample without α1PI* is still visible. In vitro, in the absence of additional
proteases, degradation of the α1PI*-NSP4 complex did not occur (Figure 3.16 D). Proteases of
the trypsin/chymotrypsin family were reported to become susceptible to degradation by several
proteases after serpin-complexation (Stavridi et al., 1996; Huntington et al., 2000).
This finding strongly indicates that NSP4 is stored and released by PMNs as an active endopro-
teinase. This result was expected, as NSP4 was not detected and most likely degraded in PMNs
of a PLS-patient (3.2.6) without DPPI convertase activity.
3.4 Is PAR-2 a potential natural substrate of NSP4?
Potential natural substrates of NSP4 were chosen on the basis of the specificity of NSP4 and
accessibility of the substrate to NSP4 during neutrophil responses. Only pericellular and mem-
brane proteins that come into close contact with active NSP4 can be cleaved by NSP4. Several
possible natural substrates of NSP4 were tested for this thesis, like complement C3, prorenin,
hepatocyte growth factor, haptoglobin or SIRP-alpha. So far, cleavage of these substrates by
NSP4 could not be shown in-vitro. Here, I will only present the data on PAR-2 as a potential
natural substrate of NSP4.
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3.4.1 PAR-2 FRET
PAR-2 is activated by proteolytic cleavage and the amino acids at the cleavage site fit very
well to the specificity profile of NSP4. Initially, I tested the cleavage of PAR-2 by NSP4 using
a FRET substrate derived from the activation cleavage site of PAR-2 (Abz-GSKGR-SLIG-Y
(NO2)-D). Figure 3.17 depicts the enzymatic activity of NSP4 towards the PAR-2 peptide sub-
strate. S-NSP4 (unconverted pro-form) and enterokinase did not cleave the PAR-2 FRET.
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Figure 3.17: Enzymatic activity of NSP4 hydrolyzing the PAR-2 peptide substrate. The
FRET substrate Abz-GSKGR-SLIG-Y (NO2)-D is derived from the activation
cleavage site of PAR-2 and was efficiently cleaved by NSP4, but not by its proform
(S-NSP4) or its convertase (EK, enterokinase). The FRET substrate was present at
200 µM, NSP4 or proNSP4 at 2.4 µM and EK at 1.2 × 10-3 U/µl (n = 2, ± SD).
3.4.2 NSP4 triggered calcium signaling in HaCaT, but not in
HT1080
Activation of PAR receptors results in intracellular calcium signaling. The effect of NSP4 on
calcium signaling in HaCaT and HT1080 cells was investigated together with Luisa-Astrid
Fratila in the laboratory of Prof. Dr. Christian Sommerhoff (Institut für Laboratoriumsmedizin,
LMU, München). Calcium signaling was monitored using Fluo-4 AM, a calcium sensitive dye.
HaCaT cells are derived from keratinocytes which predominantly express PAR-2 and lower
levels of PAR-1, -3 and -4 (Santulli et al., 1995), whereas HT1080 is a fibrosarcoma cell line that
expresses higher levels of PAR-1 and lower levels of PAR-2, -3 and -4. As positive controls we
used bovine trypsin, which activates mainly PAR-2 but also PAR-1, -3 and -4 (Steinhoff et al.,
2005), and bovine thrombin, which activates PAR-1, -3 and -4, but not PAR-2 (Shpacovitch
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et al., 2008). NSP4 addition lead to an increase in calcium levels in HaCaT cells (Figure 3.18
A), but not in HT1080 cells (Figure 3.19 A). If this process was triggered by PAR receptors,
it would suggest signaling through PAR-2, as HaCaT are high and HT1080 are low in PAR-2
receptor expression. As expected, the signal generated by trypsin was higher in HaCaT (Figure
3.18 B) than in HT1080 (Figure 3.19 B), while the effect of thrombin was stronger in HT1080
(Figure 3.19 C) than in HaCaT (Figure 3.18 C). The unprocessed zymogen of NSP4 (S-NSP4)
was used as a negative control and had no effect on the calcium levels in HaCaT (Figure 3.18
D).
We tested 2 µM, 1 µM, 100 nM and 10 nM NSP4. Only with 2 µM and 1 µM NSP4, an increase
in calcium levels could be detected. So the effect of NSP4 on HaCat was far lower compared to
the effect of trypsin, which was still detectable at 1 nM concentration. As noted in section 3.3.3,
the recombinantly expressed NSP4 is partly inactive. But even if we assume that only 40% of
NSP4 molecules are active, the concentration of NSP4 required for calcium increase in HaCaT
cells is still very high.
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Figure 3.18: NSP4 triggered calcium signaling in HaCaT cells. HaCaT cells were pretreated
with the calcium sensitive dye Fluo4 AM. In this way, intracellular increase in
calcium levels could be monitored at λE = 494 nm and λEm = 516 nm. The cells
were treated with different amounts of NSP4 (A), trypsin (B) or thrombin (C).
Stimulation by the NSP4 zymogen (S-NSP4) or NSP4 buffer (EK buffer) served as
controls and are shown in D. The time point of stimulation is indicated by a vertical
arrow. Data are representative of n = 2 experiments that were carried out together
with Luisa-Astrid Fratila (Institut für Laboratoriumsmedizin, LMU, München).
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Figure 3.19: Calcium levels in HT1080 cells after treatment with NSP4, trypsin or throm-
bin. HT1080 cells were pretreated with the calcium sensitive dye Fluo4 AM. In
this way, intracellular increase in calcium levels could be monitored at λE = 494
nm and λEm = 516 nm. The cells were treated with different amounts of NSP4
(A), trypsin (B) and thrombin (C). The time point of stimulation is indicated by an
arrow. Data are representative of n = 2 experiments that were carried out together
with Luisa-Astrid Fratila (Institut für Laboratoriumsmedizin, LMU, München).
3.4.3 PAR-2 but not PAR-1 agonists prevented NSP4 induced
calcium signaling in HaCaT cells
Although the NSP4 concentration required for calcium increase in HaCaT cells was very high
compared to trypsin, I was interested whether the calcium increase was triggered by PAR-2
activation. Many external stimuli can lead to calcium fluxes across cellular membranes. To this
76
3.4 Is PAR-2 a potential natural substrate of NSP4?
end, Luisa and I analyzed the effect of NSP4 on calcium signaling in HaCaT after desensiti-
zation with PAR-1 and PAR-2 specific agonist peptides. These peptides were derived from the
activating sequence of the respective PAR. The cells were first treated with the agonist peptides.
This should result in PAR activation and removal of the receptor from the cell surface. Subse-
quent stimulation by a PAR activating protease would then result in a reduced calcium signal.
In control experiments, successful desensitization was examined using trypsin. Pretreatment of
HaCaT with the PAR-1 agonist did not impair the calcium increase after trypsin treatment (Figu-
re 3.20 C). Treatment with the PAR-2 agonist before trypsin lead to 50% decrease of the calcium
signal that could be generated by trypsin (Figure 3.20 D). This is in complete accordance with
trypsin cleaving predominantly PAR-2, but also PAR-1, -3 and -4 with lower efficacy. Presti-
mulation of HaCaT by the PAR-1 agonist peptide before NSP4 exposure did not reduce the
calcium signal generated by NSP4 (Figure 3.20 A). However, desensitization with the PAR-2
agonist completely prevented calcium signaling in response to stimulation with NSP4 (Figure
3.20 B).
This data strongly indicates that the calcium increase in HaCaT cells in response to NSP4 was
due to PAR-2 activation by this novel neutrophil serine protease. Nevertheless, the relevance
of NSP4 activating PAR-2 in vivo is questionable because the calcium increase in HaCaT cells
was only triggered by NSP4 at rather high concentrations (1 µM).
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Figure 3.20: Calcium signaling in HaCaT in response to NSP4 or trypsin after pretreat-
ment with PAR-1 or 2 agonist peptides. After pretreatment of HaCaT with Fluo4
AM, intracellular calcium signaling was followed at λEx = 494 nm and λEm = 516
nm. First, cells were desensitized with PAR-1 activating peptides (H-Thr-Phe-Leu-
Leu-Arg-NH2) (A, C) or Par-2 activating peptides (H-Ser-Leu-Ile-Gly-Lys-Val-
NH2) (B, D) at concentrations of 200 µM and 50 µM, respectively (arrow 1) and
then treated with 1 µM NSP4 (A, B) or 0.8 µM trypsin (C, D) for comparison (ar-
row 2). Data are representative of n = 2 experiments that were carried out together
with Luisa-Astrid Fratila (Institut für Laboratoriumsmedizin, LMU, München).
3.5 NSP4 in the mouse
The mouse homolog of NSP4 (mNSP4) (gene symbol Prss57) was studied at the protein level
by expressing the mouse cDNA and its potential role in vivo was evaluated using knockout
embryos that were purchased from MMRRC (UC Davis, Davis, California, USA). Firstly, I
wanted to see whether mNSP4 featured a similar cleavage specificity to that of human NSP4.
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The two species homologs share 77.4% sequence identity. Hence, a conserved specificity and
function in human and mouse was anticipated.
3.5.1 Production of mNSP4
A precursor of mNSP4, S-mNSP4, was expressed in HEK 293E. Transfection was carried out
with 90% of S-mNSP4 plasmid replaced by filler DNA (a bacterial plasmid devoid of any mam-
malian transcription elements) (1:10). The yield of S-mNSP4 after nickel affinity chromatogra-
phy was 180 µg per 1 L expression culture. The elution fractions are shown in Figure 3.21 A.
Complete conversion of S-mNSP4 to mature mNSP4 was achieved after enterokinase digestion
(Figure 3.21 B).
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Figure 3.21: Production of mNSP4 in HEK 293E. A, Elution fractions after nickel-chelate
chromatography of S-mNSP4 after expression in HEK 293E in a volume of 600 ml.
For the transfection of cells, the plasmid encoding S-mNSP4 was reduced to 10%
and filler DNA was added to 100% (1:10). A sample of 18 µl of each fraction, con-
taining 4 ml in total, was analyzed by SDS PAGE and silver staining. S-mNSP4
is represented by two bands which are probably the result of heterogenous gly-
cosylation, as it features two N-glycosylation sites. B, S-mNSP4 was concentrated
25-fold and is shown before and after incubation with EK. Three µl of each sample
was analyzed by SDS PAGE and Coomassie Blue staining.
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3.5.2 Specificity comparison between human and mouse NSP4
The specificity of mNSP4 was analyzed in comparison to human NSP4. I used three character-
istic FRET substrates that were used for profiling the P2 position of NSP4. Figure 3.22 indicates
that mNSP4 also hydrolyzed substrates with arginine in the P1 position. Furthermore, mNSP4
displayed the same preference for Val over Ser and Asp in P2 like human NSP4.
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Figure 3.22: Specificity comparison of human and mouse NSP4. Enzymatic activity of NSP4
and mNSP4 cleaving three individual FRET substrates with Val, Ser or Asp in P2
position. NSP4 and mNSP4 were used at concentrations of 25 nM and the FRET
substrates were present at 1 µM. Fluorescent signals were monitored at λEx = 320
nm and λEm = 405 nm. Results were normalized to the signal of the substrate
cleaved best by NSP4 and are given in percent (n = 3, ± SD).
3.5.3 Analysis of mNSP4 mRNA in WT and NSP4-/- mice
The NSP4 knockout mouse model was obtained as cryopreserved embryos that were either
heterozygous for the NSP4 knockout or homozygous for the wildtype (WT) gene. The mice
were genotyped by PCR and bred to homozygosity in order to establish an NSP4-deficient
mouse colony. Non-transgenic littermates were used as WT control mice.
The rat mAb for human NSP4 did not cross-react with mNSP4. Therefore, the knockout of
NSP4 in the mouse line was confirmed by RT-PCR. The transcript of mNSP4 was detected in
bone marrow cells of WT animals but not in NSP4-/- mice. β-actin served as a control and
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its transcript could be verified in both WT and NSP4-/- mice (Figure 3.23). The expression of
NSP4 in mouse bone marrow once again suggests functional conservation in mouse and man.
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Figure 3.23: RT-PCR analysis of mNSP4 in WT and knockout mice. Bone marrow of WT
(+/+) or NSP4-/- mice was probed by RT-PCR for mRNA transcripts of mNSP4 or
mouse β-actin. Samples are shown after 3% agarose gel electrophoresis.
3.5.4 Production of reactive oxygen species (ROS) was not
impaired in NSP4-/- mice
Neutrophil function in NSP4-/- and WT mice was tested by stimulation of neutrophils with
PMA and measurements of ROS (the oxidative burst). This is a frequently used readout to
determine cellular activation of neutrophils. Activation by the phorbol ester PMA is receptor-
independent and was shown to directly activate protein kinase C (Castagna et al., 1982), resul-
ting in the production of ROS. To this end, mouse neutrophils were isolated from bone marrow
and treated with PMA. ROS production was monitored after addition of dihydrorhodamine 6G,
a dye that becomes fluorescent upon oxidation. Figure 3.24 illustrates that there was no signifi-
cant difference in PMA triggered oxidative burst in NSP4-/- compared to WT neutrophils. Thus,
the production of ROS by neutrophils was generally functional in NSP4-deficient mice.
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Figure 3.24: Oxidative burst in NSP4-/- neutrophils compared to WT neutrophils in re-
sponse to PMA. Mouse PMNs were isolated from NSP4-/- or WT-mice and sti-
mulated with PMA. Unstimulated cells were used as a control for PMA activation.
As a readout for neutrophil activation, I measured neutrophil oxidative burst over
time. For this, the cells were treated with dihydrorhodamine 6G, a dye that be-
comes fluorescent upon oxidation. The fluorescent signal was recorded at λEm =
520 nm with excitation at λEx = 485 nm. Representative Data and SD of tripli-
cates are shown in A. Results of independent experiments were normalized to the
oxidative burst in WT neutrophils (n = 4, ± SD) and are shown in B.
3.5.5 Neutrophil activation by immune complexes was not
impaired in NSP4-/- mice
In many human diseases, the formation of immune complexes (ICs) is an important trigger
of neutrophil activation and neutrophil-dependent inflammation (Jancar and Sánchez Crespo,
2005). Analysis of neutrophil function in double knockout mouse models of CG/NE (Raptis
et al., 2005) or NE/PR3 (Kessenbrock et al., 2008) revealed impaired production of ROS upon
stimulation with ICs. Activation by ICs is different from PMA activation in that it is media-
ted via Fcγ receptors and β2 integrins in PMNs (Zhou and Brown, 1994). To test activation of
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NSP4-/- neutrophils by ICs, ovalbumin (OVA) was immobilized on microtiter plates and treated
with anti-OVA rabbit serum. For unstimulated controls, treatment with anti-OVA was omitted.
Isolated neutrophils were primed with TNF-α and added to the immobilized ICs or to immo-
bilized OVA. Treatment with TNF-α increases the abundance and activity of receptors on the
plasma membrane, such as the complement receptors or Fcγ receptors. Determination of the
reactive burst in neutrophils from NSP4-/- mice in comparison to WT control mice revealed no
difference in IC-mediated neutrophil activation (Figure 3.25).
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Figure 3.25: Oxidative burst in NSP4-/- neutrophils compared to WT neutrophils in re-
sponse to immune complexes (ICs). Mouse PMNs were isolated from NSP4-/- or
WT-mice and stimulated with TNF-α and ICs (ovalbumin and anti-ovalbumin).
TNF-α primed PMNs were placed on immobilized ovalbumin without anti-
ovalbumin antibodies to serve as a control. As a readout for neutrophil activation,
I measured neutrophil oxidative burst over time. For this, the cells were treated
with dihydrorhodamine 6G, a dye that becomes fluorescent upon oxidation. The
fluorescent signal was recorded at λEm = 520 nm with excitation at λEx = 485 nm.
Representative Data and SD of triplicates are shown in A. Results of independent
experiments were normalized to the oxidative burst in WT neutrophils (n = 5, ±
SD) and are shown in B.
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4 Discussion
4.1 NSP4, a novel neutrophil protease highly
conserved in evolution
In the present study, I identified a fourth active serine protease which is stored in azurophil gran-
ules of neutrophils, and therefore gave it the name of NSP4. NSP4 has so far been overlooked
and not considered in neutrophil research. The reason for NSP4 escaping discovery for so long,
despite intense investigations of NE, CG and PR3, may be found in the lower content of NSP4
in neutrophils (Figure 3.5).
The gene of NSP4 (PRSS57) was identified in the telomeric region of the short arm of human
chromosome 19, in a distance of about 200 kb from the AZU1-PRTN3-ELANE-CFD gene
cluster. Homologs of NSP4 are also found in all known mammals that have been sequenced.
Even in birds (chicken and zebra finch) and bony fishes (Tetraodon and zebrafish), NSP4-like
genes can be identified and are physically linked to the same unrelated genes as in humans
(namely FGF22 and POLRMT). While the zebra finch genome contains only one copy, NSP4
was expanded in fishes and is represented by a cluster of several paralogous genes. The presence
of NSP4 homologs in birds and bony fishes indicates that NSP4 preceded the emergence of NE,
CG and PR3 and developed as a class 6 serine protease very early during vertebrate evolution.
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4.2 NSP4, an unusual serine protease with arginine
specificity
4.2.1 S1 pocket specificity
NSP4 is an arginine-specific serine protease. This was clearly demonstrated by PICS analysis
(Figure 3.9A), FRET libraries (Figure 3.10) and by its inhibitor profile. NSP4 was inhibited best
by classical arginine-specific protease inhibitors, like FPR-cmk (Figure 3.12), antithrombin or
C1 inhibitor (Figure 3.13).
Arginine-specific serine proteases mostly carry an aspartate residue at the bottom of their S1-
pocket (position 189, chymotrypsinogen numbering), as seen in trypsin or complement factor
D. NSP4, however, features a glycine residue at position 189. This is also highly conserved
in all NSP4 homologs from vertebrates. There is yet another critical residue determining the
binding properties of the S1 pocket. As Perona et al. (1993) have demonstrated in an anionic rat
trypsin D189G/G226D mutant, the combination of G189 and D226 can also cause a preference
for basic amino acids in the P1 position. Not only NSP4, but also NE and PR3 feature this
residue combination. In NE and PR3, however, the acidic side chain of Asp226 is shielded by
two hydrophobic side chains of Val190 (NE) / Ile190 (PR3) and Val 216 (Figure 4.1). This may
explain why the cleavage specificity of NSP4 is so unexpectedly unique and differs from all
other NSPs. Although not very common, two other natural serine proteases with arginine/lysine
specificity were described that do not occupy an aspartate residue at position 189, but at position
226. Of these two, complement factor B exhibits Asn in 189 and complement factor C2 displays
a Ser189 at the bottom of the S1 pocket (Xu, 2000).
4.2.2 The extended specificity of NSP4
Positional specificity profiling of NSP4 revealed clear preferences also for P4-P2, P1’ and P2’
positions. While small residues like Ser or Gly were favoured in P1’, FRET substrates with Val
in P1’ or P2’ were not well accepted by NSP4 (Figure 3.14A). This suggests that NSP4 does
not activate other serine protease precursors, e. g. those of the complement and coagulation
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186B       196        210        220        229
NSP4 HRRGFCSADS GGPLVCRNRA HGLVSFSGLW CGDPKTPDVY TQVSAFVAWI 
NE   RQAGVCFGDS GSPLVCNGLI HGIASFVRGG CASGLYPDAF APVAQFVNWI 
CFD  NRRDSCKGDS GGPLVCGGVL EGVVTSGSRV CGNRKKPGIY TRVASYAAWI 
.:     .** *.**:* .   .*: :       .    *  : : *: :  **   
NSP4 NECFD
Trypsin
Trypsin D189G/G226D
Gly189 Gly189Asp189
Asp226 Asp226Asp226
Gly189
Gly226
Val190Val216
P1: Arg P1: ValP1: Arg/Lys P1: Lys/Arg
A
B
Figure 4.1: Sequence alignment of residues around Ser195 in NSP4, NE and CFD, and
schematic models of the S1 specificity pockets. A, topologically aligned amino
acid residues (single letter code) are numbered according to chymotrypsinogen.
Ser195 is highlighted in bold and underlined. Residues that affect the substrate
specificity in the S1 pocket are boxed and shown in the schematic model in B.
An asterisk (*) below the alignments indicates positions which agree completely;
a colon (:) or a period (.) indicate conservation of residues with strong or weak
similarities (scoring > 0.5 or = < 0.5 in the Gonnet PAM 250 matrix), respective-
ly. B, specificity for arginine in P1 is mostly caused by an aspartate residue at the
bottom of the S1 pocket (position 189). However, as was demonstrated for the rat
anionic trypsin variant R189G/G226R, also a combination of Gly189 and Asp226
can result in a preference for arginine or lysine in P1. NSP4 and NE both feature
the Gly189/Asp226 combination. Nevertheless, only NSP4 can cleave after arginine
residues. This is most likely caused by restriction of Asp226 by Val190 and Val216
in NE.
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systems, between an Arg at the C-terminal end of a prodomain and the highly conserved N-
terminus of the serine protease domain (Arg-/-(Ile/Val)-(Ile/Val)), as seen during the activation
of serine protease cascades. This finding was also supported by the PICS analysis that revealed
a preference for small residues in P1’ like Gly or Ala.
Acidic residues close to the scissile bond in the substrate sequence seemed to prevent cleavage
by NSP4, as demonstrated for Glu in P1’, P2’, P4 and P2 and for Asp in the P3 and P2 positions
(Figure 3.14). FRET substrates with Gly in P4 or P3 were also not well cleaved by NSP4.
This knowledge about preferences is highly valuable for the identification of potential natural
substrates of NSP4.
4.3 Detection of active NSP4
When searching for the function of a protease, it is necessary to know when and where the re-
spective protease is active. Storage of NSP4 as mature, active endoprotease was already suspec-
ted as it carried a two residue long propeptide. DPPI, which cleaves off dipeptides from the
N-terminus and also activates NE, CG and PR3 during their biosynthesis in neutrophil precur-
sors, was identified as the natural convertase of NSP4 (Figure 3.8). To confirm this conclusion,
a highly specific and, in particular, a very sensitive detection method was developed. The detec-
tion of active NSP4 by complexation with α1PI* in Western blotting was based on both unique
immunological properties and catalytic activities of NSP4. With this method, I could ascertain
that NSP4 is indeed stored and released as active endoprotease by activated neutrophils (Figure
3.16E).
α1PI* can also be used to study the functional consequence of NSP4 inhibition in human
neutrophils in vitro. Systemic applications of the serpin variant, however, may result in unpre-
dictable off-target effects. It is anticipated that α1PI* inhibits other arginine-specific proteases,
e.g. those of the coagulation and complement system. There is a naturally occurring Met358Arg
α1PI variant (Pittsburgh mutation) that is known to inhibit thrombin, complement C1s, plasma
kallikrein, factor XIa and Hageman factor fragment XIIf (Scott et al., 1986). Already hetero-
zygous individuals suffer from episodic bleedings. The potential problems of a systemically
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acting α1PI variant with arginine in P1 were hereby already demonstrated. Inhibition of NSP4
by the Pittsburgh mutant is conceivable and might explain its attenuating effect on NE release
from activated neutrophils (Wachtfogel et al., 1994).
Concerning the function of NSP4, the storage and release by neutrophils as active endoprotease
alludes to a role in the context of neutrophil immune responses. NSP4 could cleave substrates
that are also stored in neutrophils or expressed by other cells that will come into close contact
with neutrophils during immune responses.
4.4 PAR-2 as a potential NSP4 substrate
The effect of PAR-2 activation in vivo can hardly be predicted. PAR-2 is ubiquitously expressed
on many different cell types. Therefore, the functions ascribed to PAR-2 are highly diverse and
complex (Steinhoff et al., 2005; Chignard and Pidard, 2006). Likewise the role of PAR-2 in
inflammation is controversially discussed. There is evidence for both a protective role (Cocks
et al., 1999), but also for a proinflammatory role in two different mouse models of colitis (Hyun
et al., 2010).
Several other proteases were already reported as activators of PAR-2, such as mast cell tryp-
tase (Steinhoff et al., 1999), trypsin IV (Cottrell et al., 2004) or kallikrein-related peptidase
14 (Gratio et al., 2011). Matriptase was even reported as PAR-2 activator in an in vivo setting
(Camerer et al., 2010). The authors suggested that activation of PAR-2 by matriptase triggered
neural tube closure in mouse embryos. Matriptase, tryptase, trypsin IV and kallikrein related
peptidase 14 could activate PAR-2 at lower concentrations (0.1 - 90 nM) than NSP4 (1 µM). In
most situations it is therefore rather unlikely that PAR-2 is activated by NSP4 in vivo.
PAR-2 is also expressed in neutrophils and stored in azurophil granules like NSP4. In this
special situation, the concentration of NSP4 could be sufficient to activate PAR-2 directly after
activation of PMNs and release of the azurophil granule content. This might then lead to an
enhanced motility of neutrophils, as was demonstrated after activation of PAR-2 by agonist
peptides or trypsin in three-dimensional collagen lattices (Shpacovitch et al., 2004). In this
89
4 Discussion
case, NSP4 would also assume an immunomodulatory function, as was proposed for NE, CG
and PR3 (Meyer-Hoffert, 2009).
Activation of PAR-2 by the other NSPs has become a rather controversial issue (Chignard and
Pidard, 2006). Based on the substrate specificities of NE, CG and PR3, the activating cleavage
site SKGR-/-SLIGKV seems to be a very unlikely target for these three NSPs. Consistent with
this, Loew et al. (2000) revealed that in a recombinant peptide sequence derived from the N-
terminal, extracellular domain of PAR-2 (Arg31 to Pro79), NE, CG and PR3 did not hydrolyze
PAR-2 at the activation cleavage site, but downstream of it. The latter cleavages that occur
C-terminally between the activation site and the first transmembrane domain are believed to
inactivate PAR-2. Accordingly, it was also reported that NE, CG and PR3 do not activate PAR-
2 but disarm the receptor, so that it cannot be activated by trypsin anymore (Dulon et al., 2003).
Contrary to this, there were two reports demonstrating that NE, CG and PR3 can also activate
PAR-2 (Uehara et al., 2002, 2003). Both articles were, however, retracted in 2010 (Sugawara
and Muramoto, 2010; Muramoto and Sugawara, 2010). Of the four NSPs, NSP4 is the most
likely protease to activate PAR-2 on neutrophils.
4.5 The NSP4-deficient mouse model
So far, no notable phenotype was discovered in the NSP4-deficient mouse model. I investigated
basic neutrophil functions by determining the activation by PMA or immune complexes, but
only on isolated neutrophils. It is quite possible that more complex inflammatory mechanisms
are disrupted in the absence of NSP4. Further investigation of the NSP4-deficient mouse model
will help in elucidating the function of this novel serine protease. Since NSP4 features a sub-
strate specificity which is highly conserved in vertebrate evolution and differs sharply from NE,
CG or PR3, a significant and relevant function for NSP4 may be postulated.
The most striking roles of NSPs were revealed using mouse models simultaneously deficient
in at least two members of the NE, CG or PR3 group (Raptis et al., 2005; Kessenbrock et al.,
2008). Analysis of a mouse deficient for NSP4 and another NSP should therefore also be very
informative. Unfortunately, a combination of NE/PR3 and NSP4 is not feasible by just crossing
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mouse lines, as the corresponding genes are located too close together (approx. 200 kb). A
combination of an NSP4 knockout mice with CG-deficiency would be feasible.
4.6 The function of NSP4
Neutrophils are highly efficient killers and eaters of invading microbes. To fulfill this task, they
are equipped with a large arsenal of microbicidal and digestive proteins. After microorgan-
isms are engulfed, antimicrobial peptides and proteins are released into the resulting phago-
lysosomes. At the same time, the membrane bound NADPH oxidase system produces large
amounts of oxygen radicals and hydrogen peroxide in a respiratory burst. These are then used
by MPO to generate the antibacterial hypochlorous acid (HOCl).
The relative importance of antibacterial biologicals like NSPs, azurocidin, defensins, lysozyme
and BPI, in comparison to chemical weapons produced by phagocytes is still in debate (Roos
and Winterbourn, 2002; Williams, 2006). There are large species differences in the composition
of granules. For example, defensins and azurocidin, an antimicrobial catalytically inactive NE
homolog, are completely absent in mice. Hence, the reported importance of NSPs for bacterial
defence might be species-dependent (Belaaouaj et al., 1998; Weinrauch et al., 2002).
Indeed, serine proteases with direct bactericidal activity do not appear as smart effective weap-
ons against bacteria. This is especially true for NSP4 with its highly restricted substrate speci-
ficity. By mutating the respective target sequences, bacteria could quickly escape the attack
from proteases. Also, many bacteria are well adjusted to the protease-rich milieu of the gastro-
intestinal tract. Moreover, microbes also produce protease inhibitors like ecotin, serpins, alpha-
2-macroglobulins or trap the active site region of proteases by peptidoglycans on their surface
(Mcgrath et al., 1995).
The adaptation of host-derived specificities in comparison to rapidly changing infectious chal-
lenges is rather slow. This suggests that NSP4, NE, CG and PR3 rather contribute to host defense
on a regulatory indirect level, by accelerating the recruitment of phagocytes, enhancing endocy-
tosis and amplifying the respiratory burst (Bank and Ansorge, 2001; Pham, 2006; Kessenbrock
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et al., 2011). For a successful clearence of bacteria, these pathogens have to be controlled be-
fore they can multiply and spread into the body. This is achieved by a rapid mobilization of
the phagocytes and clustering in high densities at infected tissue sites. Lowering the activation
threshold of neutrophils is therefore more important than adding another weapon with target-
restricted specialty to the neutrophil arsenal. However, this life-saving mechanism comes at a
high price in special instances, such as multiple organ failure in severe sepsis and local tissue
damage by dense phagocyte infiltrations due to an excess release of NSPs (Weiss, 1989).
The low abundance in neutrophils and the strict conservation of this gene in vertebrates strength-
ens the assumption that NSP4 is not just digesting bacterial proteins in the phagolysosome, but
rather regulating neutrophil responses and innate immune reactions.
4.7 Conclusions
In summary, NSP4 can be classified as a genuine member of granule-associated, pre-activated
serine proteases of neutrophils with restricted sequence specificity. NSP4 is the only arginine-
specific serine protease in neutrophils. Consequently, a non-redundant role for NSP4 may be
suspected, as the other NSPs cannot compete for NSP4 substrate cleavage sites. Nevertheless,
a synergistic role for NSP4 in combination with one or more of the other NSPs is highly plau-
sible. For a better understanding of the biological interplay of all four NSPs, NSP4 should be
considered in future studies of neutrophil immune responses.
Under clean housing conditions, the NSP4-knockout mice did not show an abnormal phenotype.
PLS patients not only lack the vast majority of NE, PR3 and CG, but also the arginine-specific
NSP4 in their neutrophils. The phenotype of PLS is relatively mild. PLS patients carry only
a marginally increased risk for bacterial infections. NSP4 might therefore appear rather dis-
pensable in general host defense. However, NSP4 clearly has specific non-redundant proteolytic
capacities and could fulfill a life-saving function under exceptional emergency conditions.
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6 Abbreviations
α1PI α1-proteinase inhibitor, α1-antitrypsin
ACT α1-antichymotrypsin
AEBSF 4-(2-Aminoethyl) benzenesulfonyl fluoride
AMC 7-Amino-4-methylcoumarin
APS Ammonium persulfate
AT Annealing temperature
BCA Bicinchoninic acid
BPI Bactericidal/permeability-increasing protein
Boc Tert-butoxycarbonyl
BSA Bovine serum albumin
CG Cathepsin G
CFD Complement factor D
cmk Chloromethyl ketone
cMyc c-Myc epitope tag
CytB Cytochalasin B
DMEM Dulbecco’s Modified Eagle’s Medium
DMSO Dimethyl sulfoxide
Dnp 2,4-Dinitrophenyl
dNTP Deoxyribonucleotide triphosphate
DPPI Dipeptidyl peptidase I
DTE Dithioerythritol
DTT Dithiothreitol
DTNB 5,5’-Dithiobis-(2-nitrobenzoic acid)
EBNA1 Epstein-Barr nuclear antigen 1
EBV Epstein-Barr virus
ECL Electrochemiluminescence
EDTA Ethylenediaminetetraacetic acid
EK Enterokinase
ESI-TOF Electrospray ionization - time-of-flight
FCS Fetal calf serum
FPLC Fast protein liquid chromatography
FRET Fluorescence/Förster resonance energy transfer
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6 Abbreviations
FRT Flp recombination target
GP67 acidic glycoprotein of AcNPV baculovirus
H6 6x His tag
HBSS Hank’s Balanced Salt Solution
HEK Human embryonic kidney cell line
HLA HLA class I antigen
HRP Horse radish peroxidase
HSA Human serum albumin
IC Immune complex
lacZ Gene encoding β-galactosidase
LAMP2A Lysosomal-associated membrane protein 2A
LB Luria-Bertani
LC-MS Liquid chromatography–mass spectrometry
λEm Emission wavelength
λEx Excitation wavelength
LPS Lipopolysaccharides
mAb monoclonal antibody
Mca 7-Methoxycoumarin-4-acetic acid
MMP-9 Matrix metalloproteinase 9
MNEI Monocyte/neutrophil elastase inhibitor
mNSP4 Mouse NSP4
MOG Myelin oligodendrocyte glycoprotein
MPO Myeloperoxidase
NE Neutrophil elastase
NGAL Neutrophil gelatinase-associated lipocalin
NGS peptide sequence with N-glycosylation site, SRMHRNGSH
NK Natural killer cells
Nma 2-(N-methylamino)benzoyl
NSP Neutrophil serine protease
NSP4 Neutrophil serine protease 4
OD Optical density
PAGE Polyacrylamide gel electrophoresis
PAR Proteinase-activated receptor
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PEI Polyethylenimine
PICS Proteomic identification of protease cleavage sites
PLS Papillon-Lefèvre syndrome
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PMA Phorbol-12-myristate-13-acetate
PMN Polymorphonuclear cells
PMSF Phenylmethylsulfonyl fluoride
PR3 Proteinase 3
PVDF Polyvinylidene difluoride
RCL Reactive center loop
RFU Relative fluorescence unit
rH Relative humidity
ROS Reactive oxygen species
RPMI Roswell Park Memorial Institute medium
RT-PCR Reverse transcription polymerase chain reaction
S S-tag peptide
Sbzl Thiobenzyl ester
SD Standard deviation
SDS Sodium dodecyl sulfate
SigIgκ Signal peptide derived from Igκ
siRNA Small interfering RNAs
SLPI Secretory leukocyte peptidase inhibitor
SN Supernatant
TNF-α Tumor necrosis factor α
WT Wildtype
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7.1 Vector maps
7.1.1 pTT5
Figure 7.1: Vector map of the pTT5 vector. The pTT5 vector contains an EBV specific origin
of replication (OriP) as well as a promoter of the cytomegalovirus (CMV), an E.
coli origin of replication (pMB1ori), an ampicillin resistance gene, an adenovirus
tripartite leader (TPL) and major late promotor (enh. MLP), splice donor (SD) and
splice acceptor (SA) sites and a rabbit beta-globin polyadenylation site (pA). All the
relevant recognition sites of the restriction enzymes are depicted. Plasmid provider:
NRC Biotechnology Research Institute.
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7.1.2 pFASTBAC1
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Comments for pFastBacTM1
4775 nucleotides
f1 origin: bases 2-457
Ampicillin resistance gene: bases 589-1449
pUC origin: bases 1594-2267
Tn7R: bases 2511-2735
Gentamicin resistance gene: bases 2802-3335 (complementary strand)
Polyhedrin promoter (PPH): bases 3904-4032
Multiple cloning site: bases 4037-4142
SV40 polyadenylation signal: bases 4160-4400
Tn7L: bases 4429-4594
pFastBacTM1
4775 bpT
n7
R f1
or
i
Tn7L
Am
pic
illi
n
pUC ori
PPH SV40 pA
Ge
nta
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in
Figure 7.2: Vector map of the pFASTBAC1 vector. PPH, Polyhedrin promoter; SV40 pA,
SV40 polyadenylation signal; Tn7L and Tn7R, Mini Tn7 elements that permit site-
specific transposition of the gene of interest into the baculovirus genome; f1 origin,
origin of replication of f1 phage, allows rescue of single stranded DNA; Ampicillin
and Gentamycin, resistence genes for selection in E. coli; pUC ori, origin of replica-
tion, permits high-copy replication and maintenance in E. coli. Source: Invitrogen.
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7.2 List of primers
DJ3305 5’-Pho-CTA GCC CCA CCA TGG CTC ACC GGC CCC CCA GCC CTG CCC
TGG CGT CCG TGC TGC TGG CCT TGC TGC TGA GCG GTG CTG CCC
GAG CTC AC-3’
DJ3306 5’-GTG AGC TCG GGC AGC ACC GCT CAG CAG CAA GGC CAG CAG
CAC GGA CGC CAG GGC AGG GCT GGG GGG CCG GTG AGC CAT GGT
GGG G-3’
DJ3312 5’-CGG CGG CTA GCA AAC ATG GAG ACA GAC AGA-3’
DJ3314 5’-TGG ACA CGT GGT TGT CGT CAT CTG CAC TGC-3’
DJ3324 5’-CGG GGT ACC AGG TTC CAC TGG TGA CTC CCT GCA GGA CTC
AGA A-3’
DJ3325 5’-GGG GGT CAC CTC GTG GCC CCC GAT GAT ACC TCC AAT CTG TTC
TCT-3’
DJ3352 5’-TCC CTG CAG GGC GAC GAC GAC GAC AAG ATC GTG GGC GGC
CAT GAG-3’
DJ3353 5’-CCC ACC GGT CAC CGA ACC ACA TCC CAG AT-3’
DJ3368 5’-TGG ACA CGT GGA TGA CGA CGA CAA GAT CGT G-3’
DJ3369 5’-CCC CAC CGG TCC GAA CCA CAT CCC AGA TC-3’
DJ3385 5’-Pho-CAG GTT CCA CTG GTA GCC GCA TGC ACC GCA ACG GCA AGG
AC-3’
DJ3386 5’-Pho-GTG GCT GCC GTT GCG GTG CAT GCG GCT ACC AGT GGA ACC
TGG TAC-3’
DJ3511 5‘-TGTATGACCTCATGACTTCAGG-3‘
DJ3512 5‘-CCCAGCCCCACAAGTAAATTAA-3‘
DJ3513 5‘-GCAGCGCATCGCCTTCTATC -3‘
DJ3559 5’-TCG AGA TCA AGC CTA GAA GT-3’
DJ3560 5’-Pho-ATA CTT CTA GGC TTG ATC-3’
DJ3569 5’-ATCCCAGATCCAGGTCACAA-3’
DJ3610 5’-ATT GCC TCG GAG AAA TGC TA-3’
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7.3 DNA and protein sequences
7.3.1 S-NSP4 (human)
The amino acid sequence is shown in single letter code. The sequence begins with the Igκ signal
peptide. The N-terminal S-tag is marked in bold and underlined. The enterokinase cleavage site
was underlined. The sequence of mature NSP4 is marked in bold. The C-terminal 6x His-tag is
marked in italics. The stop codon is represented by a star (*).
1 ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGGTTCCACTGGT 60 
1 M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  S  T  G   20 
  
61 GACGTGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGCGGAAGCGGT 120 
21 D  V  K  E  T  A  A  A  K  F  E  R  Q  H  M  D  S  G  S  G   40 
 
121 GGACACGTGGATGACGACGACAAGATCATCGGGGGCCACGAGGTGACCCCCCACTCCAGG 180 
41 G  H  V  D  D  D  D  K  I  I  G  G  H  E  V  T  P  H  S  R   60 
 
181 CCCTACATGGCATCCGTGCGCTTCGGGGGCCAACATCACTGCGGAGGCTTCCTGCTGCGA 240 
61 P  Y  M  A  S  V  R  F  G  G  Q  H  H  C  G  G  F  L  L  R   80 
  
241 GCCCGCTGGGTGGTCTCGGCCGCCCACTGCTTCAGCCACAGAGACCTCCGCACTGGCCTG 300 
81 A  R  W  V  V  S  A  A  H  C  F  S  H  R  D  L  R  T  G  L   100 
 
301 GTGGTGCTGGGCGCCCACGTCCTGAGTACTGCGGAGCCCACCCAGCAGGTGTTTGGCATC 360 
101 V  V  L  G  A  H  V  L  S  T  A  E  P  T  Q  Q  V  F  G  I   120 
 
361 GATGCTCTCACCACGCACCCCGACTACCACCCCATGACCCACGCCAACGACATCTGCCTG  420 
121 D  A  L  T  T  H  P  D  Y  H  P  M  T  H  A  N  D  I  C  L   140 
 
421 CTGCGGCTGAACGGCTCTGCTGTCCTGGGCCCTGCAGTGGGGCTGCTGAGGCTGCCAGGG 480 
141 L  R  L  N  G  S  A  V  L  G  P  A  V  G  L  L  R  L  P  G   160 
 
481 AGAAGGGCCAGGCCCCCCACAGTGGGGACACGGTGCCGGGTGGCTGGCTGGGGCTTTGTG 540 
161 R  R  A  R  P  P  T  V  G  T  R  C  R  V  A  G  W  G  F  V   180 
 
541 TCTGACTTTGAGGAGCTGCCGCCTGGACTGATGGAGGCCAAGGTCCGAGTGCTGGACCCG 600 
181 S  D  F  E  E  L  P  P  G  L  M  E  A  K  V  R  V  L  D  P   200 
 
601 GACGTCTGCAACAGCTCCTGGAAGGGCCACCTGACACTTACCATGCTCTGCACCCGCAGT 660 
201 D  V  C  N  S  S  W  K  G  H  L  T  L  T  M  L  C  T  R  S   220 
 
661 GGGGACAGCCACAGACGGGGCTTCTGCTCGGCCGACTCCGGAGGGCCCCTGGTGTGCAGG 720 
221 G  D  S  H  R  R  G  F  C  S  A  D  S  G  G  P  L  V  C  R   240 
 
721 AACCGGGCTCACGGCCTCGTTTCCTTCTCGGGCCTCTGGTGCGGCGACCCCAAGACCCCC 780 
241 N  R  A  H  G  L  V  S  F  S  G  L  W  C  G  D  P  K  T  P   260 
 
781 GACGTGTACACGCAGGTGTCCGCCTTTGTGGCCTGGATCTGGGACGTGGTTCGGAAGACC 840 
261 D  V  Y  T  Q  V  S  A  F  V  A  W  I  W  D  V  V  R  K  T   280 
 
841 GGTCATCATCACCATCACCATTGA  864 
281 G  H  H  H  H  H  H  *    287 
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7.3.2 NGS-NSP4 (human)
The amino acid sequence is shown in single letter code. The sequence begins with the Igκ signal
peptide. The N-terminal NGS-peptide is marked in bold and underlined. The enterokinase
cleavage site was underlined. The sequence of mature NSP4 is marked in bold. The C-terminal
6x His-tag is marked in italics. The stop codon is represented by a star (*).
1 ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGGTTCCACTGGT 60 
1 M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  S  T  G   20 
  
61 AGCCGCATGCACCGCAACGGCAGCCACGTGGATGACGACGACAAGATCATCGGGGGCCAC 120 
21 S  R  M  H  R  N  G  S  H  V  D  D  D  D  K  I  I  G  G  H   40 
 
121 GAGGTGACCCCCCACTCCAGGCCCTACATGGCATCCGTGCGCTTCGGGGGCCAACATCAC 180 
41 E  V  T  P  H  S  R  P  Y  M  A  S  V  R  F  G  G  Q  H  H   60 
  
181 TGCGGAGGCTTCCTGCTGCGAGCCCGCTGGGTGGTCTCGGCCGCCCACTGCTTCAGCCAC 240 
61 C  G  G  F  L  L  R  A  R  W  V  V  S  A  A  H  C  F  S  H   80 
 
241 AGAGACCTCCGCACTGGCCTGGTGGTGCTGGGCGCCCACGTCCTGAGTACTGCGGAGCCC 300 
81 R  D  L  R  T  G  L  V  V  L  G  A  H  V  L  S  T  A  E  P   100 
 
301 ACCCAGCAGGTGTTTGGCATCGATGCTCTCACCACGCACCCCGACTACCACCCCATGACC  360 
101 T  Q  Q  V  F  G  I  D  A  L  T  T  H  P  D  Y  H  P  M  T   120 
 
361 CACGCCAACGACATCTGCCTGCTGCGGCTGAACGGCTCTGCTGTCCTGGGCCCTGCAGTG 420 
121 H  A  N  D  I  C  L  L  R  L  N  G  S  A  V  L  G  P  A  V   140 
 
421 GGGCTGCTGAGGCTGCCAGGGAGAAGGGCCAGGCCCCCCACAGTGGGGACACGGTGCCGG 480 
141 G  L  L  R  L  P  G  R  R  A  R  P  P  T  V  G  T  R  C  R   160 
 
481 GTGGCTGGCTGGGGCTTTGTGTCTGACTTTGAGGAGCTGCCGCCTGGACTGATGGAGGCC 540 
161 V  A  G  W  G  F  V  S  D  F  E  E  L  P  P  G  L  M  E  A   180 
 
541 AAGGTCCGAGTGCTGGACCCGGACGTCTGCAACAGCTCCTGGAAGGGCCACCTGACACTT 600 
181 K  V  R  V  L  D  P  D  V  C  N  S  S  W  K  G  H  L  T  L   200 
 
601 ACCATGCTCTGCACCCGCAGTGGGGACAGCCACAGACGGGGCTTCTGCTCGGCCGACTCC 660 
201 T  M  L  C  T  R  S  G  D  S  H  R  R  G  F  C  S  A  D  S   220 
 
661 GGAGGGCCCCTGGTGTGCAGGAACCGGGCTCACGGCCTCGTTTCCTTCTCGGGCCTCTGG 720 
221 G  G  P  L  V  C  R  N  R  A  H  G  L  V  S  F  S  G  L  W   240 
 
721 TGCGGCGACCCCAAGACCCCCGACGTGTACACGCAGGTGTCCGCCTTTGTGGCCTGGATC 780 
241 C  G  D  P  K  T  P  D  V  Y  T  Q  V  S  A  F  V  A  W  I   260 
 
781 TGGGACGTGGTTCGGAAGACCGGTCATCATCACCATCACCATTGA 825 
261 W  D  V  V  R  K  T  G  H  H  H  H  H  H  *   274 
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7.3.3 NSP4 precursor (human)
The amino acid sequence is shown in single letter code. The sequence begins with the signal
peptide. The N-terminal prodipeptide is underlined. The sequence of mature NSP4 is marked
in bold. The C-terminal 6x His-tag is marked in italics. The stop codon is represented by a star
(*).
1 ATGGGGCTCGGGTTGAGGGGCTGGGGACGTCCTCTGCTGACTGTGGCCACCGCCCTGATG 60 
1 M  G  L  G  L  R  G  W  G  R  P  L  L  T  V  A  T  A  L  M   20 
 
61 CTGCCCGTGAAGCCCCCCGCAGGCTCCTGGGGGGCCCAGATCATCGGGGGCCACGAGGTG 120 
21 L  P  V  K  P  P  A  G  S  W  G  A  Q  I  I  G  G  H  E  V   40 
 
121 ACCCCCCACTCCAGGCCCTACATGGCATCCGTGCGCTTCGGGGGCCAACATCACTGCGGA 180 
41 T  P  H  S  R  P  Y  M  A  S  V  R  F  G  G  Q  H  H  C  G   60 
 
181 GGCTTCCTGCTGCGAGCCCGCTGGGTGGTCTCGGCCGCCCACTGCTTCAGCCACAGAGAC 240 
61 G  F  L  L  R  A  R  W  V  V  S  A  A  H  C  F  S  H  R  D   80 
 
241 CTCCGCACTGGCCTGGTGGTGCTGGGCGCCCACGTCCTGAGTACTGCGGAGCCCACCCAG 300 
81 L  R  T  G  L  V  V  L  G  A  H  V  L  S  T  A  E  P  T  Q   100 
 
301 CAGGTGTTTGGCATCGATGCTCTCACCACGCACCCCGACTACCACCCCATGACCCACGCC 360 
101 Q  V  F  G  I  D  A  L  T  T  H  P  D  Y  H  P  M  T  H  A   120 
 
361 AACGACATCTGCCTGCTGCGGCTGAACGGCTCTGCTGTCCTGGGCCCTGCAGTGGGGCTG 420 
121 N  D  I  C  L  L  R  L  N  G  S  A  V  L  G  P  A  V  G  L   140 
 
421 CTGAGGCTGCCAGGGAGAAGGGCCAGGCCCCCCACAGCGGGGACACGGTGCCGGGTGGCT 480 
141 L  R  L  P  G  R  R  A  R  P  P  T  A  G  T  R  C  R  V  A   160 
 
481 GGCTGGGGCTTCGTGTCTGACTTTGAGGAGCTGCCGCCTGGACTGATGGAGGCCAAGGTC 540 
161 G  W  G  F  V  S  D  F  E  E  L  P  P  G  L  M  E  A  K  V   180 
 
541 CGAGTGCTGGACCCGGACGTCTGCAACAGCTCCTGGAAGGGCCACCTGACACTTACCATG 600 
181 R  V  L  D  P  D  V  C  N  S  S  W  K  G  H  L  T  L  T  M 200 
 
601 CTCTGCACCCGCAGTGGGGACAGCCACAGACGGGGCTTCTGCTCGGCCGACTCCGGAGGG 660 
201 L  C  T  R  S  G  D  S  H  R  R  G  F  C  S  A  D  S  G  G   220 
 
661 CCCCTGGTGTGCAGGAACCGGGCTCACGGCCTCGTTTCCTTCTCGGGCCTCTGGTGCGGC 720 
221 P  L  V  C  R  N  R  A  H  G  L  V  S  F  S  G  L  W  C  G   240 
 
721 GACCCCAAGACCCCCGACGTGTACACGCAGGTGTCCGCCTTTGTGGCCTGGATCTGGGAC 780 
241 D  P  K  T  P  D  V  Y  T  Q  V  S  A  F  V  A  W  I  W  D   260 
 
781 GTGGTTCGGAAGACCGGTCATCATCACCATCACCATTGA 819 
261 V  V  R  K  T  G  H  H  H  H  H  H  * 272 
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7.3.4 S-mNSP4 (mouse)
The amino acid sequence is shown in single letter code. The sequence is begins with the Igκ
signal peptide. The N-terminal S-tag is marked in bold (line 2). The enterokinase cleavage site
was underlined. The sequence of mature mNSP4 is marked in bold (lines 3-14). The C-terminal
6x His-tag is marked in italics. The stop codon is represented by a star (*).
1 ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGGTTCCACTGGT 60 
1 M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  S  T  G 20 
  
61 GACGTGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGCGGAAGCGGT 120 
21 D  V  K  E  T  A  A  A  K  F  E  R  Q  H  M  D  S  G  S  G   40 
 
121 GGACACGTGGATGACGACGACAAGATCGTGGGCGGCCATGAGGTAACGCCACATTCCCGG 180 
41 G  H  V  D  D  D  D  K  I  V  G  G  H  E  V  T  P  H  S  R   60 
 
181 CCCTATATGGCCTCTGTGAGCTTCGAGGGCCATCACTACTGTGGAGGCTTCCTGATTCAT  240 
61 P  Y  M  A  S  V  S  F  E  G  H  H  Y  C  G  G  F  L  I  H     80 
 
241 ACCCATTGGGTGGTGTCAGCTGCCCATTGCTTCAGTGACAGGGACCCCTCCATGGGGCTG 300 
81 T  H  W  V  V  S  A  A  H  C  F  S  D  R  D  P  S  M  G  L   100 
 
301 GTGGTGCTGGGGGCCCACGCACTGCTCGCCCCAGAGCCCACACAGCAGACATTTAGCATT 360 
101 V  V  L  G  A  H  A  L  L  A  P  E  P  T  Q  Q  T  F  S  I   120 
 
361 GCAGCTGCTGTCAGCCATCCTGATTTCCAGCCTGCCACACAGGCCAACGATATCTGCCTG 420 
121 A  A  A  V  S  H  P  D  F  Q  P  A  T  Q  A  N  D  I  C  L 140 
 
421 CTAAGGTTGAACGGCTCTGCTGTCCTGGGCCCCGCTGTGAGGCTATTACGATTGCCTCGG 480 
141 L  R  L  N  G  S  A  V  L  G  P  A  V  R  L  L  R  L  P  R   160 
 
481 AGAAATGCTAAGCCACCTGCTGCGGGCACGCGTTGCCATGTATCCGGCTGGGGCTTCGTG 540 
161 R  N  A  K  P  P  A  A  G  T  R  C  H  V  S  G  W  G  F  V   180 
 
541 TCTGACTTTGAGGAGCCTCCGCCTGGACTGATGGAAGTCGAGGTGCGCATACTGGATCTG 600 
181 S  D  F  E  E  P  P  P  G  L  M  E  V  E  V  R  I  L  D  L   200 
 
601 AGTGTCTGCAACAGCTCCTGGCAGGGCCAGCTGAATCCTGCCATGCTCTGCACTCACAGT 660 
201 S  V  C  N  S  S  W  Q  G  Q  L  N  P  A  M  L  C  T  H  S 220 
 
661 GGGGACCGCCGGCGGCGTGGTTTCTGCTCGGCAGATTCTGGGGGACCCTTGGTCTGTGGA 720 
221 G  D  R  R  R  R  G  F  C  S  A  D  S  G  G  P  L  V  C  G   240 
 
721 AGACGGGCCCATGGTCTTGTATCTTTCTCAGGCCTCTGGTGTGGTGACCCCAAGACTCCG 780 
241 R  R  A  H  G  L  V  S  F  S  G  L  W  C  G  D  P  K  T  P   260 
 
781 GATGTCTACACTCAAGTGTCAGCGTTTGTGACCTGGATCTGGGATGTTGTTCGGACCGGT 840 
261 D  V  Y  T  Q  V  S  A  F  V  T  W  I  W  D  V  V  R  T  G   280 
 
841 CATCATCACCATCACCATTGA 861 
281 H  H  H  H  H  H  *   286 
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7.3.5 α1PI*
The amino acid sequence is shown in single letter code. The sequence is begins with the Igκ
signal peptide. The sequence of α1PI* is marked in bold. The amino acids in the reactive
center loop (RCL) that were optimized for specific interaction with NSP4 were underlined. The
C-terminal 6x His-tag is marked in italics. The stop codon is represented by a star (*).
1 ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGGTTCCACTGGT 60 
1 M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  S  T  G 20 
  
61 GAGGATCCCCAGGGAGATGCTGCCCAGAAGACAGATACATCCCACCATGATCAGGATCAC 120 
21 E  D  P  Q  G  D  A  A  Q  K  T  D  T  S  H  H  D  Q  D  H   40 
 
121 CCAACCTTCAACAAGATCACCCCCAACCTGGCTGAGTTCGCCTTCAGCCTATACCGCCAG 180 
41 P  T  F  N  K  I  T  P  N  L  A  E  F  A  F  S  L  Y  R  Q   60 
 
181 CTGGCACACCAGTCCAACAGCACCAATATCTTCTTCTCCCCAGTGAGCATCGCTACAGCC  240 
61 L  A  H  Q  S  N  S  T  N  I  F  F  S  P  V  S  I  A  T  A   80 
 
241 TTTGCAATGCTCTCCCTGGGGACCAAGGCTGACACTCACGATGAAATCCTGGAGGGCCTG 300 
81 F  A  M  L  S  L  G  T  K  A  D  T  H  D  E  I  L  E  G  L   100 
 
301 AATTTCAACCTCACGGAGATTCCGGAGGCTCAGATCCATGAAGGCTTCCAGGAACTCCTC 360 
101 N  F  N  L  T  E  I  P  E  A  Q  I  H  E  G  F  Q  E  L  L   120 
 
361 CGTACCCTCAACCAGCCAGACAGCCAGCTCCAGCTGACCACCGGCAATGGCCTGTTCCTC 420 
121 R  T  L  N  Q  P  D  S  Q  L  Q  L  T  T  G  N  G  L  F  L   140 
 
421 AGCGAGGGCCTGAAGCTAGTGGATAAGTTTTTGGAGGATGTTAAAAAGTTGTACCACTCA 480 
141 S  E  G  L  K  L  V  D  K  F  L  E  D  V  K  K  L  Y  H  S   160 
 
481 GAAGCCTTCACTGTCAACTTCGGGGACACCGAAGAGGCCAAGAAACAGATCAACGATTAC 540 
161 E  A  F  T  V  N  F  G  D  T  E  E  A  K  K  Q  I  N  D  Y   180 
 
541 GTGGAGAAGGGTACTCAAGGGAAAATTGTGGATTTGGTCAAGGAGCTTGACAGAGACACA 600 
181 V  E  K  G  T  Q  G  K  I  V  D  L  V  K  E  L  D  R  D  T   200 
 
601 GTTTTTGCTCTGGTGAATTACATCTTCTTTAAAGGCAAATGGGAGAGACCCTTTGAAGTC 660 
20 V  F  A  L  V  N  Y  I  F  F  K  G  K  W  E  R  P  F  E  V   220 
 
661 AAGGACACCGAGGAAGAGGACTTCCACGTGGACCAGGTGACCACCGTGAAGGTGCCTATG 720  
221 K  D  T  E  E  E  D  F  H  V  D  Q  V  T  T  V  K  V  P  M   240 
 
721 ATGAAGCGTTTAGGCATGTTTAACATCCAGCACAGTAAGAAGCTGTCCAGCTGGGTGCTG 780 
241 M  K  R  L  G  M  F  N  I  Q  H  S  K  K  L  S  S  W  V  L   260 
 
781 CTGATGAAATACCTGGGCAATGCCACCGCCATCTTCTTCCTGCCTGATGAGGGGAAACTA 840 
261 L  M  K  Y  L  G  N  A  T  A  I  F  F  L  P  D  E  G  K  L   280 
 
841 CAGCACCTGGAAAATGAACTCACCCACGATATCATCACCAAGTTCCTGGAAAATGAAGAC 900 
281 Q  H  L  E  N  E  L  T  H  D  I  I  T  K  F  L  E  N  E  D   300 
 
901 AGAAGGTCTGCCAGCTTACATTTACCCAAACTGTCCATTACTGGAACCTATGATCTGAAG 960 
301 R  R  S  A  S  L  H  L  P  K  L  S  I  T  G  T  Y  D  L  K   320 
 
961 AGCGTCCTGGGTCAACTGGGCATCACTAAGGTCTTCAGCAATGGGGCTGACCTCTCCGGG 1020 
321 S  V  L  G  Q  L  G  I  T  K  V  F  S  N  G  A  D  L  S  G   340 
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321 S  V  L  G  Q  L  G  I  T  K  V  F  S  N  G  A  D  L  S  G   340 
 
1021 GTCACAGAGGAGGCACCCCTGAAGCTCTCCAAGGCCGTGCATAAGGCTGTGCTGACCATC 1080 
341 V  T  E  E  A  P  L  K  L  S  K  A  V  H  K  A  V  L  T  I   360 
 
1081 GACGAGAAAGGGACTGAAGCTGCTGGGGCCATGTTCCTCGAGATCAAGCCTAGAAGTATA 1140 
361 D  E  K  G  T  E  A  A  G  A  M  F  L  E  I  K  P  R  S  I 380 
 
1141 CCCCCCGAGGTCAAGTTCAACAAACCCTTTGTCTTCTTAATGATTGAACAAAATACCAAG 1200 
381 P  P  E  V  K  F  N  K  P  F  V  F  L  M  I  E  Q  N  T  K   400 
 
1201 TCTCCCCTCTTCATGGGAAAAGTGGTGAATCCCACCCAAAAAACCGGTCATCATCACCAT 1260 
401 S  P  L  F  M  G  K  V  V  N  P  T  Q  K  T  G  H  H  H  H   420 
 
1261 CACCATTGA 1269 
421 H  H  *   422 
7.4 List of synthetic protease substrates
Sbzl substrates
Sequence Cleaving protease Provider
Boc-Ala-Pro-Nva-4-chloro-Sbzl NE, PR3 Bachem
Suc-Phe-Leu-Phe-Sbzl CG Bachem
AMC substrates
Sequence Cleaving protease Provider
H-Tyr-Arg-Phe-Arg-AMC NSP4 Novabiochem (Merck)
H-Tyr-Arg-Phe-Lys-AMC n/a Novabiochem
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Individual FRET substrates - P1’P2’
Sequence (single letter code) Cleaving protease Provider
Mca-GFPRFFP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRFVP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRFSP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRFNP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRFEP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRFRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRFGP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRVFP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRVVP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRVSP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRVNP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRVEP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRVRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRVGP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRSFP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRSVP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRSSP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRSNP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRSEP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRSGP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRNFP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRNVP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRNSP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRNNP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRNEP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRNRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRNGP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPREFP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPREVP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRESP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRENP-Lys(Dnp)-rr NSP4 EMC microcollections
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Individual FRET substrates - P1’P2’ - Continued
Sequence (single letter code) Cleaving protease Provider
Mca-GFPREEP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRERP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPREGP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRRFP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRRVP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRRSP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRRNP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRREP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRRRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRRGP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRGFP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRGVP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRGSP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRGNP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRGEP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRGRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFPRGGP-Lys(Dnp)-rr NSP4 EMC microcollections
r = D-arginine
Individual FRET substrates - P4P3
Sequence (single letter code) Cleaving protease Provider
Mca-GFYPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFAPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFSPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFNPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFDPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFGPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GAYPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GAAPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GASPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GANPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GADPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
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Individual FRET substrates - P4P3 - Continued
Sequence (single letter code) Cleaving protease Provider
Mca-GAKPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GAGPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GSYPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GSAPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GSSPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GSNPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GSDPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GSKPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GSGPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GNYPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GNAPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GNSPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GNNPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GNDPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GNKPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GNGPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GEYPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GEAPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GESPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GENPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GEDPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GEKPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GEGPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GRYPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GRAPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GRSPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GRNPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GREPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GRKPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GRGPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GGYPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GGAPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
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Individual FRET substrates - P4P3 - Continued
Sequence (single letter code) Cleaving protease Provider
Mca-GGSPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GGNPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GGDPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GGKPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GGGPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
r = D-arginine
Individual FRET substrates - P2
Sequence (single letter code) Cleaving protease Provider
Mca-GFKARSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKDRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKERSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKFRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKGRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKHRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKIRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKKRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKLRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKMRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKNRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKPRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKQRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKRRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKSRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKTRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKVRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKWRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
Mca-GFKYRSRP-Lys(Dnp)-rr NSP4 EMC microcollections
r = D-arginine
119
7 Appendix
Other FRET substrates
Sequence (single letter code) Cleaving protease Provider
Mca-GIKPRSRP-Lys(Dnp)-rr (α1PI* FRET) NSP4 EMC microcollections
Abz-GSKGR-SLIG-Y (NO2)-D (PAR-2 FRET) NSP4 EMC microcollections
r = D-arginine
7.5 Lists of NSP4 cleavage sites in PICS libraries
Nonprime-side sequences are reported up to the position P10. X denotes ambiguous nonprime
side residues. A small number of cleavage sites have P1 residues, which correspond to a po-
tential cleavage site of the digestion protease used for library generation. These cases might
be related to incomplete amine protection during library preparation. Hence, prime-side cleav-
age products with such amino-termini are omitted from the proteomic identification of protease
cleavage sites (PICS) analysis, as well as prime-side cleavage products with amino termini that
correspond to a protein amino terminus. One exemplary protein is stated for each identified
peptide sequence. X!Tandem was applied to assign peptides to tandem mass spectra and the
X!Tandem hyperscore is reported together with the PeptideProphet probability score. C signi-
fies carboxyamidomethylated cysteine and K signifies dimethylated lysine. Some peptides were
identified repeatedly by LC-MS/MS; however, the set of sequences was rendered nonredundant
before analysis in the form of sequence logos.
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7.5.1 Chymotrypsin
Nonprime sequence
(inferred from database)
Prime-side sequence
(LC-MS/MS)
PeptideProphet
probability score
X!Tandem
hyperscore
Mass
accuracy
(ppm)
Neutral
mass (Da)
Examplary
protein
accession
Discarded from
QFDAAFVPEV AAQKAPASP 0.86 25.6 −0.7 955.5 17888
YHGRVQALAD AAREAGLQF 0.96 25.2 0.6 1049.5 17897
AHEAGEFFMR AGSATVRPTEGAGGTL 1.00 45.5 −0.3 1531.7 17875
AHEAGEFFMR AGSATVRPTEGAGGTL 1.00 45.6 −1.5 1531.7 17875
GAVIAYEPVW AIGTGKSATPAQAQAVH 1.00 52.6 −0.8 1722.9 17903
GAVIAYEPVW AIGTGKSATPAQAQAVH 1.00 49.6 −1.7 1722.9 17903
NFNVPFVVVR AISDVADQQSHL 1.00 50.3 −0.9 1370.6 17863
NFNVPFVVVR AISDVADQQSHL 1.00 53.9 −1.3 1370.6 17863
MSFELPALPY AKDALAPH 0.97 32.1 −0.7 937.5 17879 X
MSFELPALPY AKDALAPH 0.99 29.3 −2.2 937.5 17879 X
KLDLERTVIR APADGWVTNL 0.84 26.8 2.0 1130.5 17896
LAVDESFQPT AVGFAEALNNKDKPE 1.00 45.9 2.2 1745.9 17899
LCRNCKIVKR DGVIRVIC 0.85 31.6 −0.9 1018.5 17896
SLXGTIIVGR DIAHAKL 0.96 36.5 −0.5 882.5 17878
SLXGTIIVGR DIAHAKL 0.83 34.3 −0.2 882.5 17878
KLTKRMRVIR EKVDATKQY 1.00 35.7 −0.9 1224.6 17904
KLTKRMRVIR EKVDATKQY 0.99 32.8 −1.1 1224.6 17904
NNPFFVSLKD GAQKEADKLGY 0.95 38.2 −0.3 1322.7 17901
NNPFFVSLKD GAQKEADKLGY 0.97 38.1 −0.5 1322.7 17901
GIANTFIAAQ GHDVGKSLY 0.82 29.7 1.7 1090.5 17892
KPEDAVLDVQ GIATVTPAIVQ 0.97 41.8 −1.2 1156.6 17899
KPEDAVLDVQ GIATVTPAIVQ 0.97 38.1 −0.9 1156.6 17899
KPEDAVLDVQ GIATVTPAIVQAC 0.90 35 −3.0 1387.7 17899
GQNVEFEIQD GQKGPAAVNVTAI 0.90 27.1 −2.2 1340.7 17881
PICS profile
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GQNVEFEIQD GQKGPAAVNVTAI 0.90 27.1 −2.2 1340.7 17881
HVIAGKAVAL KEAMEPEFKTY 0.85 36.9 −2.1 1515.7 17889 X
SGVRAIDTKC KIEQAPGQH 0.99 28.1 −0.9 1122.5 17896
PDEGIPAVCF KLKDGEDPGY 0.99 27.9 −0.8 1264.6 17877 X
PDEGIPAVCF KLKDGEDPGY 0.94 31.1 −2.7 1264.6 17877 X
PDEGIPAVCF KLKDGEDPGY 0.97 30.8 −2.6 1264.6 17877 X
KNPQKNLYTF KNQASNDLPN 1.00 24.6 −1.1 1215.6 87082 X
KNPQKNLYTF KNQASNDLPN 0.97 19.9 −1.1 1215.6 87082 X
SGGAGIQADL KTFSALGAY 0.81 30.9 −7.4 1072.5 17884 X
MVEVFLERGY KVVSGGTDNHLF 0.99 41.4 −0.6 1388.7 17889 X
AKSVKFKYPR QRKTVVADGVGQGY 0.93 29.2 −3.0 1592.8 17863
WRQKGTGRAR SGSIKSPIW 0.89 30.7 0.0 1089.6 17897
ARPPLVVISR SHADAELKEY 1.00 42.2 −2.0 1277.6 17906
ARPPLVVISR SHADAELKEY 1.00 42.1 −2.0 1277.6 17906
KEASAGKLVR TLAAVRDAKEAA 1.00 42.3 −1.9 1330.7 17904
KEASAGKLVR TLAAVRDAKEAA 1.00 39.5 −1.0 1330.7 17904
LSQYDFPGDD TPIVRGSAL 0.97 31 −1.0 1000.5 17897
RDXKGAVASL TSVAKLPF 0.83 24.9 0.5 977.5 17871 X
VVNTIRGIVK VAAVKAPGF 1.00 41.8 −1.2 974.5 17905
KHLPEPFRIR VIEPVKR 0.91 41.5 1.3 955.6 87082
KHLPEPFRIR VIEPVKR 0.98 41.7 −0.7 955.6 87082
DIVWDFRLPR VKSISASGH 0.98 33.5 −1.4 1000.5 17877
MSTAKL VKSKATNLLY 0.99 27.3 −0.6 1279.7 17870 X
CKPTSPGRRH VVKVVNPELH 0.96 29.1 −1.9 1248.7 17897
CKPTSPGRRH VVKVVNPELH 0.94 29.4 −1.0 1248.7 17897
PICS profile
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GYTLNGRTIR AAMVTVAKAKA 1.00 43.6 −2.3 1203.7 17889
GYTLNGRTIR AAMVTVAKAKA 1.00 50.5 −1.6 1203.7 17889
KYYDPRVWLR AGQTSMIARLE 0.93 37.1 −0.6 1263.6 17892
KYYDPRVWLR AGQTSMIARLE 1.00 48.2 −0.2 1263.6 17892
KYYDPRVWLR AGQTSMIARLE 0.97 40.8 −0.6 1263.6 17892
SQASDSYYYR AKQAVYR 0.78 25.4 −1.4 950.5 17886
PFLEHDDANR ALMGANMQR 0.99 38 −0.7 1078.5 17904
PFLEHDDANR ALMGANMQR 1.00 41.9 −2.1 1078.5 17904
FQPTAVGFAE ALNNKDKPE 0.80 37.3 −0.6 1171.6 17899 X
KLEHAVPMAK ALVAGGVRVLE 1.00 38 −2.8 1170.6 17881
KLEHAVPMAK ALVAGGVRVLE 1.00 49.3 −0.4 1170.6 17881
APDQTTTIVR ANSSTTTAAEPLKM 0.93 30.3 −0.8 1536.7 17886
APDQTTTIVR ANSSTTTAAEPLKM 0.96 37 −1.0 1536.7 17886
LAVDESFQPT AVGFAEALNNKDKPE 1.00 53.5 0.0 1745.9 17899
HVSPGALDAE AYGVKSTIED 1.00 35.1 7.3 1197.6 17905 X
GCVELVQPGG FDELVQIYE 0.91 27.5 0.5 1242.5 14569
VALKEAMEPE FKTYQQQVAK 1.00 33.1 0.4 1383.7 17889 X
LVVSTLNNPF FVSLKDGAQKE 1.00 46.1 −4.4 1364.7 17901
LVVSTLNNPF FVSLKDGAQKE 1.00 42.3 −3.6 1364.7 17901
LTASTVIQYR GAIIPREAMPA 0.96 29.6 −0.5 1212.6 87082
ESGVLNQQPY GFNTRFE 0.76 23.4 −2.2 957.4 17877
ESGVLNQQPY GFNTRFE 1.00 27.3 0.3 957.4 17877
GNGDCHIILR GGKEPNYSAK 0.90 30.1 −1.5 1193.6 17869
GNGDCHIILR GGKEPNYSAK 0.97 33.3 0.3 1193.6 17869
TTHKTLAGPR GGLILAKGGSEE 1.00 37.2 −0.4 1245.6 17889
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TTHKTLAGPR GGLILAKGGSEE 1.00 37.2 −0.4 1245.6 17889
TTHKTLAGPR GGLILAKGGSEE 1.00 37.4 −0.5 1245.6 17889
TEEYGNMIDM GILDPTKVTR 0.97 43.4 −1.5 1214.7 17905
TEEYGNMIDM GILDPTKVTR 0.82 36.2 −2.5 1214.7 17905
GAILVVAATD GPMPQTRE 0.99 34.8 0.3 1002.4 17897
YTSPRVMQAQ GSQLTNKYAE 0.93 29.5 −0.9 1225.6 17889
IEDVFSISGR GTVVTGRVE 0.97 38 −1.3 1004.5 17897
IEDVFSISGR GTVVTGRVE 0.96 41.7 −2.4 1004.5 17897
ARGAIFGLTR GVNANHIIR 0.82 38.9 −2.3 1080.5 17903
ARGAIFGLTR GVNANHIIR 1.00 50.6 −1.4 1080.5 17903
GDGVGMAIRA GVPVQDM 0.80 22.6 −1.6 832.3 17869
QLQQVLMMSR HNLRAPLANNGSVLE 0.75 37.4 1.9 1691.8 17872
QLQQVLMMSR HNLRAPLANNGSVLE 1.00 52.6 1.0 1691.8 17872
SNYFFDTTQG HSQINGCTVR 0.77 25.4 −0.8 1258.6 87082
IVGGGIANTF IAAQGHDVGKSLYE 0.99 38.6 0.4 1602.8 17892
IVGGGIANTF IAAQGHDVGKSLYE 1.00 38.8 −0.1 1602.8 17892
WWMLHEETVY KGGDTVTLNE 0.75 28.5 −0.9 1148.5 87082
GKSASAKSLF KLQTLGLTQ 1.00 35.2 −1.1 1116.6 17887
GKSASAKSLF KLQTLGLTQ 1.00 31.7 −0.8 1116.6 17887
KNPQKNLYTF KNQASNDLPN 1.00 33.4 −1.6 1215.6 87082
KNPQKNLYTF KNQASNDLPN 0.99 21.7 −2.3 1215.6 87082
KNPQKNLYTF KNQASNDLPN 1.00 30 −1.4 1215.6 87082
VYIEGQLRTR KWTDQSGQDRYTTE 1.00 38.5 −0.3 1829.8 17904
VYIEGQLRTR KWTDQSGQDRYTTE 1.00 42 0.4 1829.8 17904
ETGYSNKVLD LIAHISK 0.91 34.5 −0.8 896.5 17880
QKEADKLGYN LVVLDSQNNPAKE 1.00 37.5 −0.7 1541.8 17901
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SNYQPSPMVR MMKADAAPVSAQE 0.99 35.2 1.5 1463.6 17892
SNYQPSPMVR MMKADAAPVSAQE 1.00 35 0.0 1463.6 17892
AQKEADKLGY NLVVLDSQNNPAKE 0.95 37.6 0.9 1655.8 17901
AQKEADKLGY NLVVLDSQNNPAKE 1.00 37.9 −0.2 1655.8 17901
AQKEADKLGY NLVVLDSQNNPAKE 1.00 44.7 −0.2 1655.8 17901
KDPLDNTYTR NMYIVKH 0.99 32 −0.6 1019.5 17874
KDPLDNTYTR NMYIVKH 1.00 28.4 −0.1 1019.5 17874
AESVKNIFGY QYTIPTHQGRGAE 0.95 35.1 −0.3 1544.7 87082
AESVKNIFGY QYTIPTHQGRGAE 1.00 39.2 −0.9 1544.7 87082
GINCNLTLLF SFAQARACAE 1.00 31.2 −2.7 1197.5 17861
YAKDGISYTF SIVPNALGKDDE 0.91 36.7 −2.3 1372.7 17871
YAKDGISYTF SIVPNALGKDDE 0.99 40.1 0.6 1372.7 17871
EMFGYATQLR SLTKGRASYTME 0.78 32.3 −0.1 1458.7 17897
KGLNVMQNLL TAHPDVQAVFAQNDE 1.00 34.4 4.9 1728.8 17901
KGLNVMQNLL TAHPDVQAVFAQNDE 1.00 48.3 −2.1 1728.7 17901
KGLNVMQNLL TAHPDVQAVFAQNDE 1.00 41 −2.0 1728.7 17901
CKKNPQKNLY TFKNQASNDLPN 0.91 24.4 −0.7 1463.7 87082
CKKNPQKNLY TFKNQASNDLPN 1.00 30.8 1.3 1463.7 87082
CKKNPQKNLY TFKNQASNDLPN 0.98 24 −0.3 1463.7 87082
SVKNIFGYQY TIPTHQGR 0.93 33.5 −1.2 996.5 87082
SVKNIFGYQY TIPTHQGR 1.00 37.3 −0.3 996.5 87082
SVKNIFGYQY TIPTHQGRGAE 0.76 34.3 −1.4 1253.6 87082
KEASAGKLVR TLAAVRDAKEAA 0.95 34.8 −1.4 1330.7 17904
VQVNEADALY TNPAQARE 1.00 41.3 −2.3 973.4 87082
VQVNEADALY TNPAQARE 1.00 38.6 −2.2 973.4 87082
EHAVPMAKAL VAGGVRVLE 1.00 47.4 −1.0 986.5 17881125
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MVMPGDNIKM VVTLIHPI 1.00 28.6 3.2 978.6 17897
GVKLINAVQD VYLDSKITIA 0.91 25.8 −1.6 1237.7 87082
KTTTTERILF YTGVNHKIGE 0.96 34.8 −0.1 1232.6 17897
KTTTTERILF YTGVNHKIGE 0.95 32.9 0.2 1232.6 17897
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VHLEGGFVGM AAAPSGASTGSR 1.00 58.1 1.0 1119.5 17891
VHLEGGFVGM AAAPSGASTGSR 1.00 55 −0.5 1119.5 17891
EEAEKITTVQ AAIDYINGHQA 1.00 41.7 0.5 1259.6 17873
EEAEKITTVQ AAIDYINGHQA 1.00 45.3 −1.5 1259.6 17873
HLEGGFVGMA AAPSGASTGSR 0.98 33 −0.5 1048.5 17891
LEEIGVVCQQ AGGHAAFVDAGK 1.00 57.2 −2.8 1215.6 87082
LEEIGVVCQQ AGGHAAFVDAGK 1.00 53.8 −0.5 1215.6 87082
EWAKHNINVN AIAPGYMATNNTQQLR 1.00 77.6 0.4 1835.9 17892
EWAKHNINVN AIAPGYMATNNTQQLR 1.00 49.6 −3.1 1835.9 17892
VDHGKTTLTA AITTVLAK 0.65 33 −1.4 931.5 17897
VDHGKTTLTA AITTVLAK 0.85 32.8 −7.5 931.5 17897
HIPADQFPAQ ALACELYK 0.74 39.1 −1.9 1082.5 87082
HIPADQFPAQ ALACELYK 0.99 37.9 −0.4 1082.5 87082
HIPADQFPAQ ALACELYK 1.00 41.8 0.2 1082.5 87082
EVMGGLGGFG ALCALPQK 0.81 30.8 −3.3 1015.5 17888
GDGTTTATVL AQAIITEGLK 0.90 45.5 −0.1 1158.6 17905
GDGTTTATVL AQAIITEGLK 0.83 49.5 4.0 1158.6 17905
LAVDESFQPT AVGFAEALNNK 1.00 49.6 2.3 1248.6 17899
LAVDESFQPT AVGFAEALNNK 0.99 45.4 0.6 1248.6 17899
LAVDESFQPT AVGFAEALNNKDKPE 1.00 53.4 0.4 1745.9 17899
LAVDESFQPT AVGFAEALNNKDKPE 1.00 57.1 0.4 1745.9 17899
NPDEAVAIGA AVQGGVLTGDVK 1.00 61.9 −1.8 1258.7 17861
DLNPKAMTPV AWWMLHEE 1.00 38 0.0 1188.5 87082
KVQNASYQVA AYLADEIAK 1.00 41.7 −1.1 1108.5 17877
KVQNASYQVA AYLADEIAK 0.84 35.2 0.1 1108.5 17877
GTNTIGSSEA CMLGGMAMK 1.00 44.8 0.4 1113.5 17877
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GTNTIGSSEA CMLGGMAMK 1.00 44.8 0.4 1113.5 17877
GTNTIGSSEA CMLGGMAMK 1.00 37.9 −3.0 1113.5 17877
TPTRHYAHVD CPGHADYVK 1.00 42.4 −4.3 1161.5 17897
TPTRHYAHVD CPGHADYVK 1.00 42.5 −1.7 1161.5 17897
GNARQNLATF CQTWDDENVHK 1.00 45.2 −3.1 1546.6 17877
GNARQNLATF CQTWDDENVHK 1.00 51.6 −1.4 1546.6 17877
DYDRITKLAR EAVEGAKL 0.99 31 −0.5 931.5 17881 X
DYDRITKLAR EAVEGAKL 1.00 37.8 −2.1 931.5 17881 X
ESKKGYINSL GALTGGQALQQAK 1.00 65.8 −2.1 1357.7 17904
ESKKGYINSL GALTGGQALQQAK 1.00 65.8 −1.6 1357.7 17904
VDESFQPTAV GFAEALNNKDKPE 0.97 41.7 2.7 1575.8 17899
VDESFQPTAV GFAEALNNKDKPE 0.87 45.9 0.9 1575.8 17899
APAELLFEEF GFTVDNVVAK 1.00 38 −0.9 1164.6 48994
APAELLFEEF GFTVDNVVAK 1.00 41.1 −1.6 1164.6 48994
KTDQKVVTLS GFVESQAQAEEAVK 1.00 49.6 −0.8 1607.7 17908
KTDQKVVTLS GFVESQAQAEEAVK 1.00 57.3 2.7 1607.7 17908
RGWQVPAFTL GGEATDIVVMR 0.99 38 0.6 1234.6 17877
RGWQVPAFTL GGEATDIVVMR 1.00 41.9 −0.4 1234.6 17877
EAVAIGAAVQ GGVLTGDVK 0.90 38.3 −1.1 960.5 17861
KYLSDHPKLQ GIAQQNSFK 0.88 35.2 4.7 1107.5 17877
KPEDAVLDVQ GIATVTPAIVQACTQDK 1.00 45.7 −2.5 1888.0 17899
KPEDAVLDVQ GIATVTPAIVQACTQDK 1.00 57.1 −0.7 1887.9 17899
KPEDAVLDVQ GIATVTPAIVQACTQDK 1.00 53.3 −1.6 1887.9 17899
VGVDVVAEAT GLFLTDETAR 0.78 29.1 −1.7 1209.6 17880
VGVDVVAEAT GLFLTDETAR 1.00 42.7 3.7 1209.6 17880
YLFVDMAHVA GLVAAGVYPNPVPH 1.00 54.2 3.4 1477.7 17889
YLFVDMAHVA GLVAAGVYPNPVPH 1.00 50.1 0.0 1477.7 17889
ITEGLKAVAA GMNPMDLK 0.98 36.5 1.3 1020.4 17905
ITEGLKAVAA GMNPMDLK 0.95 36.5 −2.6 1020.4 17905
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ITEGLKAVAA GMNPMDLK 0.95 36.5 −2.6 1020.4 17905
CIAAGIASLW GPAHGGANEAALK 1.00 72 −1.8 1307.6 17869
CIAAGIASLW GPAHGGANEAALK 1.00 75.9 −0.9 1307.6 17869
NAAADLAAIS GQKPLITK 0.77 23.1 −3.5 1027.6 17897
KLGPYEFICT GRPDEGIPAVCFK 0.83 36.6 −2.5 1560.7 17877
KLGPYEFICT GRPDEGIPAVCFK 1.00 39.7 1.1 1560.7 17877
NYRNHFVTIL GTIQGEQPGFINK 1.00 58.9 −0.3 1503.7 87082
NYRNHFVTIL GTIQGEQPGFINK 1.00 53.3 0.4 1503.7 87082
FRNAEFLQAY GVAIADGPLK 0.82 38.6 −0.2 1055.6 17875
KARGITINTS HVEYDTPTR 0.81 33.2 −2.9 1204.5 17897
KARGITINTS HVEYDTPTR 0.97 33.2 −1.6 1204.5 17897
WDFRLPRVKS ISASGHK 0.65 23.5 −1.6 814.4 17877
WDFRLPRVKS ISASGHK 0.70 26.8 −1.6 814.4 17877
KNPQKNLYTF KNQASNDLPN 1.00 26.9 −1.6 1215.6 87082
KNPQKNLYTF KNQASNDLPN 1.00 30.1 −2.0 1215.6 87082
GEIEFWFAMI KVTTIIVM 0.73 20 3.1 1019.6 48994
NLKAMYSIAK KYDIPVVMDSAR 1.00 38.9 1.7 1508.7 87082 X
NLKAMYSIAK KYDIPVVMDSAR 0.97 33.7 −1.4 1508.7 87082 X
GETEDATIAD LAVGTAAGQIK 0.89 37.1 −0.1 1143.6 17891
GETEDATIAD LAVGTAAGQIK 1.00 41.2 −0.5 1143.6 17891
DLRCVNMVAD LWHAPAPK 0.82 32.4 −1.5 1034.5 17877
DLRCVNMVAD LWHAPAPK 0.91 30 1.9 1034.5 17877
TNTIGSSEAC MLGGMAMK 1.00 42 −0.8 953.4 17877
TNTIGSSEAC MLGGMAMK 1.00 38.7 0.5 953.4 17877
AELDDIFSVQ NLMHPAYK 0.98 32.4 −1.6 1088.5 87082
AELDDIFSVQ NLMHPAYK 0.93 38.8 −1.7 1088.5 87082
ALNMIDYGLD NLPGGPL 0.68 26.4 −2.2 754.4 17890
GLEEIGVVCQ QAGGHAAFVDAGK 1.00 78.5 −1.8 1343.6 87082129
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GLEEIGVVCQ QAGGHAAFVDAGK 1.00 77.7 −1.1 1343.6 87082
DGLEEIGVVC QQAGGHAAFVDAGK 1.00 86.9 −0.8 1471.7 87082
DGLEEIGVVC QQAGGHAAFVDAGK 1.00 86.9 −0.5 1471.7 87082
GLKQCKANPW QQFAETHNK 1.00 44.5 −0.7 1217.5 17871
GLKQCKANPW QQFAETHNK 0.98 39.3 −0.8 1217.5 17871
EHDPMEIWAT QSSTLVEVLAK 0.93 35.3 0.2 1289.7 17903
EHDPMEIWAT QSSTLVEVLAK 0.97 39.3 −2.2 1289.7 17903
AESVKNIFGY QYTIPTHQGR 1.00 46.3 −1.7 1287.6 87082
AESVKNIFGY QYTIPTHQGR 1.00 46.3 −1.0 1287.6 87082
PYIVATITSN SAGGQPVSLANLK 0.94 35.1 0.3 1356.7 87082
PYIVATITSN SAGGQPVSLANLK 1.00 42 −2.4 1356.7 87082
ARLMATMKEA SAGKLVR 0.98 32.7 0.2 845.5 17904
YAGQDIVSNA SCTTNCLAPLAK 1.00 45.4 −6.1 1450.7 17880
RKIKAAQYVA SHPGEVCPAK 0.99 43.7 −0.6 1196.5 17868
RKIKAAQYVA SHPGEVCPAK 1.00 38.5 −0.8 1196.5 17868
RKIKAAQYVA SHPGEVCPAK 1.00 47.8 −0.8 1196.5 17868
PFACIAAGIA SLWGPAHGGANEAALK 0.96 39.7 1.3 1693.8 17869
PFACIAAGIA SLWGPAHGGANEAALK 0.97 43.9 −1.7 1693.8 17869
HDPMEIWATQ SSTLVEVLAK 0.95 35.2 −0.8 1161.6 17903
HDPMEIWATQ SSTLVEVLAK 0.99 38.2 0.0 1161.6 17903
RTMACGIAGL SVAADSLSAIK 1.00 56.7 −0.1 1176.6 17871
RTMACGIAGL SVAADSLSAIK 1.00 65.1 4.3 1176.6 17871
RTMACGIAGL SVAADSLSAIK 1.00 50.7 −5.6 1176.6 17871
CKKNPQKNLY TFKNQASNDLPN 1.00 29.6 −0.6 1463.7 87082
CKKNPQKNLY TFKNQASNDLPN 0.98 26.7 1.4 1463.7 87082
KEASAGKLVR TLAAVRDAKEAA 0.99 38.5 −0.6 1330.7 17904 X
KEASAGKLVR TLAAVRDAKEAA 0.99 43.5 −1.0 1330.7 17904 X
KEASAGKLVR TLAAVRDAKEAA 0.99 35.7 −0.8 1330.7 17904 X
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KEASAGKLVR TLAAVRDAKEAA 0.97 34.6 0.1 1330.7 17904 X
EEKARGITIN TSHVEYDTPTR 1.00 46.4 0.9 1392.6 17897
EEKARGITIN TSHVEYDTPTR 1.00 46.3 −1.4 1392.6 17897
TTGEHEVSFQ VHSEVFAK 0.83 27.9 −0.7 1031.5 17906
QQAVAAHKFN VLASQPADFDR 0.81 25.5 −0.7 1305.6 17901
PDEAVAIGAA VQGGVLTGDVK 0.99 40.8 −0.2 1187.6 17861
PDEAVAIGAA VQGGVLTGDVK 0.99 46.6 −1.8 1187.6 17861
MVMPGDNIKM VVTLIHPI 0.83 26.1 0.3 978.6 17897
MVMPGDNIKM VVTLIHPI 0.99 29.7 −1.4 978.6 17897
131
132
8 Publications and Meetings
8.1 Publications in peer-reviewed journals
• Perera NC, Schilling O, Kittel H, Back W, Kremmer E, Jenne DE. NSP4, an elastase-
related protease in human neutrophils with arginine specificity. Proc. Natl. Acad. Sci. U
S A. 2012 Apr 17;109(16):6229-34. Epub 2012 Apr 2.
• Perera NC, Jenne DE. Perspectives and potential roles for the newly discovered NSP4 in
the immune system. Expert Rev. Clin. Immunol. 2012 Aug;8(6):501-3 (Editorial)
• Perera NC, Wiesmüller K, Torp Larsen M, Schacher B, Eickholz P, Borregaard N, Jenne
DE. NSP4 is stored in azurophil granules and released by activated neutrophils as active
endoprotease with restricted specificity. J. Immunol. 2013 Sep 1;191(5):2700-7. Epub
2013 Jul 31.
• O’Donoghue AJ, Jin Y, Knudsen GM, Perera NC, Jenne DE, Murphy JE, Craik CS and
Hermiston T. Global Substrate profiling of proteases in human Neutrophil Extracellular
Traps reveals consensus motif predominantly contributed by Elastase. Accepted by PLoS
One. 2013 Aug 12.
8.1.1 Conference abstract
• Perera NC, Torp Larsen M, Wiesmüller K, Borregaard N, Jenne DE. 1.102 NSP4 is
stored in azurophilic granules and released by activated neutrophils as an active endopro-
tease with restricted specificity. Eur. J. Clin. Invest. 2013; 43: 36.
133
8 Publications and Meetings
8.2 Presentations at international conferences
8.2.1 Oral presentations
• A novel granule-associated serine protease in human neutrophils. 26th International Win-
ter School on Proteinases and Their Inhibitors. Italy, 2009. (Best talk award)
• A Novel Granule-Associated Serine Protease of Human Neutrophils. Gordon Research
Conference: Proteolytic Enzymes and Their Inhibitors. Italy, 2010.
• NSP4 is a novel granule associated serine protease of human neutrophils. 28th Interna-
tional Winter School on Proteinases and Their Inhibitors. Italy, 2011.
• Substrate specificity profiling of NSP4, the novel serine protease in human neutrophils.
29th International Winter School on Proteinases and Their Inhibitors. Italy, 2012.
• NSP4 is stored in azurophil granules and released by activated neutrophils as an active
endoprotease with restricted specificity. 30th International Winter School on Proteinases
and Their Inhibitors. Italy, 2013.
8.2.2 Poster presentations
• A Novel Granule-Associated Serine Protease of Human Neutrophils. Gordon Research
Conference: Proteolytic Enzymes and Their Inhibitors. Italy, 2010. (Baxxter Poster
Prize)
• NSP4 is stored in azurophil granules and released by activated neutrophils as active en-
doprotease. 47th Annual Scientific Meeting of the European Society for Clinical Investi-
gation (ESCI). Portugal, 2013. (ESCI Travel Grant)
134
Eidesstattliche Erklärung 
 
Ich versichere hiermit an Eides statt, dass die vorgelegte Dissertation von mir 
selbständig und ohne unerlaubte Hilfe angefertigt ist. 
 
 
 
München, den ............................................        ............................................................. 
 
        (Unterschrift) 
 
 
 
 
 
Erklärung 
 
Hiermit erkläre ich, * 
 
   dass die Dissertation nicht ganz oder in wesentlichen Teilen einer anderen 
Prüfungskommission vorgelegt worden ist. 
 
 
   dass ich mich anderweitig einer Doktorprüfung ohne Erfolg nicht unterzogen 
habe. 
 
  dass ich mich mit Erfolg der Doktorprüfung im Hauptfach .................................. 
und in den Nebenfächern ............................................................................................ 
bei der Fakultät für ..................................... der .......................................................... 
  (Hochschule/Universität)  
unterzogen habe. 
 
   dass ich ohne Erfolg versucht habe, eine Dissertation einzureichen oder mich 
der  Doktorprüfung zu unterziehen. 
 
 
 
 
München, den...............................   ........................................................................................ 
       (Unterschrift) 
 
 
 
*) Nichtzutreffendes streichen   
